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Abstract 
Pseudaminic acid is a non-mammalian nonulosonic acid and a component in a number 
of bacterial surface structures, including Pseudomonas aeruginosa lipopolysaccharide 
and pili. It has been shown to play a role in virulence in pathogens such as influencing 
motility in Campylobacter jejuni whose flagellin is glycosylated with pseudaminic acid 
structures. Therefore pseudaminic acid processing enzymes have been identified as 
putative drug targets but are yet to be fully characterised.  
Although generally harmless to healthy individuals, Pseudomonas aeruginosa is the 
most prevalent lung disease in sufferers of cystic fibrosis and is implicated in the 
majority of cystic fibrosis deaths. Chronic infections are associated with progression into 
a mucoid phenotype whereby eradication of the pathogen is almost impossible. An 
enzyme associated with the mucoid phenotype (PA2794) has been putatively assigned 
as a pseudaminidase and this project aimed to unequivocally assign this enzyme using 
pseudaminic acid analogues. However strategies to synthesise pseudaminic acid are 
currently unsuitable for large scale (< 50 mg) production and hence chemical probes for 
the characterisation of pseudaminic acid processing enzymes are not currently 
available. 
It was attempted to attain a PA2794 crystal structure with pseudaminic acid in complex. 
However this was inconclusive in elucidating the PA2794 natural substrate and further 
investigations prevented due to the lack of availability of the putative ligand. Therefore 
efforts were turned towards the design of a strategy for the synthesis of pseudaminic 
acid on a large scale, to allow for the pseudaminic acid chemical probes to be developed.  
The proposed synthesis utilised the Campylobacter jejuni pseudaminic acid biosynthetic 
enzymes to convert UDP-GlcNAc into pseudaminic acid in one-pot. Expression was 
optimised for each enzyme and modified to ensure enzyme solubility. A coupled PseB, 
PseC activity assay was implemented to follow conversion to the unwanted PseB by-
product, and conditions adjusted to perturb this reaction. Additionally co-factor 
substitutes were explored in order to make large scale synthesis economically viable. A 
route for the large scale enzymatic production of pseudaminic acid was optimised, 
allowing for an economically viable, efficient and high yielding synthesis. 
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activated and isoleucine-stabilised water molecule as a nucleophile to attack at the anomeric 
centre. 
15 
 
Scheme 3.5 C. jejuni PseI pseudaminic acid synthetase PEP condensation mechanism. 
Scheme 3.6 A chemoenzymatic route to the PseG substrate, UDP-6-deoy-AltdiNAc (3.9). 
Scheme 3.7 One-pot enzymatic production of Pse5Ac7Ac (1.13) from UDP-GlcNAc (3.1). 
Scheme 4.1 PseB catalysed oxidation, dehydration and reduction of the substrate UDP-GlcNAc 
(3.1) to form the initial product UDP-4-keto-6-deoxy-˪-IdoNAc (3.7) which is in equilibrium with 
the hydrated form (4.2) in aqueous conditions. 
Scheme 4.2 C. jejuni interlinking schemes from UDP-GlcNAc to two deoxysugar intermediates 
(3.7, 4.1) in the biosynthetic pathways of two sugars important for protein glycosylation. 
Scheme 4.3 The proposed PseC mechanism transferring an amino group from the PMP co-
factor, generated in situ, to the keto-sugar (3.8) via formation of an external aldimine (4.10) that 
crystal structures have been shown as present in the active site during the reverse reaction.  
Scheme 4.4 C. jejuni PseB and PseC full reaction scheme highlighting conversion to the PseB 
inverted by-product (4.1) and the non-enzymatic production of the hydrated PseB products (3.2, 
3.12). 
Scheme 4.5 The coupled C. jejuni PseB and PseC reaction converting UDP-GlcNAc (3.1) to the 
second Pse5Ac7Ac (1.13) biosynthetic intermediate UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8). 
Scheme 4.6 Partial PseB mechanism highlighting the D2O solvent molecule utilised during the 
mechanism and the corresponding product detected by negative ESI LC-MS whereby all of the 
labile deuterium have undergone solvent exchange with the H2O/MeCN mobile phase. 
Scheme 4.7 Partial PseC mechanism in deuterium proposing formation of a stable C4 carbon-
deuterium bond and the resulting sugar identified by negative ESI LC-MS. 
Scheme 5.1 C. jejuni Pse5Ac7Ac (1.13) biosynthetic pathway highlighting the acetyltransfer step. 
Scheme 5.2 Acetyltransfer mechanism for synthesis of UDP-4-acetamido-4,6-dideoxy-β-ɩ-
AltNAc (3.9) showing the C. jejuni PseH catalytic acid; Tyr128, and the proposed water mediated 
amine deprotonation.  
Scheme 5.3 A synthetic route of acetyltransfer to GlcN (5.3) to produce GlcNAc (5.4).  
Scheme 5.4 Mechanism for the acetyl transfer from acetyl-thiocholine iodide (5.5) to CoA 
(5.1). 
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Scheme 5.5 Acetyltransferase catalysed acetylation of GlcN-1-P utilising the natural co-factor 
acetyl-CoA (5.1) or N-acetylcysteamine thioester (5.9). 
Scheme 5.6 A chemo-enzymatic route to the Pse5Ac7Az (5.10) utilising a combination of 
enzymatic and chemical steps. 
Scheme 5.7 Chemical acetylation of UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8) to afford UDP-4-
acetamido-4,6-dideoxy-β-˪-AltNAc (3.9) using a silver acetate catalyst (5.15) to activate the 
acetic anhydride making it more susceptible to nucleophilic attack. 
Scheme 5.8 Enzymatic synthesis of UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8) followed by 
chemical acetylation to UDP-4-acetamido-4,6-dideoxy-β-˪-AltNAc (3.9) using a silver acetate 
catalyst (4 equiv) and acetic anhydride (11.5 equiv) in MeOH, at room temperature for 3 hrs. 
Scheme 5.9 Regeneration of acetyl-CoA (5.1) in situ during the enzymatic synthesis of UDP-4-
acetamido-4,6-dideoxy-β-˪-AltNAc (5.9). 
Scheme 5.10 Synthetic route to N-acetyl cysteamine thioacetate; addition of acetic anhydride 
to cysteamine HCl in H2O at pH 8.0, 0 °C, followed by stirring at pH 7.0 at 0 °C for 2 hrs.  
Scheme 5.11 The resonance forms of esters and thioesters. 
Scheme 5.12 Introduction of desired C7 functionality in pseudaminic acids utilising a co-factor 
substitute. 
Scheme 5.13 Three synthetic strategies for coupling azidoacetic acid and N-acetylcysteamine 
HCl to form N-acetylcysteamine thioazidoacetate (5.26). 
Scheme 5.14 One-pot enzymatic route to Pse5Ac7Az (5.10), utilising the C. jejuni Pse5Ac7Ac 
(1.13) biosynthetic enzymes and an azido-tagged PseH co-factor substitute (5.26). 
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 Cell surface glycosylation 
1.1.1 The role of carbohydrates 
Carbohydrates are the most abundant group of compounds on Earth and play a vast role across 
a multitude of biological processes.5 However, in contrast to proteins, there is no strict template 
for the biosynthesis of carbohydrates which results in significant heterogeneity, and an extra 
level of complexity in research. Historically, carbohydrates were considered as merely structural 
molecules or as an energy source, with significance research efforts focussed on diet and 
nutrition. This has somewhat limited investigations into their other biological roles in health and 
disease, such as their prevalence on cell surfaces and when attached to proteins (wherein they 
are known as glycans).6 The vast complexity, diversity and heterogeneity of glycan structures7 
has also contributed to the lag in their functional understanding compared to other cell surface 
biomolecules. It has recently become clear however that a greater emphasis needs to be placed 
on the study of glycans in order to truly understand and manipulate biological systems. Indeed, 
the degree and type of glycosylation on both mammalian and bacterial cell surfaces regulates a 
multitude of biological processes and they are essential for facilitating cellular communication.8 
 
 
Figure 1.1 Fischer projections of hexose examples, glucose and mannose, displaying the potential for 
different diastereomers and enantiomers. 
The inherent complexity of carbohydrates begins at the monosaccharide building block level, 
with even simple hexose carbohydrate molecules (e.g C6H12O6) having a large number of 
different configurational arrangements. The number of available diastereomers increases as the 
chain length increases, in addition to the existence of pairs of enantiomers (ᴅ and ˪) (Figure 1.1). 
Further complications arise due to some monosaccharides being able to exist in ring open forms 
and hence can interconvert between 5- and 6-membered furanose or pyranose rings as well as 
between different anomeric configurations (α or β) (Figure 1.2).   
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Figure 1.2 The different structural forms of ᴅ-glucose. 
As carbohydrates possess multiple hydroxylated stereocentres the structural diversity range of 
oligosaccharides increases with length. Hence upon “polymerisation” the number of both linear 
and branched structures accessible increases exponentially, further increasing the complexity 
of even simple carbohydrate studies.7 In nature only a small portion of the potential 
oligosaccharide configurations are utilised, and their state of “polymerisation” is regulated by 
glycosyltransferases (GTs) and glycosylhydrolases (GHs).9 GTs catalyse the biosynthesis of a 
glycosidic bond via condensation at the anomeric position of an “activated donor” and the 
hydroxyl of an acceptor molecule whilst GHs catalyse hydrolysis of such glycosidic bonds 
(Scheme 1.1). 
 
Scheme 1.1 General reaction for the glycosyltransferase (GT) catalysed formation of a glycosidic linkage 
between two monosaccharides and the glycosylhydrolase (GH) catalysed cleavage of a glycosidic bond. 
Glycans are often covalently linked to other molecules to form a complex variety of 
glycoconjugates such as glycolipids, glycoproteins and glycosides. Cell surfaces can also be 
decorated with glycoconjugates which form a dense layer surrounding the cell called the 
glycocalyx.10 The glycocalyx is dynamic but essential and plays a variety of physiological roles 
including communicating information about the cell to extracellular moieties, such as what type 
of cell it is, and if the cell is diseased or healthy.11   
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1.1.2 Nomenclature 
As the biological significance of carbohydrates became more apparent, a small number of 
monosaccharides were found to be abundant in vertebrates and hence symbol representations 
were assigned to enable facile depictions of these structures. Although first used sporadically, 
symbolic representations of glycans quickly gained popularity and it was deemed necessary to 
implement a standardised system. The fundamentals of such a system were initially developed 
in the late 1990s,5 via extension of the monosaccharide symbols first presented by Kornfeld 
during the discussion of complex oligosaccharide synthesis.12 Symbol representations were 
assigned to the monosaccharides that early investigations had found to be the most common in 
higher animal oligosaccharides. Basic shapes were utilised that were either blank, half-filled or 
fully filled to depict the monosaccharide (Figure 1.3).5 Although this simplistic approach was 
successful for the facile representation of the most abundant monosaccharide building blocks, 
it heavily  restricted the number of monosaccharides that could be represented in this way. As 
the diversity of characterised glycals increased and research expanded to invertebrates, a 
plethora of other sugars were discovered that could not be satisfactorily represented by this 
symbol system. 
 
 
Figure 1.3 Symbols assigned to the most abundant vertebrate monosaccharides in order to standardise 
depiction of glycans 
This original categorisation was thoroughly revised ten years after publication whereby the 
Consortium for Functional Glycomics (CFG) updated the system to include colour and a wider 
number of monosaccharides.13 This was quickly criticised for still being rather limiting 
considering the increasing number of important monosaccharides being studied and was 
reorganised in 2015 to give the system that is universally adopted today.14 The introduction of 
colour and a systemisation of symbols allowed for representation of a much greater number of 
monosaccharides (Figure 1.4a). Sugars of the same functionality (hexoses, hexosamines, acidic 
sugars etc.) were designated the same shape with differences in their stereochemistry reflected 
by a change in colour (e.g. galactose stereochemistry is yellow, mannose is green etc.).  
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Figure 1.4 An updated symbolic representation of monosaccharides a) the general symbolic 
representation devised in 2015 and b) the assignment of symbols to monosaccharides that were unknown 
upon publication but that have recently been characterised. 
Ongoing modifications are being made to the CFG symbols as required to expand the different 
monosaccharides represented by symbols that were originally annotated as unknown, such as 
to include rare non-mammalian monosaccharides (Figure 1.4b). Additionally as this system was 
designed for representing complex glycans an outline was also proposed for detailing the type 
and position of bonding between sugars. The orientation of the symbols relative to each other 
can be used to depict the binding site or writing within the bond can be used (Figure 1.5).14  
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Figure 1.5 Glycan structure examples using the CFG standardised system in either the written format or 
with the monosaccharides represented by symbols, with or without additional bond information for a) an 
example N-glycan and b) an example plant glycan. 
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1.1.3 Bacterial glycans 
Bacteria also utilise glycans in a number of different cell surface structures for protection, 
recognition and to regulate permeability. The most exposed layer of bacterial cells are 
decorated with carbohydrates in different forms; the capsular polysaccharide (CPS), 
lipopolysaccharide (LPS), peptidoglycan and on flagellin and pili. Therefore these carbohydrate 
structures have extracellular interactions that are essential for pathogenicity and virulence.15 
According to their different glycocalyx structures bacteria can be categorised into two groups; 
Gram positive or Gram negative, and are characterised as such based on whether they retain 
the Gram stain.16 Gram positive bacteria have a thick peptidoglycan layer and hence retain the 
crystal violet stain to a much higher degree than Gram negative bacteria that have a thinner, 
less accessible peptidoglycan layer. To confirm the presence of Gram negative bacteria, after 
washing away the crystal violet, a positively charged secondary stain, such as safranin, is applied 
and binds to cell membranes. This stain will also bind to Gram positive bacteria but be over-
powered by the crystal violet stain allowing for the two groups of bacteria to be distinguished 
by a difference in colour.   
Gram positive bacteria (Figure 1.6) have a phospholipid bilayer cell membrane littered with 
permeability mediating proteins and receptor proteins which can span the bilayer. They also 
have a thick peptidoglycan cell wall that can account for 90 % of their dry weight,17 composed 
of polysaccharide chains of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) 
cross linked with peptides to form a lattice.18 This cell wall further mediates permeability and 
aids in preventing the cell from bursting due to osmosis. Teichoic acids span the peptidoglycan 
layer and consist of poly(alditolphosphates), which can be anchored to the membrane through 
disaccharides modified with lipids (lipoteichoic acid). The teichoic acids can bind to host 
receptors and initiate immune responses however the exact molecular interactions for binding 
are currently unknown.19 
Gram negative bacteria also have a phospholipid bilayer cell membrane and peptidoglycan 
layer20 (Figure 1.7) however the latter is much thinner than in Gram positive bacteria. This 
decrease of structural rigidity from the peptidoglycan is compensated for by a secondary 
phospholipid bilayer that can be heavily functionalised with lipopolysaccharides (LPS). The LPS 
has roles in cell signalling,21 bacterial toxicity22 and protection23 and is exposed on the cell 
surface in non-capsulated Gram negative strains. Interactions between LPS molecules and 
cations allows for aggregation 24 and prevents diffusion of small hydrophobic compounds to the 
cell surface. Upon infection the LPS allows for bacterial survival in harsh conditions25 and LPS-
defective mutants have been shown to be eradicated by a number of antibiotics.26 
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Figure 1.6 Gram positive bacteria cell wall with the thick layer of peptidoglycan surrounding a 
phospholipid bilayer. 
  
 
Figure 1.7 Gram negative bacteria cell wall with the thin layer of peptidoglycan between two phospholipid 
bilayers with an outer layer of lipopolysaccharides. 
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 Glycosyl hydrolases 
1.2.1 An overview of glycosyl hydrolases 
The ever-emerging biological importance of glycans and the vast array of glycoconjugates has 
highlighted a plethora of enzymes that are required for the synthesis and regulation of such 
structures. One class of glycosyl processing enzymes are the glycosyl hydrolases (GHs) which 
catalyse hydrolysis of a glycosidic bond between two carbohydrates or between a carbohydrate 
and another moiety.6 Glycosyl cleavage is an important biological process greatly influencing 
cellular regulation processes such as differentiation, adhesion, development, immune 
responses, and infection. 
A recent surge in the assignment of GH encoding genes necessitated the requirement for a 
classification system and led to the formation of the CAZy (Carbohydrate Active Enzymes) 
database.27 This database categorises GHs into different families based on their sequence 
similarity. Identification and characterisation of GHs has promoted their utilisation in a 
multitude of practical applications such as; therapeutic targets, biomass conversion, and even 
as synthetic catalysts through transglycosylation (reverse hydrolysis). The diversity of substrates 
and hydrolysis processes required is reflected in the number of GH structures, which display 
specificity to the glycosyl donor.28  
GHs can also be categorised into retaining GHs or inverting GHs based on the stereochemistry 
at the anomeric centre of their products relative to the stereochemistry of the substrate.29 
Hydrolysis with retention generally occurs via a double displacement mechanism with the two 
catalytic residues consistently being held 5.5 Å apart.29 Glutamic acid or Aspartic acid are 
generally employed as the acidic residue that assists departure of the alkoxide leaving group 
whilst a nucleophilic residue (commonly a carboxyl group) attacks the anomeric centre. An 
active site water molecule is then activated by the general base to attack the anomeric centre, 
releasing the hydrolysed product with retention of stereochemistry (Scheme 1.2a). When the 
catalytic residues are held further apart,29 a concerted line of attack occurs with direct 
displacement of the leaving group with a water molecule. An acidic residue activates a water 
molecule at the anomeric carbon whilst a basic residue donates a proton to promote removal 
of the leaving group giving rise to inversion at the anomeric carbon (Scheme 1.2b).  
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Scheme 1.2 General glycosidase hydrolysis mechanisms resulting in a) retention or b) inversion of the 
configuration of the anomeric bond. 
 
GHs have been identified as particularly useful for biotechnological applications as they catalyse 
the degradation and recycling process of cellular structures. GHs have been explored as catalysts 
for the production of bioethanol from biomass as a potential substitute to gasoline30  and can 
also provide a route to synthetically challenging small molecules, whereby a careful concoction 
can catalyse selective degradation of abundant materials into the desired small molecules.  
These molecules can then be further processed into materials of high value from cheap readily 
available reagents.31  
Additionally some GHs have lower substrate specificity and can been used more crudely in place 
of non-selective chemical degradation processes. For example cellulase degradation activity of 
a number of xylanases has been explored for utilisation during the paper recycling process as an 
alternative to the harsh chemical conditions otherwise required.32 Instead of screening an 
extensive list of different GH enzymes, detailed structural and mechanistic studies of a few 
xylanases provided insight into their substrate specificity and highlighted mutations that could 
be made to alter this specificity as desired as well as enhancing activity.33 
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1.2.2 Neuraminidase structure and mechanisms 
Nonulosonic acids, or sialic acids as they are commonly referred to, (Figure 1.8) are often 
displayed as the terminal sugar on cell surface structures expressed in higher eukaryotes, viruses 
and bacteria.13 Sialic acids have importance in a range of biological functions including 
embryonic development,34 signalling35 and adhesion.36 In nature they are present as a diversely 
functionalised class of nine carbon containing carbohydrates, the most prevalent of which is N-
acetylneuraminic acid (Neu5Ac 1.1).37 Diversity arises mainly from the incorporation of different 
functionality at C4, C5, C7, C8 and C9,38 for example Neu5Ac (1.1) has a C5 acetamido group 
whereas in 2-Keto-3-deoxynonic acid (KDN 1.2) it is replaced by a hydroxyl and N-
glycolylneuraminic acid (Neu5Gc 1.3) has a modified C5 acetamido group with the addition of 
an hydroxyl (Figure 1.8). 
 
Figure 1.8 Examples of sialic acid structures prevalent in nature with different C5 functionality. 
Sialic acids, such as Neu5Ac (1.1), are routinely found linked in the alpha conformation 
predominantly via α2-3, α2-6 or α2-8 linkages (1.4-1.6)39 (Figure 1.9). Sialidases/neuraminidases 
are utilised to specifically cleave the glycosidic bond between sialic acids and other moities. 
These enzymes make up an extremely important class of glycosidases and mammalian, viral and 
bacterial neuraminidases have been discovered for cleavage of both native and non-self sialic 
acids highlighting their importance in symbiosis and infection.  
 
Figure 1.9 Different natural Neu5Ac (1.1) linkages; α2,3 (1.4), α2,6 (1.5), and α2,8 (1.6). 
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Based on their sequence homology neuraminidases are classified into five different families 
GH33, GH34, GH83 (exo-sialidases) or GH58 (endo-sialidases) using the CAZy system.9 To date, 
all exo-sialidases investigated have been found to hydrolyse sialic acid with a retention of 
stereochemistry.40 However recent research investigating an endo-sialidase from Escherichia 
coli (E. coli) found that this enzyme hydrolysed sialic acid polymers with an inversion of 
stereochemistry.41 Although they belong to a number of different GH families the catalytic 
domain of exo-sialidases has been found to be the highly conserved six-bladed β-propeller 
(Figure 1.10a).42 Although neuraminidase sequences have a low overall homology, there are a 
number of characteristic motifs that are conserved across all neuraminidases.43 For example all 
neuraminidases encode between three and five Asp boxes43 – a sequence motif that gives rise 
to β-hairpin folds in topologically equivalent locations. The Asp boxes are thought to be too 
remote from the active site to be directly involved in the cleaving of glycosidic bonds, however 
they are important for the protein 3-D structure (Figure 1.10a).1 A second motif is also conserved 
across neuraminidases; a RIP/RLP sequence with the arginine configured so that it protrudes 
into the active site, aiding substrate binding via interactions with the sialic acid carboxylate 
group (Figure 1.10a).43 This arginine makes up one of three that are all situated in the active site 
to stabilise the sialic acid carboxylate group (Figure 1.10b).44 
 
Figure 1.10 Crystal structure of a typical sialidase (PDB 1EUS)1 with a) the conserved Asp boxes (magenta) 
and RIP motif (cyan) highlighted in the full structure and, b) the active site with catalytic residues (sea 
green) and three interacting arginine residues (lilac) highlighted. 
Neuraminidases cleave Neu5Ac (1.1) with retention of the anomeric stereochemistry following 
the general double displacement mechanism described previously (Scheme 1.3). There is a 
conserved active site aspartic acid that is typical of GHs that first acts as an acid and then as a 
base as the reaction proceeds.45 However, neuraminidases are unique amongst GHs as the 
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enzymes do not employ a carboxylic acid based residue as the nucleophile but instead use a 
conserved glutamate-activated tyrosine (Figure 1.10b).46 It has been proposed that the use of 
tyrosine reduces Coulombic repulsion that occurs between the catalytic residue and the 
carboxylate group of the sialic acid.47 
 
Scheme 1.3 A typical retaining sialidase double displacement mechanism, using an α-linked Neu5Ac (1.1) 
as an example substrate. 
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1.2.3 Human neuraminidases 
Humans express four different neuraminidases (NEU1, NEU2, NEU3, and NEU4) which are 
essential for development and abnormal functioning of these enzymes has been linked to 
genetic diseases and cancer.48 The regulation of Neu5Ac (1.1) on human cells is important for 
many biological processes including; cell differentiation,49 antigen masking and apoptosis.50 
Neuraminidases can also modulate the recycling of glycans preventing the need for recurrent 
de novo biosyntheses of certain glycoconjugates.51 
The requirement of four different human sialidases highlights the importance and widely 
distributed uses of cellular sialylation in humans. Each of the sialidases differs in activity 
conditions, substrate specificity and cellular localisation; for example, NEU1, NEU3 and NEU4 
display optimal activity at acidic pH whereby NEU2 cleaves Neu5Ac (1.1) at near neutral.52 NEU3 
displays the highest substrate specificity with Neu5Ac (1.1) cleavage limited to specific 
gangliosides53 whereby the others display activity to a variety of glycoconjugates. NEU2 is 
dispersed within the cytoplasm,54 whereas NEU1 and NEU3 are predominantly localised at the 
cell edges in lysosomes55 or associated with the plasma membrane56 respectively. NEU4 has 
been found in a number of organelles and research shows it to predominantly expressed in the 
liver, with detectable levels in the kidney, heart and brain.57 
The impact of Neu5Ac (1.1) cleavage can be tentatively summarised, however, this process is 
involved in complex pathways where the chronology of cause and effects are difficult to assign 
and the pathway molecular mechanisms are not fully understood. The majority of research has 
been undertaken on NEU1 as this enzyme is the most highly expressed and functioning. 
However research surrounding NEU3 is slightly less complex as it is more specific, and only 
directly contributes towards the physiological function, and catabolism, of gangliosides.53 
Gangliosidic Neu5Ac (1.1) cleavage can still affect a cascade of many different biological 
processes, for example, Neu5Ac (1.1) hydrolysis is involved in mediating release of ceramide and 
sphingosine58 which can act as signalling and regulatory molecules, as well as being recycled for 
glycolipid biosynthesis.  
At the lysosome, NEU1 catalysed cleavage of Neu5Ac (1.1) signals for further glycoconjugate 
degradation. NEU1 is implicated in the complex machinery for regulating lysosomal exocytosis,59 
involving lysosomal docking to the plasma membrane. This mechanism has an important role in 
membrane repair as well as pathogenic removal through the cellular immune response.60  NEU1 
is also integral to regulation of Neu5Ac (1.1) on cell surface glycoconjugates. In this way it has 
also been shown to be an important signalling regulator for biological processes such as cell 
adhesion,61 elastogenosis62 and phagocytosis.63 
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NEU1 has also been implicated in the immune response with inhibition of NEU1 resulting in a 
reduced ability for macrophages to produce cytokines and engulf bacteria. This is partially 
attributed to NEU1 (and NEU3) catalysed desialylation of monocytes allowing them to be more 
sensitive to bacterial LPS, inducing production of specific cytokines.64 Additionally it has been 
shown that NEU1 expression is significantly increased during lymphocyte activation with a 
higher concentration of NEU1 displayed on the cell surfaces. This increase in NEU1, in turn, has 
been shown to increase production of interleukin-4 which can be critical for immunity against 
some viral infections.65 
Currently, NEU1 is the only human neuraminidase whose mutations have been directly linked 
with a genetic disease-sialidosis. This is a lysosomal storage disease caused by excessive storage 
of glycoconjugates in the lysosome due to a lack of desialyation signalling further degradation 
of these molecules.55 Type I sialidosis doesn’t usually present until a patients second or third 
decade but can quickly progress quickly and can cause myoclonus, seizures and visual defects 
associated with “cherry-red spot”.66 Treatment is patient centred with emphasis placed on 
managing the symptoms rather than regulation of sialyation as therapeutics for this do not 
currently exist.abram67 Generally Type II sialidosis is more severe than Type I and is 
characterised by the early onset, mucopolysaccharidosis-like phenotype and, in most cases, a 
drastically reduced life expectancy.68 For example, severe pre-birth deficiencies in NEU1 
resulting in Type II sialidosis can cause sufferers to be still born or die soon after birth with 
excessive sialylation leading to a number of health complications such as an enlarged spleen and 
liver, fluid accumulation and abnormal bone development.69 
Considering the impact of glycoconjugates in the hallmarks of cancer, it is unsurprising that 
tumorous cells display an altered cell surface finger print compared to non-cancerous cells.70 
One of these fundamental differences, is an overall increase in the amount of Neu5Ac (1.1) 
present on cancer cell surface glycoconjugates. Not only does the hypersialylation increase 
siglec binding hence aiding in immune response evasion but it can also enhance tumour 
progression by regulating a number of mechanisms.71 Neuraminidase expression levels in 
tumorous cells have also been found to be abnormal52 and influence the cells ability for 
increased cell proliferation and cell death resistance.72 For example, NEU3 in cancer colon has 
and up-regulated expression; increasing ganglioside de-sialylation and revealing glycolipid 
structures that are important for reducing apoptosis.73 
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1.2.4 Neuraminidases as therapeutic targets  
Bacteria and viruses also utilise neuraminidases for their own biological processes and to aid in 
the invasion of hosts. In particular neuraminidase activity has been found to enable increased 
binding between bacteria and host epithelial cells, although the molecular interactions of the 
resulting binding are unknown.74 For example, pre-treatment of human cells with a viral 
neuraminidase has been shown to allow for an increased adhesion by a number of different 
bacterial cells including Streptococcus pneumoniae (S. pneumoniae).75 As well as displaying 
importance during initial colonisation, S. pneumoniae nanA was found to be important for the 
longevity of infection both in the respiratory tract and blood samples.76 The cell surface 
neuraminidase in Capnocytophaga canimorsus (C. canimorsus) has also been shown be essential 
for bacterial persistence by de-glycosylating host Neu5Ac (1.1) to reveal glycoproteins that could 
act as a source of carbon and nitrogen to sustain the bacteria.77 
One of the most exclusively studied types of neuraminidase includes those displayed on the 
outer surface of the influenza virus. This enzyme adopts the canonical neuraminidase fold (six-
bladed β-propeller) and has the strictly conserved neuraminidase catalytic residues, however 
homology across the rest of the sequence with other neuraminidases is low.78 To initiate 
infection, the virus needs to be able to pass along the respiratory tract, however the host has 
evolved a protective barrier in the form of a mucus layer containing Neu5Ac (1.1) glycoproteins. 
Another viral surface protein, hemagglutinin, binds to host glycoproteins to initiate infection 
and then neuraminidase activity is required at this stage to allow the virus to progress along the 
epithelial cells.79 The neuraminidase is also employed following viral replication to release the 
virions from the viral surface to prevent viral aggregation and promote dispersion.80 The 
neuraminidase activity has been shown to be essential for effective influenza viral infections and 
hence has been a target for numerous therapeutics. 
To aid drug design Lipinski suggested four objectives that if a molecule adhered to, it should be 
well absorbed by the body; < 5 hydrogen bond donors, < 10 hydrogen bond acceptors, 
molecular weight < 500 g mol-1 and calculated log P < 5.81 It was deemed that if a molecule met 
at least three of these requirements then it could be an orally administered drug based on its 
predicted solubility and permeability,82 however many exceptions to the rule have occurred. 
Following these guidelines, potential Neu5Ac-based neuraminidase inhibitors are attractive as 
Neu5Ac (1.1) meets the requirements; has 9 hydrogen bond acceptors, a molecular weight of 
309 g mol-1 and calculated log P of -3.5. Therefore putative inhibitor analogues display potential 
to be well-absorbed, orally administrated drugs.  
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N-substituted oxamic acids, such as N-phenyloxamic acid (1.7) (Figure 1.11), were identified as 
prudent neuraminidase inhibitors in the 1960s.83 However these molecules lost all activity 
during in vivo experiments and displayed a lack of enzymatic specificity so were deemed 
unsuitable as therapeutics.84 Subsequent research focussed on developing inhibitors that had 
higher selectivity for neuraminidases and, preferentially targeting the viral, and/or bacterial 
enzymes over the host (mammalian) neuraminidases.  
 
Figure 1.11 A selection of neuraminidase inhibiting structures; a) Neuraminidase inhibitors and b) existing 
anti-viral therapeutics. 
Insight into the double displacement neuraminidase mechanism with the predicted formation 
of oxocarbenium ion transition states29 (Scheme 1.3) allowed for the mechanism based design 
of a transition state analogue; 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5Ac2en) (1.8) 
as a potential inhibitor (Figure 1.11a).84  Although inhibition ability was improved from previous 
candidates, this was true for mammalian and pathogenic neuraminidases alike and hence fine-
tuning of this molecule was required in order to gain the desired neuraminidase selectivity.85 
Crystal structures of the influenza neuraminidase86 enabled structure based drug design and 
comparison of neuraminidase active sites allowed for discovery of selective inhibitors of 
pathogenic neuraminidases.85 For example, 4-amino-Neu5Ac2en (1.9) binds with a stronger 
affinity to influenza A neuraminidase compared to neuraminidases from other species (Figure 
1.11a).85 A number of drugs based on the Neu5Ac2en (1.8) inhibitor structure, are commercially 
available such as Zanamivir87 (1.10) which simply has the C4 hydroxyl substituted with a 
guanidine group, and Oseltamivir88 (active metabolite 1.11) whose structure varies more greatly 
from Neu5Ac2en (1.8) (Figure 1.11b). Oseltamivir (active metabolite 1.11) importantly still 
mimics the neuraminidase transition state through its sp2 appended carboxyl and a C5 
acetamido group. 
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 Pseudomonas aeruginosa 
1.3.1 An overview of Pseudomonas aeruginosa 
Pseudomonas aeruginosa (P. aeruginosa) is a versatile, gram negative, opportunistic bacteria. It 
is ubiquitous inhabiting terrestrial, aquatic, animal, human and plant environments alike and 
thrives on moist surfaces and predominantly invokes illness in immuno-compromised humans 
or those with loss of a physical barrier to infection e.g burns or lesions. P. aeruginosa 
colonisation can result in a number of different infections such as urinary tract infections,89 
respiratory system infections,90 and a variety of systemic infections depending on the site of 
affliction.91 This bacteria is generally considered an aerobic pathogen,92 however reports suggest 
that it can adapt to microaerobic or anaerobic growth if required.93 For the majority of healthy 
individuals P. aeruginosa cannot establish an infection and the immune system can overcome 
minor infections. However for immunocompromised individuals, particularly those in hospital, 
this infection can manifest and cause considerable illness. P. aeruginosa has also been shown to 
affect sufferers of cystic fibrosis (CF) with the bacteria displaying many features that contribute 
to significant health issues and even mortality. 
Pseudomonas was first recorded in the 1860s when Fordos investigated a blue-green stain on 
surgical dressings and numerous other hospitalised articles94 and Lucke discovered its 
association with a rod-shaped organism.95 This pigment was later assigned as pyocyanin, a toxin 
released by bacteria such as P. aeruginosa.96 Although full pathogenesis is still yet to be detailed 
it is thought to be multifactorial and a number of virulence factors have been identified: 
production of extracellular proteases for adherence and invasion of host cells, binding to sugars 
on host epithelial cells, toxin secretion, and biofilm formation. Toxin production is thought to 
stimulate the symptoms displayed by patients including fever, low blood pressure, reduced 
urine production, and confusion. Site specific symptoms can also occur such as the development 
of pneumonia in infected lungs. 
Research suggests that P. aeruginosa survival centres around the bacteria having two different 
phases of infection; an initial acute phase whereby the bacteria become established, before 
major modifications and diversification of these colonies to produce a chronic infection.97 This 
complicates treatment designs as acute infection is difficult to detect using available methods 
and upon entering the chronic phase the bacteria are much less susceptible to antibiotic attack. 
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1.3.2 Pseudomonas aeruginosa infection 
P. aeruginosa infections are almost always associated with hosts who have a compromised 
immune defense, for example patients undergoing chemotherapy.98  Although it can colonise 
multiple environmental niches, P. aeruginosa most commonly manifests in the lungs.99  During 
acute infection, P. aeruginosa have high expression of virulence factors such as the flagella and 
secretion of toxins,100 for example, production of pyocyanin protects the bacteria from the 
immune system by triggering neutrophil apoptosis.101 Isolates display a metabolistic and 
mutational rate similar to that of P. aeruginosa isolates from inanimates and are more sensitive 
to antibiotics and immune defences compared to the chronic phase.102 It is apparent that during 
acute infection the bacteria’s main purpose is to establish an infection of the lungs and to 
regulate gene expression to adapt to their new environment.  
The infected environment creates a pressure over P. aeruginosa to select for an adapted 
population leading to diverse colonies which vary greatly from the bacteria involved in early 
onset. These typically have a reduction of virulence factors, are mucoid and mutations are 
selected to reduce quorum sensing103 and increase alginate biosynthesis.104 It is these 
adaptations to the environment (further discussed below) that promotes the permanent 
survival of P. aeruginosa. The extreme diversification of the bacteria during chronic infection 
renders it virtually impossible to eradicate, as a concoction of complex mechanisms would be 
required to eliminate all of the bacteria.  
Biofilm production; during chronic infection there is an increase in the production of an 
extracellular matrix predominantly composed of the negatively charged polysaccharide - 
alginate.105 This is achieved via a mutation of mucA, a gene that expresses a cytoplasmic 
membrane bound protein which acts as an anti σ factor,106 blocking transcription of algT which 
encodes a protein required for expression of the alginate operon.107 Mutations occur preventing 
mucA from binding allowing for an increased expression of σ22 and consequently algT and 
alginate.108 Subsequently, the formation of biofilms provides a mucus layer around the bacteria, 
protecting it from antibiotic attack and immune defences.109 Biofilms also allow for greater 
bacterial diversification which further increases multi-antibiotic resistance. They also aid in 
dispersal events of non-mucoid colonies resulting in the spread of P. aeruginosa to new 
respiratory niches.110 
Reduction of virulence factors; chronic P. aeruginosa isolates are often characterised as lacking 
in pili and flagella thus allowing them to evade some host immune defences.111 Additionally, 
these appendages are of little use after biofilm production whereby the matrix prevents 
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significant movement and so mutations reducing their production prevents a mass energy 
waste.112 
Mutators; alongside variability gained from acute infections diversity is also achieved in chronic 
infections by mutators which occur across chronic populations of P. aeruginosa.112 Mutators can 
mutate up to 1000 times faster than non-mutators and as such promote survival against 
unpredictable stress factors that often occur in the cystic fibrosis lung environment.113 
Additionally the ability of P. aeruginosa to hypermutate promotes the occurrence of sub-
populations with different phenotypes thus allowing for a potential increase in multi-antibiotic 
resistance.114 
Altered metabolic pathways; although P. aeruginosa maintains core metabolism pathways 
throughout infection, isolates from the chronic stage also displayed an adaptation strategy. 
Induction of substrate-specific metabolic pathways occurs allowing for growth in limited 
nutrient environments.115 During the chronic phase, carbon metabolism is regulated by 
catabolite repression control, whereby short chain fatty acids, amino acids and polyamines are 
preferentially metabolised over carbohydrates.116 In cystic fibrosis the sputum often contains 
increased amounts of DNA, lipids, mucin and amino acids that can be used to support growth 
after bacterial manipulation. P. aeruginosa has been shown to up-take these nutrients from the 
sputum and although their uses are unclear, high levels of auxotrophs are often detected in 
isolates.117 
Production of energy under microaerobic or anaerobic conditions; P. aeruginosa is classified 
as an aerobic bacteria, employing oxygen as the terminal electron acceptor.118 However, during 
chronic infection the environment in the lungs can be microaerobic or, as biofilms develop and 
thicken, completely anaerobic.100 P. aeruginosa is able to survive under these conditions by 
upregulating different metabolic pathways and regulators and employing a number of different 
energy producing strategies.119 For example under anaerobic conditions P. aeruginosa: 
− Up-regulates production of the nonspecific OprF porin to allow for diffusion of nitrate 
and nitrite present in the mucus into the cell.120 In low oxygen environments these 
compounds can act as alternate electron acceptors thus allowing for energy production 
via denitrification.  
− Increases expression of proteins involved in arginine metabolism to exploit an increased 
up-take of arginine as a carbon and energy source.121 
− Can use pyruvate as an energy source in niches that are deficient in the compounds 
described above that are otherwise employed for energy production.122  
39 
 
1.3.3 Cystic Fibrosis 
Cystic fibrosis (CF) affects around 100,000 people worldwide and in the U.K alone, every week 
five babies are born with this disease. Sufferers of CF have a highly decreased life expectancy 
with 39 years being the average age of death across Europe (2008-2009).123 CF is caused by 
mutations in the recessive cystic fibrosis transmembrane conductance regulator (CFTR) gene 
which has been shown to encode a protein chloride channel.124 This channel is located on the 
apical membrane of epithelial cells thus mutations can disrupt transport of chloride ion into and 
out of cells.125 Thus causing these tissues to carry defects in the absorptive and secretory 
processes producing an abnormal environment across a number of organs126 and leads to a 
reduction of efficacy. This is particularly significant in the lungs and pancreas where there is an 
accumulation of a more viscous mucus due to osmotic abnormalities, leading to a reduction in 
the delivery of oxygen and digestive enzymes to the blood and digestive system respectively.127 
 Early research regarding CF focussed on identification of the gene responsible for the disease,128 
the protein it encodes129 and the mutations that give rise to the CF phenotype.130 Four 
transcribed sequences thought to contain the CF locus were genetically analysed and a locus on 
human chromosome 7 was found to contain the CFTR nucleotide sequence.131 Transcripts of this 
gene were more prevalent in organs that are directly affected by CF such as the lung and sweat 
glands but there was no significant difference between the number of transcripts in CF tissues 
compared to controls. The complete cDNA sequence was identified and an open reading frame 
encoding a peptide chain of 1480 amino acids, including the initial methionine codon, was 
suggested.129 This polypeptide displays two membrane-spanning domains, two nucleotide-
binding domains and a regulatory domain. It was found to contain characteristics homologous 
to P-glycoprotein132 and thus it was predicted to be an ion transport channel.  
Expression of CFTR into cells that did not natively contain it resulted in an increase in chloride 
conductance when coordinated by ATP133 and provided evidence for CFTR classification as a 
chloride channel mediated by cAMP dependent phosphorylation of the regulatory domain. 
Comparisons of the nucleotide sequence of the CF open reading frame and that from unaffected 
individuals led to the identification of a three base pair deletion resulting in a loss of the 
phenylalanine 508 residue (∆Phe-508).126 Phe508 lies in a sequence highly conserved across 
similar proteins of the nucleotide-binding domain and its mutation has been shown to result in 
a loss of secondary structure and hence the majority of ∆Phe-508CFTR remains in the 
endoplasmic reticulum.134  
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Subsequent research concluded that ∆Phe-508CFTR is not the only mutation that gives rise to 
CF and multiple different mutations can occur.135 However this is by far the most prevalent 
mutation in cystic fibrosis patients; accounting for about 70 % of cases.130 These mutations can 
be categorised according to how they disrupt the normal functioning of CFTR; Class I severely 
reduces protein production,136 Class II causes defective folding,137 Class III produces channels 
that have defective regulation,138 Class IV generates CFTR that can be membrane bound but has 
defective pore properties.139 Class I and Class II cause the most severe symptoms and Class II is 
the most common as it hosts the ∆Phe-508CFTR mutation. 
Up until recently most therapeutics for CF sufferers have targeted management of the 
symptoms instead of attempting to address the causes of these symptoms. For example, 
treatments have focussed on attempting to remove lung mucus using a combination of enzymes 
such as pulmozyme®140 or hypertonic saline to break down the mucus,141 bronchodilator 
drugs142 to relax airways and physiotherapy treatments involving massaging of the back and 
chest. Additionally, other enzymatic treatments are prescribed to target affected organs such as 
the pancreas to aid in regaining proficient absorption of necessary nutrients.143 However, 
although these methods can extend life expectancy and reduce discomfort in CF patients, 
mortality and quality of life is still vastly reduced for sufferers of the disease.  
Recent research has instead focussed on directly tackling the genetic mutation and attempting 
to prevent the detrimental effect this displays on sufferers organs, and in particular their lungs. 
In vitro gene therapy trials proved promising, successfully delivering CFTR cDNA to the airway 
epithelium and correcting the chloride transport defect.144 However, this achievement was 
difficult to replicate in vivo with debates occurring over the type of cells to target and the 
optimal vector to use. 
Genome editing has also been explored as a potential treatment of CF whereby a zinc finger 
nuclease binds to the gene locus nearby the target mutation enabling an endonuclease to cleave 
the DNA allowing for recombination with a non-mutated DNA template.145 “Potentiators” have 
also been developed to regulate the function of the mutated chloride ion channels. This class of 
therapeutics is designed to increase the time that CFTR channels remain open therefore 
allowing for the sufficient movement of chloride ions across the membrane.146 In order to reduce 
mortality rates in CF sufferers, referrals for lung transplants are considered for patients with 
advanced CF and results have been encouraging however this is not a viable option in many 
cases and thus only examined in extremes.147  
  
41 
 
1.3.4 Pseudomonas aeruginosa infection in CF sufferers 
Alongside the issues associated with mutation of the CFTR gene, chronic bacterial infections can 
also occur that are normally eradicated in non-cystic fibrosis individuals. CFTR has been shown 
to act as a receptor for P. aeruginosa binding it to airway walls to aid removal.148 However, in its 
mutated form it is hypothesised that this CFTR-bacterial interaction is disrupted so P. aeruginosa 
removal is consequently reduced. P. aeruginosa is the most common lung disease associated 
with CF and is directly responsible for decreasing the median survival of CF sufferers by over ten 
years.149 A number of P. aeruginosa strains have been genetically sequenced and analysis 
showed each to contain a core genome that has about a 70 % sequence identity across strains.150 
Of these, the PA14 strain is the most common worldwide151 and has high virulence caused by 
pathogenicity islands that are lacking in less virulent strains such as PAO1.152 The P. aeruginosa 
Liverpool epidemic strain (LESB58) is the strain most frequently associated with lung infection 
in CF sufferers153 and displays a wider antibiotic resistance, enhanced virulence and morbidity 
compared to other strains such as PA01.154 Although P. aeruginosa chronic infection has 
historically been limited to CF sufferers and immunocompromised individuals, it has recently 
been reported that this LESB58 strain was able to infect and establish chronic colonisation in 
healthy individuals.153 
Accumulation of the natural P. aeruginosa virulence factors selected for by the pressures of their 
environment and the issues associated with CF contributes highly to patient mortality and 
quality of life. For example P. aeruginosa alginate adds to the already unusually viscous mucus 
in the sputum of CF sufferers thus advancing respiratory insufficiency.155 An additional 
complication for the lungs of CF sufferers infected with P. aeruginosa is the host immune 
response producing a combination of defences that flood to the lungs. A vicious circle of events 
exists whereby infection signals for an over-whelming immune response, which produces 
inflammation and secretion of proteinase enzymes156 which in turn stimulates mucus 
production and promotes the P. aeruginosa bacterial infection. It is not exactly clear how the 
defective chloride ion transport associated with CF leads to a heightened susceptibility and 
longevity of P. aeruginosa infection although hypotheses based around the altered lung surface 
fluid do exist. For example, it has been found that bacterial activity is present in all lung surface 
fluid but most humans can prevent long-term infection using host immune defences. However, 
a higher sodium chloride concentration in the lung fluid of cystic fibrosis sufferers results in them 
lacking the ability to kill some bacteria such as P. aeruginosa.157 It has also been suggested that 
a lack of diffusion of the surface fluid which normally lines the epithelial cells damages the cilia 
and hence they lose bacteria removal efficacy.158   
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1.3.5 Existing treatment for Pseudomonas aeruginosa 
As a result of the challenges associated with P. aeruginosa infections there has been an 
increased focus on therapeutics that directly target elimination of it from CF sufferers lungs. 
Although acute infection is not associated with an immediate decline in lung function, if left 
untreated the bacteria evolve into the highly damaging chronic phase.159 Therefore if P. 
aeruginosa infection is detected in the acute phase, aggressive treatment with antimicrobial 
therapy is used which often results in effective eradication due to the lack of protection available 
to the bacteria in this phase.160 P. aeruginosa treatment employs a combination of a β-lactam 
to block synthesis of the bacterial cell wall161 and an aminoglycoside antibiotic that selectively 
disturb bacterial protein synthesis.162  
Although somewhat effective for acute infections, neither of these mechanisms can target P. 
aeruginosa in the mucoid form; β-lactams are only active against rapidly dividing bacteria 
whereas growth slows in the chronic phase93 and aminogylcosides require internalisation by 
bacterial transport mechanisms which have a highly reduced activity during the anaerobic 
growth that often occurs in the chronic phase.93 Therefore for such treatments to be successful 
it is paramount that detection techniques with an increased sensitivity are developed and 
alternative methods investigated to target P. aeruginosa in its chronic phase.  
Vaccines for CF sufferers have been proposed as another viable strategy to protect this 
vulnerable group from P. aeruginosa infections as they don’t rely on early detection of the 
infection. Nasal and oral vaccines directed toward OprF and Oprl proteins have undergone drug 
trials in healthy individuals and specific antibodies were produced but only partial protection 
was achieved.163 Other research has focussed on directing drugs to target specific P.aeruginosa 
virulence factors. For example, other potential vaccines are under investigation that stimulate 
the production of flagella binding antibodies.164 
Another obvious target for therapeutic disruption is biofilm formation as this occurs in 
conjunction with transition to the chronic phase165 and is heavily involved in bacterial 
protection166 and enabling differentiation.167 This formation of biofilms, which occurs in some 
strains during established infections,168 acts as a physical barrier rendering the bacterium 
virtually impermeable to antibiotics169 and creates an internal environment. Therefore 
therapeutics that prevent P. aeruginosa residing in a mucoid state could be essential for 
enabling treatment of infected individuals, either individually or as part of a multi-drug therapy.  
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1.3.6 PA2794; a potential Pseudomonas aeruginosa therapeutic target 
Genetic analysis of various strains of P. aeruginosa from CF patient isolates and non-CF patient 
isolates revealed a major distinction to be the expression of nan1 (coding for a protein termed 
PA2794). Bacterium collected from CF patients displayed a significantly higher prevalence of 
nan1 expression compared to the other isolates170 and a nan1 knockout was found to be unable 
to colonise the respiratory tract.171 Therefore it was suggested that this gene was influential in 
the ability of some P. aeruginosa strains to colonise the lungs of CF patients. One such role of 
nan1 was proposed to be in adhesion as a correlation was found between P. aeruginosa isolates 
with the nan1 gene and an increased ability to adhere to buccal epithelial cells.172 Another 
potential function was identified when knock-out study of the PA2794 gene locus resulted in a 
reduction in the propensity of the bacteria to form biofilms.173 This role was further confirmed 
by an increase in biofilm production following up regulation of the PA2794 locus.171 However, it 
is unclear how the predicted function of the PA2794 enzyme relates to its apparent importance 
to the P. aeruginosa pathogenic phenotype.  
Early investigations of PA2794 resulted in its assignment as a GH and specifically a 
neuraminidase based on its sequence containing the typical bacterial sialidase motifs.174 
However the importance of Neu5Ac (1.1) cleavage in relation to biofilm formation was disputed 
as Neu5Ac (1.1) was known not to be a component of P. aeruginosa biofilm.175 Therefore it was 
hypothesised that the role of PA2794 in infection could be to catalyse the cleavage of Neu5Ac 
(1.1) on host cells. It was suggested that the extracellular PA2794 enzyme could be involved in 
the cleavage of mammalian Neu5Ac (1.1) exposing a glycan receptor on epithelial cells which 
the bacteria could bind to during initial infection.176 However, previous studies have 
demonstrated that P. aeruginosa isolates from cystic fibrosis differed to isolates from other 
environments in that they did not anchor to the epithelial cells,177 rendering cleavage of Neu5Ac 
(1.1) for P. aeruginosa host binding as unbeneficial for infection. Therefore it was suggested that 
the natural substrate may be a different glycosidically linked nonulosonic sugar, such as 
pseudaminic acid (Pse5Ac7Ac, 1.13). 
Although the natural substrate has not been identified, research suggests that this gene may be 
influential in the propensity for P. aeruginosa to colonise the lungs of CF patients, especially 
during the mucoid phase whereby current treatments are largely ineffective.93 Therefore this 
enzyme presents as an ideal drug target and full enzymatic characterisation would aid in rational 
drug design.  
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 Pseudaminic acids 
1.4.1 Pseudaminic acid structures 
Nonulosonic acids can differentiate in their stereochemistry as well as functionality. 
Pseudaminic acids are rare, non-mammalian nonulosonic acids that belong to this class of 
carbohydrates, and are epimeric at the C5, C7 and C8 positions when compared to Neu5Ac (1.1) 
stereochemistry (Figure 1.12). The general term pseudaminic acid usually relates to the 
Pse5Ac7Ac (1.13) structure which has the most similar functionality to Neu5Ac (1.1), except that 
an acetamido group replaces a hydroxyl at C7 and C9 is de-hydroxylated (Figure 1.12). 
Pse5Ac7Ac (1.13) was first discovered as a component of P. aeruginosa and Shigella Boydii (S. 
Boydii) LPS and NMR used to assign the configuration of this new carbohydrate as ɩ-glycero-ɩ-
manno.178 This carbohydrate has since been identified as biosynthesised by a number of gram 
negative bacteria, including pathogens Aeromonas caviae (A. caviae),179 Helicobacter pylori (H. 
pylori)180 and Campylobacter jejuni (C. jejuni)181 and more recently it has also been discovered 
in a gram positive bacteria; Bacillus thuringiensis (B. thuringiensis).182 
 
Figure 1.12 The structurally related nonulosonic acids; Neu5Ac (1.1) and Pse5Ac7Ac (1.13). 
During the initial identification of Pse5Ac7Ac (1.13), a derivative was also tentatively assigned 
with NMR peaks observed consistent with an N-(3-hydroxybutyryl) group at the C5 position.178 
Subsequent research on other pseudaminic acid structures has highlighted that derivatisation 
of the C5 and C7 acetamido groups is common (Figure 1.13).2 For example, C. jejuni flagellin 
protein is extensively glycosylated with pseudaminic acid in the form of Pse5Ac7Ac (1.13), 
Pse5Am7Ac and minor amounts of other derivatives.183 
 
Figure 1.13 Examples of some pseudaminic acid derivatives.2 
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Pse5Ac7Ac (1.13) and derivatives are most common on bacterial cell surfaces with reports of 
LPS and CPS containing pseudaminic acids as well as pseudaminic acid glycosylated flagella and 
pili. As well as differentiation occurring from the different functionalities present on the C5 and 
C7 acetamido groups2 (Figure 1.13) structural variations occur via the numerous glycosidic 
linkages available in Pse5Ac7Ac (1.13) containing carbohydrates. Unusually for sialic acids, there 
is evidence for Pse5Ac7Ac (1.13) linked in both the α2- and β2- conformation, for example P. 
aeruginosa O13 LPS incorporates a Pse5Ac7Ac(α2-3)˪-FucAm bond (1.14)184 whereas E.coli O136 
LPS has a  Pse5Ac7Ac(β2-4)ᴅ-Gal (1.15) (Figure 1.14).185 Additionally Pse5Ac7Ac (1.13) is more 
commonly found linked within the glycan in LPS and CPS structures rather than at the terminal 
position which is more typical of sialic acids.  
 
 
Figure 1.14 Examples of pseudaminic acid cell surface structures, showing a selection of the different 
glycosidic linkages utilised in nature. 
As well as glycosidic bonds forming with hydroxyls in the sugar ring of Pse5Ac7Ac (1.13), certain 
derivatives allow for binding to the functional groups. For example, the Sinorhizobium fredii (S. 
fredii) CPS is a Pse5Ac7hydroxybutyryl homo-polysaccharide (1.16) with the α glycosidic linkage 
between the anomeric postioin and the hydroxyl group on the C5 N-hydroxybutyryl (Figure 
1.14).186 Investigations into P. aeruginosa PA1244 pili highlighted a pseudaminic acid derivative 
as the terminal sugar of a trisaccharide (1.17) with each pilin monomer found to be glycosylated 
with one trisaccharide (Figure 1.14).187 This trisaccharide (1.17) has also been shown to be the 
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repeating unit in the LPS of P. aeruginosa belonging to the O7 serotype.188 The incorporation of 
pseudaminic acid derivatives are utilised in many P. aeruginosa strains however heterogony 
exists within both the pseudaminic acid derivative utilised and the glycan sequence and 
structure. 
The positioning of pseudaminic acid derivatives on bacterial cell surface structures such as 
flagella, pili, CPS and LPS, suggests a potential pathogenic role.189 Therefore research focussed 
on confirming whether incorporation of Pse5Ac7Ac (1.13) (and derivatives) offers a selective 
advantage has shown that Pse5Ac7Ac (1.13) can have a direct role in the functioning of virulence 
factors.2 For example, C. jejuni flagellin proteins (such as FlaA1) are glycosylated with Pse5Ac7Ac 
(1.13) monosaccharides (or a derivative) at 19 sites.183 Mutations to C. jejuni Pse5Ac7Ac (1.13) 
biosynthetic genes resulted in incorrectly assembled flagellar and reduced motility.190 Similarly 
H. pylori FlaA and FlaB flagellin proteins have been found to be exclusively glycosylated with 
Pse5Ac7Ac (1.13) and prevention of flagellin glycosylation resulted in no detectable flagella and 
non-motile bacterium.180 As motility has previously been shown to be a key factor in the ability 
of these two bacteria to establish an infection,191-192 it can be suggested that therapeutics 
targeting the Pse5Ac7Ac (1.19) flagellin glycosylation process could reduce the virulence of such 
bacteria. 
Furthermore it has been proposed that Pse5Ac7Ac (1.13) has a role in bacterial evasion from 
the host immune system as it has structural similarities with Neu5Ac (1.1) (a prevalent host 
sugar). Therefore glycosylation with this sugar may prevent the pathogenic bacteria from being 
recognised as a foreign body. For example, many pathogens manipulate host immune system 
by binding to receptors promoting interleukin-10 induction which can supress immune 
responses.193 C. jejuni FlaA1 was found to be important for binding to siglec-10 (a host immune 
system glycan receptor) and when mutations prevented glycosylation with Pse5Ac7Ac (1.13) 
there was a significant decrease in the induction of interleukin-10. Thus suggesting that 
Pse5Ac7Ac (1.13) can be recognised by siglec-10 and can mediate immune responses.194  
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1.4.2 Chemical synthetic routes towards pseudaminic acid 
Although Pse5Ac7Ac (1.13) is structurally similar to the ubiquitous, commercially available sugar 
Neu5Ac (1.1) (Figure 1.16), synthesis of Pse5Ac7Ac (1.13) has proven to be much more 
challenging. The main complications can be attributed to the epimeric stereochemistry at the 
C5 position and the different desired functionality and stereochemistry on the propyl chain. A 
number of syntheses have been attempted but an economically viable, facile, high yielding 
synthesis is yet to be developed which would allow for large scale synthesis of this rare sugar. 
Chemical syntheses of Pse5Ac7Ac (1.13) have tended to adopt one of two approaches; synthesis 
of the biosynthetic precursor (or stereoisomers thereof) followed by a condensation reaction to 
attach the functionalised propyl chain, or via manipulation of structurally similar nonulosonic 
acids to gain the desired pseudaminic acid functionality and stereochemistry.  
 
Scheme 1.4 Attempted synthetic routes to Pse5Ac7Ac (1.13) producing a number of stereoisomeric 
products adapted from a) Knirel195 and b) Ito196. Reagents and conditions:  
a) 1) Seventeen steps; (i) Bu2SnO, benzene, reflux, then BnBr, Bu4NBr, benzene, reflux. (ii) MeONa, MeOH. 
(iii) 2,2-dimethoxypropane, PTSA, acetone, rt. (iv) oxalyl chloride, DMSO, i-Pr2NEt, CH2Cl2, -60 °C. (v) 
NaBH4, aq EtOH, rt. (vi) 80 % aq AcOH, 40 °C. (vii) Bu2SnO, benzene, reflux. (viii) BzCl, benzene, 0 °C-rt. 
(ix) Tf2O, pyridine, CH2Cl2, 0 °C. (x) Bu4NN3, toluene, 60 C. (xi) NaN3, DMF, dibenzo-18-crown-6, rt. (xii) 
NaN3, DMF, r.t. (xiii) LiAlH4, THF, 0 °C-r.t. (xiv) Ac2O, MeOH, r.t. (xv) MsCl, pyridine, CH2Cl2, 0 °C-r.t. (xvi) 
AcONa, aq 2-methoxyethanol, reflux. (xvii) H2, Pd(OH)2/C, aq MeOH, 35 °C.   
2) One step; (i) oxalacetic acid, Na2B4O7, pH 10.5, r.t. 
b) 1) Nine steps; (i) BaO, Ba(OH)2, DMF, benzyl bromide then formic acid, rt, 18 hrs. (ii) I2, PPh3, imidazole, 
THF, 0 °C, 2 hrs. (iii) TIPSOTf, 2,6-lutidine, CH2Cl2, 12 hrs. (iv) t-BuOK, THF, 70 °C, 10 hrs, then TBAF, THF, 
2 hrs. (v) H2, RhCl(PPh3)3, benzene, EtOH, 3 hrs. (vi) Dess-Martin periodinane, NaHCO3, CH2Cl2, 17 hrs. (vii) 
MeONH2.HCl, NaHCO3, MeOH, 65 °C, 17 hrs. (viii) SmI2, MeOH, THF, 12 hrs, then Ac2O, pyridine, 6 hrs. (ix) 
H2, Pd(OH)2, EtOH, 4 hrs.  
2) Three steps; (i) In, 0.1 N HCl-EtOH (1:6) 40 °C, 12 hrs. (ii) O3, MeOH, -78 °C, then 30 % H2O2, H2O, HCO2H, 
90 min. (iii) TEA-H2O (1:3), 0 °C, 2 hrs. 
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Knirel et al detailed the first synthesis of Pse5Ac7Ac (1.13) in 2001 using the first approach 
detailed above (Scheme 1.4a).195 Although this was a significant breakthrough, issues were 
highlighted, such as the lengthy 17-step synthesis of the precursor sugar (1.19) for which many 
steps only gave poor yields and required expensive and toxic reagents. The ultimate 
disadvantage of this synthesis was that it was impossible to control stereochemistry of the 
product during conversion from the key intermediate (1.19) and oxalacetic acid, thus only 
forming Pse5Ac7Ac (1.13) as the minor product. Ito et al followed a similar approach and 
documented a novel synthesis to the biosynthetic precursor (1.22) with the aim that the 
alternative stereochemistry of this sugar would improve the stereoselectivity of the 
condensation reaction.196 Unfortunately two stereoisomers (1.23) prevailed and optimisation 
could still only select for the desired conformation marginally more than the undesired (Scheme 
1.4b). Additionally this synthesis also suffered from requiring toxic and costly reagents with 
steps that only produced low yields of desired product. 
Scheme 1.5 Attempted synthetic routes to Pse5Ac7Ac (1.13) from Neu5Ac (1.1) via a key 5,7 bis-azide 
intermediate (1.25). Reagents and conditions: 
1) Six steps; (i) NaNO2, Ac2OH-AcOH (2:1), 0 °C, 1 hr, then 50 °C, 6 hrs. (ii) MeONa, MeOH. (iii) 2,2-
dimethoxypropane, PTSA, acetone, r.t. (iv) Imidazole, TBDMS-Cl, DMF, r.t, 16 hrs. (v) Ac2O, pyridine, r.t, 
overnight. (vi) Tf2O, pyridine, CHCl2, -78 °C, 10 mins, then 0 °C, 1 hr and 0 °C-r.t 5 hrs. 
2) One step; NaN3, DMF, Ar (g), 0 °C, then 4 °C, 24 hrs. 
3) Thirteen steps; (i) 50 % aq. TFA, CHCl2 0-r.t, 2 hrs. (ii) TBDMS-Cl, imidazole, DMF, r.t, 16 hrs. (iii) Dess-
Martin periodinane, CHCl2, r.t, 2 hrs. (iv) BH3.THF, THF, r.t, 16 hrs. (v) Ac2O, pyridine, DMAP, r.t, 12 hrs. 
(vi) p-TSOH.H2O, Pd(OH)2/C, H2, MeOH, r.t, 2 hrs. (vii) Ac2O, pyridine, r.t, 12 hrs. (viii) TFA, THF-H2O (4:1), 
r.t, 30 mins. (ix) NaOMe, MeOH, r.t, 2 hrs. (x) I2, PPh3, imidazole, THF, 60 °C, 2 hrs. (xi) iPr2EtN, Pd(OH)2/C, 
H2, MeOH, r.t, 16 hrs. (xii) aq. NaOH (1 M), 40 °C, 1 hr. (xiii) Dowex-50WX8(H+), 80 °C, 36 hrs. 
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A second approach has been explored by Kiefel197 who noted that a protected 5,7 bis-azide 
(1.25) with the desired stereochemistry could be produced from the readily available Neu5Ac 
(1.1) to form a key intermediate in the pathway to Pse5Ac7Ac (1.13) (Scheme 1.5). However 
even synthesis of this intermediate required vast optimisation with each step requiring multiple 
attempts in order to produce satisfactory yields.197 Further issues developed later in the 
pathway when upon reduction of the azides, undesired products were predominantly formed 
with little desired Pse5Ac7Ac (1.13) under a number of different conditions.198 Eventually a 
synthesis to Pse5Ac7Ac (1.13) was reported in 17 steps using the optimised synthesis of the bis-
azide (1.25) (Scheme 1.5).198 All of these chemical syntheses suffer from being unable to control 
stereoselectivity, use of expensive and/or toxic reagents and ultimately have only been able to 
produce minor amounts of Pse5Ac7Ac (1.13) in very low yields. Additionally, major 
modifications of these syntheses would be required in order to introduce different 
functionalities at the desired sites to mimic the natural derivatives or produce chemical probes.  
A new chemical route has recently been developed involving two chain elongations to produce 
pseudaminic acid structures, including those with different acetamido functionalities, which can 
undergo glycosylation.199 Protected ˪-allo-threonine (1.27) was synthesised from the low-cost ˪-
threonine starting material (1.26), protected (1.28) and reacted with a glycine thioester isonitrile 
(1.29) in an aldol-type reaction200 to produce two stereoisomers of a di-amino skeleton (1.30) 
(Scheme 1.6). To drive the stereoselectivity of the coupling reaction to that of the desired 
product a large screen of ˪-allo-threonine (1.20) protecting groups, solvents and catalysts was 
completed and achieved a maximal selectivity of 5:1 desired:undesired.199 After conversion of 
the thioester (1.30) to an aldehyde (1.31), the second elongation step was performed utilising 
an indium-mediated Barbier-type allylation201 (1.33) and resulting isomers purified. Partial 
deprotection followed by alkene cleavage and acetylation led to the formation of a cyclised 
sugar (1.35) with the same stereochemistry as Pse5Ac7Ac (1.13) (Scheme 1.6). This product was 
then used in the desired glycosylation as well as being used to yield Pse5Ac7Ac (1.13) via 
removal of the protecting groups.  
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Scheme 1.6 A novel synthetic route to pseudaminic acid derivatives producing a protected nonulosonic 
sugar with the desired pseudaminic acid stereochemistry. Reagents and conditions: 
1) Six steps; (i) SOCl2, MeOH, reflux. (ii) AcCl, ET3N, CHCl2. (iii) SOCl2. (iv) 10 % aq. HCl, reflux. (v) CbzCl, 
Na2CO3, H2O. (vi) MeI, KHCO3, DMF. 
2) One step; DMP, BF3.OEt2, DCM, 12 hrs.  
3) Four steps; (i) NaBH4, CaCl2, EtOH-THF, 24 hrs. (ii) BAIB, TEMPO, CH2CL2, 0 °C-r.t, 10 hrs. (iii) LiOTf, 
iPr2Net, DCE-DMF, r.t, 3 hrs. (iv) THF-H2O, reflux, 10 hrs.  
4) One step; Et3SiH, Pd/C, THF, 3 hrs.  
5) One step; Indium powder, NH4Cl, EtOH, 2 hrs.  
6)  Six steps; (i) Dess-Martin periodinane, CHCl2, 0 °C, 2 hrs. (ii) TBAF, HOAc, THF, 1 hr. (iii) NaBH(OAc)3, 
HOAc, MeCN, -40 to -20 °C, 10 hrs. (iv) HOAc, H2O, 50 °C, 20 hrs. (v) 3 % aq. HCl in MeOH, 0 °C to r.t, 8 
hrs. (vi) TrocCl, 0.5 M Na2CO3, MeCN, 2hrs. 
7)  Two steps; (i)O3, CHCl2, -78 °C, 30 mins, then Me2S. (ii) Ac2O, pyridine, DMAP. 
8) Six steps; (i) TolSH, BF3.OEt2, CHCl2, 16 hrs. (ii) BnOH, TolSCl, AgOTf, AW-300 MS, -78 °C. (iii) Zn (s), 
Ac2O, HOAc, 40 °C, 3 hrs. (iv) Pd/C, H2, NH4OAc, MeOH-CH2Cl2, 1 hr. (v) aq. LiOH, MeOH-THF (4:1), r.t, 
24 hrs. (vi) Pd/C, H2, MeOH-H2O, 12 hrs. 
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This work not only constitutes a significant improvement in the synthesis of Pse5Ac7Ac (1.13); 
higher yields, lower cost of reagents, higher control of stereochemistry, but allows for other 
natural pseudaminic acid structures to be synthesised which has long since been a desired 
synthetic characteristic, but previously unachievable. Despite these advantages, this chemical 
synthesis to Pse5Ac7Ac (1.13) is still lengthy, time-consuming and requires high skill for optimal 
production. Furthermore, it would be deemed unsuitable for large scale synthesis of Pse5Ac7Ac 
(1.13) due to low atom economy and yield. Notably, the highest yield of Pse5Ac7Ac (1.13) 
recorded was 11 % from any chemical method discussed and only produced 15 mg Pse5Ac7Ac 
(1.13).199  
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 Aims 
Following the discovery of the first example of the N-linked glycosylation biosynthetic 
pathway in 2002,202 the study of protein glycosylation in bacteria has undergone an 
exponential research boom which has revealed a plethora of new carbohydrate 
processing enzymes which are potential antibacterial therapeutic targets. Enzymes 
active on non-mammalian glycans hold particular promise for biochemical 
characterisation and inhibition as the workload of designing small molecules with 
specificity for only a bacterial enzyme with no off target binding to human enzymes is 
greatly increased. One such sugar is pseudaminic acid which has been identified on a 
number of different pathogens and is associated with virulence,2 for example as a 
constituent of Pseudomonas aeruginosa LPS and pili.178, 187 Specifically, the 
uncharacterised enzyme, PA2794 from Pseudomonas aeruginosa has been shown to be 
involved in biofilm formation173 and has been identified as a putative pseudaminidase.3 
Although the proposed function has yet to be unequivocally defined, transition state 
mimics, akin to those used as inhibitors of neuraminidases, but based on the 
pseudaminic acid scaffold, have been proposed as potential inhibitors of PA2794.3 These 
may have therapeutically beneficial effects on biofilm formation in P. aeruginosa, with 
specific application in the treatment of cystic fibrosis patients colonised by this 
archetypal biofilm bacteria.173 
Primary aims of this thesis were therefore to 1) definitively assign the function of 
PA2794 and elucidate the mechanistic and structural details of its proposed activity on 
pseudaminic acid. It follows that any structural insight gained could be used to guide 
rational drug design efforts in a longer term goal. However the characterisation of 
PA2794 and other potential processing enzymes would require access to a number of 
pseudaminic acid based chemical probes and analogues which have not previously been 
synthesised. Therefore another primary aim of the project was 2) to develop a strategy 
for the production of the pseudaminic acid derivative, Pse5Ac7Ac (1.13) on a large scale 
(>100 mg) in order to supply the quantity of material required for future studies into 
the synthetic derivatisation into chemical based enzymatic probes. 
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As detailed in section 1.4.2, the existing synthetic routes to Pse5Ac7Ac (1.13) have a 
number of shortcomings, and as such were deemed unfitting for development in this 
project. Instead we envisaged that the Pse5Ac7Ac (1.13) enzymatic pathway could be 
recapitulated in vitro to ensure production of the sugar on a large scale in a simple and 
economically viable process. Although previous research had demonstrated that the 
Pse5Ac7Ac (1.13) biosynthetic enzymes could be utilised in a one-pot system to 
synthesise Pse5Ac7Ac (1.13) from UDP-GlcNAc (3.1),203 the method has yet to be utilised 
widely in the literature, and is also unsuitable for large scale production of Pse5Ac7Ac 
(1.13). This is likely due to limitations arising from enzyme insolubility, unwanted by-
product formation, the excessive cost of required co-factors and the challenges of final 
purification of Pse5Ac7Ac (1.13). 
Therefore, herein we sought to optimise this biosynthetic strategy, specifically focussing 
on the development of an augmented chemoenzymatic route, where; 
i) the production of biosynthetic enzymes was optimised, 
ii) the ratio of enzyme concentration was optimised through biochemical 
exploration, and 
iii) the cost, scalability and flexibility of pseudaminic acid production were 
improved through co-factor replacement.  
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2.1 Introduction 
2.1.1 Neuraminic acid analogues as chemical probes  
Characterising carbohydrate processing enzymes holds a high degree of interest due to the 
ubiquitous and complex nature of sugar molecules and their role in mediating disease and 
infection.13 In order to characterise and categorise such enzymes it is desired to; observe 
activity, elucidate mechanisms and investigate essential enzymatic components. Such 
information is often acquired utilising a combination of structural analysis204 and in vitro 
biochemical assays,205 which require isolated, purified enzyme and analogues of the natural 
substrate/product.206  
Neuraminidases have been extensively studied due to their importance in controlling the level 
of Neu5Ac (1.1) glycosylation which is essential for normal cell functioning48 and interactions 
with invading cells during in infection.74 For example, microorganisms have been shown to 
cleave host Neu5Ac (1.1) from cell surface structures to enable adhesion to the remaining cell 
surface structure207 and have their own sialic acid glycosylation which can aid in preventing 
activation of immune responses.208 As Neu5Ac (1.1) is a ubiquitous terminal saccharide in 
glycoproteins and glycolipids in the cell membrane,209 thorough investigations of 
neuraminidases have been utilised to understand the specifics of each enzyme. This detailed 
characterisation using a number of different Neu5Ac (1.1) analogues has enabled rational drug 
design and allowed for selective targeting of the desired neuraminidase.210  
 
Scheme 2.1 Neu5Ac (1.1) anomeric configurations as the monosaccharide in aqueous solution and during 
GT catalysed glycosylation and GH catalysed cleavage. 
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Neu5Ac (1.1) is exclusively bound as the α-anomer in glycans (5.1), and all exo-neuraminidases 
have been found to release Neu5Ac (1.1) with retention of the α-configuration.211 However in 
solution, mutorotation to the β-anomer quickly occurs as this is the more thermodynamically 
favourable configuration (Scheme 2.1). This β-configuration is retained during the enzyme 
catalysed formation of the nucleotide activated sugar212 and hence sialyltransferases are utilised 
to invert the stereochemistry to the α-anomer (2.1) during the enzyme catalysed glycosidic bond 
formation (Scheme 2.1).213 As a result all GH and GT Neu5Ac (1.1) chemical probes have been 
designed to mimic the anomeric configuration and any commercially available probes are 
exclusively α-linked. A number of methods exist for quantifying neuraminidase activity and 
either utilise coupled reactions or modified substrates to increase sensitivity.  Neuraminidase 
activity kits are commercially available and quantify release of Neu5Ac (1.1) by addition of 
reagents that react with free Neu5Ac (1.1) to convert it into colorimetric products. For example, 
the thiobarbituric assay relies on oxidation of free Neu5Ac (1.1) to form β-formylpyruvic acid 
(2.2) which can then react with added thiobarbituric acid (2.3) to produce a chromophore (2.4) 
(Scheme 2.2).214 Therefore enzymatic activity for Neu5Ac (1.1) cleavage can be calculated based 
on detection of the chromophore (Abs532) which is more sensitive than detecting Neu5Ac (1.1). 
 
Scheme 2.2 Thiobarbituric assay; a coupled reaction to observe enzymatic cleavage of Neu5Ac (1.1). 
Neu5Ac (1.1) is oxidised so that it can act as a linker for two thiobarbituric acid (2.3) molecules producing 
a chromophore that can be detected as an indicator of linked Neu5Ac (2.1) cleavage. 
However the most common method for neuraminidase activity quantification utilises Neu5Ac 
(1.1) glycosidically linked to a fluorophore such as 4-methylumbelliferone (2.5)215 or para-
nitrophenol (2.6) and measures the release of said fluorophore (Figure 2.1a). These assays have 
been shown to be both more sensitive and specific than the coupled assays. Additionally unlike 
coupled reactions, they don’t require the use of multiple steps or addition of other reagents to 
favour a secondary reaction to convert Neu5Ac (1.1) into a more detectable structure. However 
although it can be normalised, it doesn’t make use of the natural substrates and hence the 
absolute activity of the enzyme of interest cannot be calculated. For example, some 
neuraminidase active sites may be able to better accommodate the fluorophore, affecting the 
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observed activity of the enzyme. Therefore complementary assays are often used, alongside 
structural observations in order to fully understand and compare the observed neuraminidase 
activity with fluorometric assays. 
 
Figure 2.1 Structures of Neu5Ac (1.1) chemical probes; a) Neu5Ac fluorophores 4-methylumbelliferyl-α-
Neu5Ac (2.5) and p-nitrophenyl-α-Neu5Ac (2.6), and b) a neuraminidase inhibitor Neu5Ac2en (1.8) and 
covalent inactivator 2,3-difluoro-Neu5Ac (2.7). 
Alongside the proposal of Neu5Ac2en (1.8) as a neuraminidase inhibitor, mechanistic and 
structural insight into neuraminidases allowed for predictions of structures that could act as 
neuraminidase covalent inactivators. In turn these inactivators have been used to further probe 
the active site for extra details, such as for identification of catalytic residues and for observation 
of the sugar conformation in the enzyme-bound intermediate (Scheme 1.3, Page 33). 
Knowledge of the retaining mechanism led to the design of molecules that were proposed to 
increase the rate of formation of the enzyme-bound intermediate but decrease the rate of the 
deglycosylation step, to prevent release of Neu5Ac (1.1). Fluorinated Neu5Ac analogues were 
identified as ideal candidates as they could drastically change the reactivity of the sugar 
molecule without incurring potential steric issues. In order to attenuate release of Neu5Ac (1.1), 
structures were designed that would de-stabilise formation of the oxocarbenium ion transition 
state such as introduction of an electronegative group at the C3 position. As both the 
glycosylation and deglycosylation steps occur via an oxocarbenium ion transition state both 
steps of the reaction would be slowed. Therefore to compensate for this in the glycosylation 
step, addition of a good leaving group but poor nucleophile at C2, was suggested, to promote 
attack of the nucleophilic residue and increase formation of the enzyme-bound intermediate. 
Incorporation of fluorine at the C2 and C3 positions in Neu5Ac (2.7) has been shown to increase 
the first step in the neuraminidase mechanism and drastically reduce the second step; trapping 
the sugar in the enzyme bound state (Scheme 1.3). Hence enzyme crystallographic studies in 
complex with 2,3-difluoro-Neu5Ac (2.7) have aided in identification of the nucleophilic catalytic 
residue and prediction of active site residues involved in intermediate interactions (Figure 2.1b). 
58 
 
2.1.2  PA2794 as a pseudaminidase   
Although a plethora of research exists surrounding the biosynthesis of Pse5Ac7Ac (1.13),2, 216 
investigations into pseudaminic acid processing enzymes are very rare.  This is mainly attributed 
to the lack of access to pseudaminic acid analogues required for probing enzymatic reactions. 
However a motility-associated factor protein, maf1, that is considered a transferase enzyme, 
has been investigated in A. caviae for its ability to transfer pseudaminic acid onto flagellin.217 
Additionally, A. baumannii KpsS1 has been identified as putative pseudaminyl transferase based 
on its sequence homology to a E. coli Kdo transferase.218 A glycosidase from P. aeruginosa 
PA2794, has also been tentatively assigned as a pseudaminidase based on its sequence 
homology to neuraminidases and information gained from the crystal  structure.3  
Biochemical assays in an attempt to identify the PA2794 natural substrate have thus far been 
inconclusive.  In vitro activity assays monitoring the release of Neu5Ac (1.1) often suggest very 
muted activity and different studies are contradictory in their results. For example, early 
research reported detection of PA2794 cleaved Neu5Ac (1.1) in a fluorogenic assay and 
thiobarbituric assay using a partially purified enzyme,219 however, subsequent fluorogenic 
assays using pure protein have failed to reproduce such results.3 Therefore other structurally 
related nonulosonic acid structures, such as Pse5Ac7Ac (1.13), have been considered for their 
potential as the natural product (Figure 2.2). 
 
Figure 2.2 Nonulosonic acid structures proposed as the potential PA2794 product. 
In order to gain further information on the natural substrate of PA2794, X-ray crystallography 
studies were performed. The X-ray crystal structure of PA2794 highlighted that the enzyme 
displays the neuraminidase characteristic six-bladed β-propeller domain174 which, in PA2794, is 
linked to an immunoglobulin-like domain (Figure 2.3).3 The PA2794 C-terminus domain has a 
similar structure to the M. viridifaciens neuraminidase (R.M.S 2.32 Å for 282 Cα atoms) although 
they do not display high sequence homology.3 As with neuraminidases the three PA2794 Asp-
boxes are situated between the blades and overlap significantly with three of the Asp-boxes 
from the M. viridifaciens neuraminidase (Figure 2.3). The structural conservation of the Asp 
boxes highlights importance of this moiety in forming the overall fold of the catalytic domain. 
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Figure 2.3 Overall crystal structure of PA2794 (lilac) (PDB 2W38)3 overlaid with the M. viridifaciens 
neuraminidase (light blue) (PDB 1EUS)1 with the characteristic Asp-box sites highlighted (purple-PA2794 
and dark cyan-neuraminidase). 
Bacterial exo-sialidase active site residues are generally well conserved,174 with 
invariantcatalytic residues and active site side chain conformations, however the PA2794 active 
site deviates from some of these features. In particular, PA2794 orientates a phenylalanine ring 
with an alternate conformation to archetypal sialidases such as a sialidase from 
Micromonospora viridifaciens (M. viridifaciens).1 During in silico docking studies, the Phe129 ring 
conformation was shown to sterically clash with the C5 N-acetyl in Neu5Ac2en (1.8) but 
accommodate the stereoisomeric C5 N-acetyl of Pse5Ac7Ac (1.13) (Figure 2.4a).3 An arginine 
triad exists in the active site of all characterised neuraminidases that interacts with the 
carboxylate group. PA2794 displays arginine residues at sites equivalent to the second and third 
arginine residues in neuraminidases but a histidine residue occupies the site of the first arginine 
(Figure 2.4a).3 
The tyrosine-glutamine pair that are canonical in neuraminidases were identified as the most 
likely residues to act as a catalytic nucleophile in PA2794 (Tyr297-Glu182). Comparison of the 
side chain configurations of these residues with the M. viridifaciens neuraminidase shows that 
they are held in very similar conformations with access to the predicted substrate binding site 
(Figure 2.4b). PA2794 displays a loop in the active site that is homologous to neuraminidases 
and commonly consists of an aspartic acid that acts as the catalytic acid/base residue. However 
in PA2794 at the equivalent site in the loop there is no aspartic acid residue. Instead, the 
predicted acid/base catalytic residue is His45 which can exist as both an acid and base through 
a charge relay system with a nearby Tyr and Glu (Figure 2.4b).3  
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Figure 2.4 Crystal structure of PA2794 active site residues (purple) (PDB 2W38)3 overlaid with a sialidase 
(cyan) in complex with Neu5Ac2en (1.8) (green, ball and stick model) (PDB 1EUS).1 Highlighting differences 
in a) the orientation of conserved neuraminidase active site residues, and b) the arrangement of the 
catalytic residues. 
These structural differences imply that the PA2794 enzyme is a nonulosonic acid GH, but not a 
neuraminidase. In particular the orientation of the Phe129 ring indicates that the enzyme is a 
pseudaminidase based on the Pse5Ac7Ac (1.13) stereochemistry at the C5 position. Additionally 
this prediction is rationalised as Pse5Ac7Ac (1.13) is a natural P. aeruginosa nonulosonic acid 
and expression of a pseudaminidase could aid in control of the level of glycosylation of the LPS 
and pili.178, 184, 188 Investigation of the structure of P. aeruginosa O-7 and O-9 antigens in 1984 
identified a trisaccharide repeating unit with a novel sugar structure; Pse5Ac7Ac (1.13) in the 
terminal position.178 
 
Figure 2.5 Pseudomonas aeruginosa surface structures a) the O-7 antigen repeating unit and glycosylating 
trisaccharide of strain 1244 pili (2.8) and b) the structure of the O-9 antigen repeating unit (2.9). 
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Further research has elucidated the precise structure of these antigens in each serotype showing 
that Pse5Ac7Ac (1.13) is actually most commonly found as α-linked Pse5RHb7Fo (2.8) in O-7 
antigens (Figure 2.5a) and β-linked Pse5Ac7RHb (2.9) in O-9 antigens (Figure 2.5b), with some 
structures also acetylated at the C4 hydroxyl. The O-7 α-linked trisaccharide has also been found 
to glycosylate P. aeruginosa 1244 pilin (Figure 2.5b)187 and stimulate an immune-response in 
mice models that targets the P. aeruginosa O-7 antigen.220 Based on the prediction that a 
pseudaminic acid glycoside is the natural substrate for PA2794, it is unsurprising that attempts 
to characterise this enzyme with neuraminic acid glycosides were unsuccessful. As the proposed 
mechanism3 is consistent with that of the retaining exo-sialidases,40 it was suggested that 
effective pseudaminidase probes (2.10-2.14) could be designed based on the Neu5Ac analogues 
(1.8, 2.5-2.7) (Figure 2.6). For example, it was hypothesised that pseudaminidase activity could 
be measured via monitoring release of a fluorophore from an α- or β- linked Pse5Ac7Ac 
glycoside (2.10, 2.11) (Figure 2.6a). Additionally it was noted that Pse5Ac7ac2en (2.12) should 
behave as an inhibitor and that di-fluorinatedPse5Ac7Ac (2.13, 2.14) (Figure 2.6b) have 
potential as covalent inactivators for the reasons discussed above with Neu5Ac analogues. 
 
Figure 2.6 Proposed structures of pseudaminic acid chemical probes; a) α- and β- linked fluorophores 
(2.10, 2.11) and b) the structure of the predicted pseudaminidase intermediate (2.12) and covalent 
inactivators (2.13, 2.14). 
Unfortunately, as previously discussed, even the synthesis of the most simple pseudaminic acid; 
Pse5Ac7Ac (1.13) is challenging and currently there are no efficient strategies to synthesise 
Pse5Ac7Ac (1.13) on a large scale (> 100 mg) which would allow for further modifications to 
form the desired chemical probes. Although full characterisation is desired it was proposed that 
preliminary investigations of PA2794 could still aid in rational drug design by elucidating the 
natural substrate. Therefore initial investigations focussed on attempting to attain structural 
evidence for the natural substrate utilising crystal structures in complex with Pse5Ac7Ac (1.13). 
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2.2 Expression and purification of PA2794 and PA2794 F129A 
2.2.1 Transformation and expression of PA2794 and a PA2794 F129A mutant 
A recombinant plasmid based on pET15b was designed containing a T7 promoter site upstream 
of a number of sequences coding for restriction enzymes and a hexa-his tag coding sequence 
upstream of a thrombin cleavage site. To afford PA2794 with a N-terminal hexa-His tag, the 
plasmid was designed to incorporate the PA2794 gene sequence into the plasmid between NdeI 
and BamHI restriction enzyme sites using codons optimised for E. coli (Appendix 1). The 
resulting recombinant plasmid (purchased from GenScript) was transformed via heat shock into 
chemically competent E.coli BL21 DE3 cells and deemed successful by a display of ampicillin 
resistance during growth on LB agar.  
Incorporation of the PA2794 recombinant plasmid did not appear to be detrimental to bacterial 
growth which was monitored prior to induction of the protein of interest. Although a protocol 
for expression and purification of PA2794 has previously been determined, incubation 
temperature and time after induction were investigated in order to optimise expression levels 
(Table 2.1). Prior to induction, a culture sample was taken from each condition and treated 
exactly the same but without the addition of IPTG to provide an indication of the expression 
levels of E. coli proteins. Expression levels were determined using SDS PAGE analysis of crude 
lysates from small scale grows up under these induction conditions (Figure 2.7).  
Samples that had been induced with IPTG displayed an over-expressed protein between the 
marker 45.0 kDa and 66.2 kDa bands (Figure 2.7a) which was much less prominent in samples 
that had not been induced (Figure 2.7b). Therefore this band was tentatively assigned as 
corresponding to the desired protein PA2794 (47.1 kDa). There were a number of other 
significant proteins detected by SDS-PAGE, such as one at ~ 25 kDa, which were thought to 
potentially be truncated PA2794 protein and could require further investigation of expression 
conditions. However as these were also present in the non-induced samples they were assigned 
as highly expressed E. coli proteins and not over-expressed truncated PA2794 (Figure 2.7).  
Upon varying the concentration of IPTG there was no significant difference observed in the level 
of expression between induction with 0.1 mM and 0.5 mM IPTG. However, it was apparent that 
expression levels could be slightly increased by inducing at a temperature of 37 °C compared to 
16 °C and by leaving the cells to grow for longer periods of time (Figure 2.7a). Therefore, in 
subsequent grow ups, expression conditions involved incubation of cells at 37 °C for 18 hrs 
following induction with IPTG.  
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Table 2.1 Expression trial conditions to optimise production of PA2794. 
Condition A B C D E F G H 
Post induction 
incubation time 
4 hrs 18 hrs 
IPTG 
concentration 
0.1 mM 0.5 mM 0.1 mM 0.5 mM 
Post induction 
incubation temp 
16 °C 37 °C 16 °C 37 °C 16 °C 37 °C 16 °C 37 °C 
 
 
Figure 2.7 SDS PAGE analysis of crude lysate samples of the PA2794 enzyme a) under different induction 
conditions after induction with 0.1 mM (A, B, E, F) or 0.5 mM (C, D, G, H) IPTG and b) under these 
conditions but with no induction with IPTG.  
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Mutation of the PA2794 phenylalanine 129 to an alanine residue was carried out on this 
recombinant plasmid to afford an enzyme that has previously been suggested to increase 
PA2794 activity with Neu5Ac (1.1) analogues. The forward primer was designed to replace the 
phenylalanine129 codon (TCC) with the most similar codon for an alanine (GCC). PCR utilising a 
Phusion site-directed mutagenesis kit was carried out with a number of different annealing 
temperatures (55 °C-72 °C) and the DNA amplification analysed on an acrylamide gel. The 
presence of a single band on the gel demonstrated successful amplification of a specific length 
of DNA. However the DNA band appeared slightly higher on the gel than expected under all 
conditions, suggesting the amplified DNA may have more base pairs than the desired 
recombinant plasmid (7.2 Kilobases) (Figure 2.8). As it was very unlikely that a larger piece of 
DNA had been amplified with no amplification of the desired plasmid, it was instead suggested 
that this was the correct stretch of DNA and the apparent increase in number of base pairs was 
attributed to analysis error. For example, it is hard to distinguish between the standards with 
large numbers of kilobases as the resolution between them is low. Additionally it was noted that 
the PCR samples were in a different buffer to that of the standards and hence this may affect 
their diffusion through the gel. In order to fully assess the success of the PCR reaction the DNA 
was extracted from the gel and transformed via heat shock into chemically competent E.coli 
BL21 DE3 cells.  
 
Figure 2.8 DNA agarose gel following a point mutation PCR of PA2794 pEt15b recombinant plasmid. 
The growth of these colonies on ampicillin containing LB agar suggested successful amplification 
and transformation of the recombinant plasmid and sequencing of a number of colonies 
(Appendix 2) showed incorporation of the F129A mutation in all cases. Prior to DNA extraction 
the individual colonies were cultured overnight (10 mL LB containing ampicillin 100 µg mL-1) and 
a small sample inoculated on LB agar containing ampicillin 100 µg mL-1 to ensure that colonies 
were available containing the DNA that had been sequenced.   
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2.2.2 Purification of PA2794 and PA2794 F129A 
Following induction of the desired enzyme (PA2794 and PA2794 F129A) in E. coli BL21 DE3 cells 
on a large scale (3 L LB), cell pellets were resuspended and lysed in Tris-HCl buffer (50 mM, pH 
7.5), 10 % glycerol containing 10 mM imidazole, Benzonase (25 U/L grow up) and protease 
inhibitor tablet (used as instructed). Initial purification from other buffer soluble proteins was 
attempted by loading onto a Nickel affinity column and applying an increasing imidazole 
concentration gradient in Tris-HCl buffer (50 mM, pH 7.5) and 10 % glycerol. Presence of a UV 
Abs280 peak during washing with higher concentrations of imidazole (after loading and washing 
the column with low concentrations of imidazole) confirmed over-expression of the His6-tagged 
PA2794 protein (Appendix 3). The eluted protein corresponding to the predominant UV Abs280 
peaks was confirmed as the desired PA2794 or PA2794 F129A enzyme by SDS-PAGE analysis 
which displayed over-expressed protein with the expected molecular weight (Figure 2.9a,b).  
 
Figure 2.9 SDS PAGE analysis of a) PA2794 and b) PA2794 F129A after purification using a Nickel affinity 
column. 
Although this method was successful in purifying PA2794 and PA2794 F129A from the majority 
of the other proteins, impurities are still evident in both samples, especially for enzyme collected 
at the lower concentrations of imidazole. It was proposed that in subsequent purifications this 
could be improved upon by increasing the gradient of imidazole less steeply or by introducing 
step-wise increments in imidazole concentration instead of application of a linear gradient. 
However size exclusion was utilised to improve the purity of the PA2794 and PA2794 F129A 
samples. Elution of the column in Tris-HCl buffer (50 mM, pH 7.5) and 10 % glycerol, resulted in 
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the desired highly pure PA2794, or PA2794 F129A, as observed by one symmetrical peak in the 
gel filtration UV trace (Appendix 4) and only one protein band in the SDS PAGE analysis of the 
fractions whereby an increase in Abs280 was detected (Figure 2.10a,b).  
It was apparent from the SDS PAGE gels that considerably less PA2794 F129A enzyme was 
expressed compared to the native PA2794 enzyme. However satisfactory yields of 9 mg per L of 
LB grow up for PA2794 and 4 mg per L of LB culture for PA2794 F129A were extracted.  Following 
purification, enzymes were concentrated to 3.5 mg mL-1 in Tris-HCl buffer (50 mM, pH 7.5), 10 
% glycerol and flash frozen prior to storage at -80 °C.  
 
 
Figure 2.10 SDS PAGE analysis of a) PA2794 and b) PA2794 F129A following purification with a size 
exclusion column (120 mL, HiLoad 16/600) after a Nickel affinity column.  
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2.3 Characterisation of PA2794 and PA2794 F129A 
2.3.1 PA2794 apo crystal structures 
Crystallisation conditions for PA2794 had been previously published and were utilised as the 
initial conditions for investigations. Sitting drop trays containing well solutions of Bicine (0.1 M, 
pH 4.5, 5.0 or 5.5) and PEG 6K (14 % - 28 %) and drops consisting of 0.3 µL or 0.5 µL PA2794 (3.5 
mg mL-1) and 0.5 µL well solution were constructed. Crystals were observed developing across 
a number of conditions and all formed were cubic and well defined after 10 days. A number of 
drops only contained a single crystal with the maximum recorded size of ~ 0.1 mm x 0.1 mm x 
0.1 mm (Figure 2.11a). However numerous small crystals developed in the drops containing well 
solutions with higher PEG 6 K concentrations (24 % - 28 %) which were deemed too small for 
using in crystallography analysis (Figure 2.11b). Generally to produce crystals suitable for X-ray 
analysis, optimal conditions were; a well solution of Bicine (0.1 M, pH 4.5), PEG 6K 14% -22% or 
Bicine (0.1 M, pH 5.0), PEG 6K 16% - 22%, and a drop consisting of an equal ratio of mother 
liquor and PA2794 enzyme (3.5 mg mL-1).  
 
Figure 2.11 Image of PA2794 crystals developed in well solutions composed of a) Bicine (0.1 M, pH 5.0), 
18 % PEG 6K and b) Bicine (0.1 M, pH 5.0), 24 % PEG 6K   
An individual crystal was removed from the drop, placed in a solution containing the well solutes 
and cryoprotectant (20 % glycerol) and flash frozen. In order to determine if the crystals 
contained regularly orientated proteins and would provide high resolution electron density, in-
house diffraction tests were performed. Crystals displaying a regular diffraction pattern to a 
resolution of 2.3-2.5 Å were selected as suitable for further analysis and stored in liquid nitrogen 
prior to data collection.  
After the collection of X-ray crystallography data (Diamond synchrotron, Oxford), molecular 
replacement using the previously published crystal data was employed to solve the electron 
density and provide a base structure for refinement (CCP4I2). Refinement of the PA2794 apo 
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structure was carried out (RefMac5, Coot) and the electron density was assigned to all of the 
438 residues with a resolution of 1.2 Å and the majority was in strong agreement with the 
previously published structures. However this structure was determined at a higher resolution 
than the published data (1.6 Å) and allowed for the extension of the N-terminal to assign the full 
enzymatic sequence (Figure 2.12). The PA2794 crystal had one monomer per asymmetric unit 
and assigned to the P213 space group with the dimensions a = b = c = 126.6 Å, α = β = γ = 90 ° 
(with data collection statistics reported in Appendix 5). 
 
Figure 2.12 The fully assigned PA2794 crystal structure (ice blue) resolved to 1.2 Å, with the active site 
residues highlighted (grey). 
Overlaying this refined structure with that of the previously published structure shows a strong 
agreement of the overall structure (R.M.S 0.19 Å for 432 Cα atoms) (Figure 2.13a) including the 
conformations of residues in the active site (Figure 2.13b). Importantly the proposed catalytic 
residues are displayed in the same orientation and hence support the mechanism previously 
proposed by Xu et al3 (Figure 2.13b). This mechanism suggests a His-Tyr-Glu charge relay system 
could be utilised as the acid/base catalyst, if there was a rotation of the loop to allow for His45 
to be orientated closer to the sugar. Unfortunately no further evidence was gained for this 
putative acid/base catalytic residue, with the proposed His45, Tyr21, Glu315 charge relay 
system occupying the same orientation as the published structure.3 Additionally the 
conformation of the Phe129 ring overlaps with the previously published (Figure 2.13b), with no 
electron density corresponding to other conformations supporting the notion that this enzyme 
would not be able to accommodate the transition states of nonulosonic acids with an equatorial 
C5 group when in the 2C5 conformation. 
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Figure 2.13 Overlay of the published PA2794 structure (PDB 2w38, lilac, dark purple) and the newly 
refined structure (ice blue, grey), demonstrating the similarity of a) their overall structure, b) active site 
side chain conformations c) electron density observed in the active site, fitted to a bicine molecule. 
Careful allocation of the electron density to the apo structure displays a bicine molecule at the 
edge of the active site which was not assigned in the published structure (Figure 2.13c). It was 
proposed that even though this molecule did not fully occupy the active site it may still compete 
with potential ligands and perturb crystallisation of PA2794 in complex with Pse5Ac7Ac (1.13). 
Additionally both structures have a number of glycerol molecules associated with the enzyme 
however, these were identified in different areas in the different structures indicative that many 
residue sequences can interact with these molecules. 
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2.3.2 PA2794 ligand bound crystal structures 
Based on the existing structural data, a glycosidically linked pseudaminic acid derivative is still 
the main candidate for the PA2794 natural substrate. However structural evidence for this 
hypothesis is lacking as a crystal structure has not been solved complexed with a ligand in the 
active site. In order to rectify this, crystallisation conditions were screened in an attempt to 
collect diffraction data of PA2794 in complex with Pse5Ac7Ac (1.13).  Due to the potential 
competition from bicine molecules that were observed in the active site of an apo structure, 
alternative crystallography conditions were utilised for the following data collection. 
Sitting drop trays containing well solutions of imidazole (0.1 mM, pH 7.5, 8.0 or 8.5) and PEG 8K 
(4 % - 18 %) were constructed. Drops consisting of 0.3 µL or 0.5 µL PA2794 (3.5 mg mL-1) and 0.5 
µL well solution were added alongside the corresponding well solution. Cubic crystals developed 
under some of these new conditions however these crystals were smaller than the previously 
used conditions, even after storage for two weeks.  
Solid Pse5Ac7Ac (1.13) was introduced into drops containing crystals and monitored by eye for 
diffusion throughout the drop. Addition of Pse5Ac7Ac (1.13) caused the immediate 
disintegration of the crystals, suggesting that it was altering the composition of the drop and 
having a detrimental effect on the integrity of the crystalline protein. It was proposed that 
addition of 1 mM Pse5Ac7Ac (1.13) in mother liquour may invoke less drastic changes in the 
drop composition and thus this alternate method for Pse5Ac7Ac (1.13) addition was attempted. 
Addition of Pse5Ac7Ac (1.13) in this way did not appear to affect the crystals and crystals were 
fished after an hour, held in a drop of the mother liquor with 20 % glycerol and flash frozen. 
Electron density data for this crystal was collected as before; with the ligand checked in house 
then sent to the Diamond Synchrotron for data collection. Molecular replacement of the 
resulting data was carried out using the apo structure from this research (CCP4i2), refinement 
was carried out (RefMac5, Coot) and the graphics developed (CCP4MG). 
Co-crystallisation conditions involved addition of Pse5Ac7Ac (1.13) to the purified PA2794 
enzyme to a concentration of 1 mM. Sitting drop trays containing well solutions of imidazole 
(0.1 mM, pH 7.5, 8.0 or 8.5) and PEG 8K (4 % - 18 %) were constructed. Drops consisting of 0.3 
µL or 0.5 µL PA2794 (3.5 mg mL-1), Pse5Ac7Ac (1 mM) and 0.5 µL well solution were added 
alongside the corresponding well solution. No crystalline substances were observed under any 
of the conditions, suggesting that either addition of Pse5Ac7Ac (1.13) had altered the drop 
conditions, preventing crystallisation, or that binding of Pse5Ac7Ac (1.13) had invoked a 
conformational change that would require alternate conditions for crystallisation.   
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Following refinement, the crystal structure developed in the alternate crystallisation conditions 
was superimposed with the apo structure from crystals developed under the original conditions 
(Figure 2.15a). There was some deviation in the position of electron density assigned to solute 
molecules but there was precise agreement (R.M.S 0.20 Å for 432 Cα atoms) between the 
conformation of the PA2794 residues (Figure 2.15a,b). Electron density was observed in the 
PA2794 active site that could not be attributed to the enzymatic structure, however it was much 
smaller than expected for the desired Pse5Ac7Ac (1.13) ligand (Figure 2.15c). Fitting of 
molecules to the electron density elucidated that it could be assigned as a glycerol molecule in 
a favourable rotamer (Figure 2.15b).  
 
Figure 2.15 Overlay of the PA2794 apo structure (ice blue, grey) and the structure soaked with a potential 
ligand; Pse5Ac7Ac (1.13) (coral, gold), demonstrating the similarity of a) their overall structure, b) active 
site side chain conformations and the position of binding of an active site solute molecule, c) electron 
density observed in the active site, fitted to a glycerol molecule.  
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The presence of the bicine (2.15) and glycerol (2.16) molecules in the active site are somewhat 
expected when considering that they mimic portions of the Pse5Ac7Ac (1.13) structure (Figure 
2.16) and are present in high concentrations. Both the glycerol and bicine molecules are bound 
in the active site proximal to where the C6 sugar propane chain is predicted to bind (Figure 2.16).  
Hence it was postulated that attempts to soak Pse5Ac7Ac (1.13) to PA2794 crystals may have 
been unsuccessful due to the glycerol molecule blocking access to the binding site. Even though 
in silico studies have previously demonstrated that Pse5Ac7Ac (1.13) can be docked into the 
PA2794 active site in an energetically favourable conformation,3 it was also hypothesised that 
structural modifications may be required for optimal Pse5Ac7Ac (1.13) binding. Therefore 
providing an explanation for why crystals failed to develop in co-crystallisation trials and why 
crystallised PA2794 does not appear to have a high affinity for Pse5Ac7Ac (1.13).  
 
Figure 2.16 Comparison of the structures of bicine (grey, 2.15) and glycerol (gold, 2.16) and the postions 
they were observed compared to the predicted sugar binding site. 
To promote crystallisation of PA2794 in complex with Pse5Ac7Ac (1.13), it was attempted to 
eliminate the use of bicine or glycerol (or other structurally related molecules) to prevent 
competition for binding with the active site. Although crystallisation conditions without the use 
of bicine have been established previously,3 conditions have not been identified without 
inclusion of glycerol.  
Glycerol was removed from the PA2794 storage buffer (Tris-HCl (50 mM, pH 7.4), 10 % glycerol) 
using 30 kDa molecular weight cut off falcon tubes. Three repeats of addition of 9 mL Tris-HCl 
(50 mM, pH 7.4) followed by concentration of the enzyme to 1 mL was utilised to buffer 
exchange the glycerol out of solution. However during this process precipitation of the PA2794 
enzyme occurred suggestive that the glycerol is required in aqueous solution to prevent 
exponential protein aggregation at this concentration. Additionally it was found that the 
precipitated protein did not re-solubilise upon addition of glycerol up to 20 %.  
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2.4 Conclusions and Future work 
A F129A mutation was successfully introduced to the PA2794 gene and recombinant plasmids 
transformed into E. coli cells for both the native and mutant genes. Expression conditions were 
optimised for both enzymes and procedures established to obtain enzymes with high purity. 
Crystallisation of PA2794 was achieved and the whole structure refined to a resolution of 1.2 Å, 
including the N-terminal sequence that had previously not been assigned. The introduction of 
the putative Pse5Ac7Ac (1.13) ligand was attempted pre- and post- crystallisation of PA2794. 
However electron density within the active site could only be assigned to solute molecules. 
As the supply of pure Pse5Ac7Ac (1.13) was limited, attempts at screening new PA2794 
purification and crystallisation conditions for enzyme complexes with Pse5Ac7Ac (1.13) were 
discontinued. It was acknowledged that in order to fully characterise this putative 
pseudaminidase (and other pseudaminic acid processing enzymes), access to a supply of 
pseudaminic acid chemical probes is required. Therefore this research turned to focussing on 
the design of a strategy for the large scale (> 100 mg) production of Pse5Ac7Ac (1.13) that could 
be further modified into the desired analogues for probing pseudaminic acid processing 
enzymes. 
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3. Chapter 3 Pseudaminic acid biosynthesis 
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3.1 Introduction 
3.1.1 Sialic acid biosynthesis 
Commonly, sialic acids are biosynthesised from the activated sugar UDP-GlcNAc (3.1),39 and are 
then converted to their glycosyl donor activated analogues by enzyme catalysed transfer of a 
CMP group. In bacteria Neu5Ac (1.1) synthesis from UDP-GlcNAc (3.1) requires only two 
enzymes; a UDP-GlcNAc 2-epimerase to hydrolyse the UDP group and alter the stereochemistry 
at C2,221 and a Neu5Ac synthase that catalyses the condensation reaction of ManNAc (3.2) and 
phospho-enol-pyruvate (PEP) to produce the nonulosonic acid, Neu5Ac (1.1).222 In non-
mammalian higher organisms the pathway follows the same initial step to ManNAc (3.2) 
however prior to the condensation step, a ManNAc kinase phosphorylates the C6 position 
(3.3).223 Mammals follow the same synthetic pathway but only require one enzyme; the 
bifunctional UDP-GlcNAc 2-epimerase/ManNAc kinase to synthesise  ManNAc-6P (3.3).224 This 
group is consequently removed after formation of the nonulosonic acid (3.4) to produce Neu5Ac 
(1.1), in all organisms Neu5Ac (1.1) can then be activated with CTP form CMP-Neu5Ac (3.5) to 
enable transfer onto other structures (Scheme 3.1). It was hypothesised that the Pse5Ac7Ac 
(1.13) biosynthetic pathway would resemble this biosynthetic route; with enzymes catalysing 
the conversion of the UDP-GlcNAc starting material into an intermediate that could undergo a 
Pse5Ac7Ac synthetase catalysed reaction to produce Pse5Ac7Ac (1.13).  
 
Scheme 3.1 The biosynthetic pathway from UDP-GlcNAc (3.1) to CMP-Neu5Ac (3.5) in bacteria and 
mammals. 
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3.1.2 Identification of the pseudaminic acid biosynthetic enzymes 
H. pylori and C. jejuni flagella are predominantly glycosylated with Pse5Ac7Ac (1.13), and 
derivatives, therefore the flagellin glycosylation gene clusters in these bacteria were inspected 
for potential pseudaminic acids biosynthetic genes. Schirm et al. initially identified four genes 
(HP0326A, HP0326B, HP0840 and HP0178) in H. pylori that were found to be essential for 
production of CMP-Pse5Ac7Ac (3.6).180 HP0840 was identified as the first enzyme in the 
Pse5Ac7Ac (1.13) biosynthetic pathway and upon inactivation of this gene there was an 
accumulation of UDP-GlcNAc (3.1) providing evidence for this as the Pse5Ac7Ac (1.13) 
biosynthetic starting material.225 Sequence homology assigned the HP0178 enzyme as a Neu5Ac 
synthetase and identified the HP0326A protein to have the highest homology with CMP-sialic 
acid synthetases.180 Thus it was proposed that the final stages of the biosynthetic pathway to 
CMP-Pse5Ac7Ac (3.6) did indeed mimic that of CMP-Neu5Ac (3.5) and that other biosynthetic 
enzymes would be required to process UDP-GlcNAc (3.1) into the Pse5Ac7Ac synthetase 
precursor (3.10).  HP0326B displayed homology with a GT suggesting it may be required for the 
processing of CMP-PSe5Ac7Ac (3.6) rather than involved in Pse5Ac7Ac (1.13) synthesis. 
However upon mutation of this gene there was an accumulation of Pse5Ac7Ac biosynthetic 
intermediates (3.7, 3.8, and 3.9) rather than the expected CMP-Pse5Ac7Ac (3.6) that would 
accumulate if the gene encoded for a GT.180 
UDP-GlcNAc (3.1) dehydratase/aminotransferase pairs were isolated and their reaction 
products analysed by NMR. H.pylori (HP0840/HP0366) and C. jejuni (Cj1293/Cj1294) products 
(3.7 and 3.8) were assigned as the first two intermediates in the Pse5Ac7Ac (1.13) biosynthetic 
pathway based on their observed stereochemistry (Scheme 3.2).226 HP0326B and HP0327 were 
identified as potential Pse5Ac7Ac (1.13) biosynthetic genes by gene comparison to bacterial 
species known to produce CMP-Pse5Ac7Ac (3.6). Sequence homology of HP0327 suggested the 
enzyme was the acetyl-transferase required to install the second acetamido group (3.9).227 
Although HP0326B had originally been assigned as a GT and not part of the biosynthetic 
pathway, it was suggested that if the sugar was “transferred” onto a water molecule, this would 
result in the apparent UDP hydrolysis producing the desired sugar (3.10).228 Thorough structural 
and biochemical analyses of each enzyme has led to confirmation of all of the biosynthetic 
intermediates and have been shown as analogous in H. pylori and C. jejuni. These five 
biosynthetic enzymes required for the production of Pse5Ac7Ac (1.13) are now generally termed 
as PseB, PseC, PseH, PseG, PseI with the Pse5Ac7Ac CMP-synthetase labelled as PseF (Scheme 
3.2).203 
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 Scheme 3.2 The CMP-Pse5Ac7Ac (3.16) biosynthesis detailing the C. jejuni and H. pylori pathway (blue) 
with any enzymatic deviations observed in A. caviae (red) and B. thuringiensis (green) highlighted. 
A slightly different Pse5Ac7Ac (1.13) biosynthetic pathway has been assigned in A. cavaie; 
another pathogen that displays Pse5Ac7Ac (1.13) on its flagellin as well as in the LPS.  Mutations 
to the flm gene locus caused loss of motility, flagella and the LPS suggesting this locus has a role 
in flagellar assembly and LPS biosynthesis.229 A cluster of genes in this locus displayed homology 
to the biosynthetic genes found in C. jejuni and H. pylori and comparison displayed conserved 
domains for FlmA with PseB, FlmB with PseC and NeuB with PseI. However in A. cavaie the FlmD 
protein was much larger than expected and displayed conserved domains with both PseH and 
PseG suggesting this protein catalyses both the desired amine acetylation and UDP-hydrolysis.229 
The A. cavaie enzymes have not been as rigorously investigated as the C. jejuni and H. pylori 
enzymes and full biochemical analysis of the route in this organism is yet to be carried out.  
Further deviations from the original Pse5Ac7Ac (1.13) biosynthetic pathway were discovered 
when the pathway from the gram positive bacteria B. thuringiensis was investigated. An operon 
was identified containing seven genes that were proposed to encode enzymes in the CMP-
Pse5Ac7Ac (1.13) biosynthetic pathway.182 Sequence alignment allocated homologues for the 
PseC, PseH, PseG, PseI and PseF enzymes and two B. thuringiensis enzymes that were predicted 
as dehydratases. LC/MS and NMR characterisation of the product of each enzymatic reaction 
showed that two enzymes were required to carry out the PseB function. The first enzyme (Pen) 
converts UDP-GlcNAc (3.1) into UDP-6-deoxy-D-GlcNAc-5,6-ene (3.11) and the second (Pal) acts 
as a C4 oxidase and C5,6 reductase resulting in epimerisation at C5 compared to the original 
starting material (3.1).182 
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3.1.3 Pseudaminic acid biosynthetic enzyme structure and function 
PseB is the first enzyme in the pathway and converts UDP-GlcNAc (3.1) to UDP-4-keto-6-deoxy-
L-IdoNAc (3.7). The proposed reaction mechanism follows three sequential steps; oxidation of 
the C4 hydroxyl, dehydration at C6 to form the alkene, followed by reduction to the methyl.230 
Initially controversy over the H. pylori PseB co-factor occurred with spectrophotometric studies 
showing that NADP+ in the reaction mixture was not used by the enzyme at all and that 
additional NAD+ could be used but with a very poor efficiency.225 Furthermore conversion to the 
PseB product (3.7) was observed without addition of potential co-factor molecules. Therefore it 
was suggested that PseB may behave equivalently to some UDP-GlcNAc C4 epimerases; with the 
NAD(P)+ co-factor remaining tightly bound to the enzyme during purification and throughout 
the reaction with internal regeneration. This was confirmed when crystal structures of PseB 
revealed electron density concurrent with a bound NADPH molecule even without addition of 
exogenous molecules to the enzyme (Figure 3.1).230 The deeply buried co-factor is surrounded 
by residues orientated to have favourable interactions with the molecule including multiple H-
bonding residues (Figure 3.1). 
 
 
Figure 3.1 H. pylori PseB (PDB 2GN4)230 crystal structure in complex with the UDP-GlcNAc substrate (3.1) 
(green) and the tightly bound NADPH co-factor (red) and close-ups of the substrate and co-factor binding 
sites displaying the numerous hydrogen bonds between molecules and enzyme.230 
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PseC was identified as the second enzyme in the Pse5Ac7Ac (1.13) biosynthetic pathway, acting 
as an aminotransferase to catalyse synthesis of UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8) from 
the 4-keto derivative (3.7). H. pylori PseC was found to share sequence similarity with PLP-
dependent aminotransferases, and assigned as a Type 1 aminotransferase.231 PLP-dependent 
aminotransferases undergo two subsequent half-transamination reactions; an acetyl transfer to 
the PLP (3.12) co-factor by an acetyl donor followed by aminotransfer from this to the sugar 
(3.7). Lys183 was predicted as the catalytic active site residue in H. pylori PseC. During the first 
half transamination, initially an enzyme-PLP Schiff base forms (3.14), then a free amino donor 
(3.15) releases the enzyme from the internal aldimine (3.14) forming an external aldimine (3.16) 
via a transaldimination reaction. Finally hydrolysis occurs resulting in release of a glyoxylic acid 
(3.18) to produce free PMP (3.13) in the active site (Scheme 3.3).231 
 
 
 
Scheme 3.3 The first half-transamination reaction of PLP-dependent aminotransferases, catalysing 
conversion of PLP (3.11) to PMP (3.12) utilising a free amino donor (3.14). 
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PseH is the third enzyme in the H. pylori and C. jejuni Pse5Ac7Ac (1.13) biosynthetic pathways 
and catalyses acetyl transfer from acetyl-CoA to the C4 amine formed in the previous step to 
yield UDP-4-amino-4,6-dideoxy-AltdiNAc (3.9).203 Surprisingly it was found that C. jejuni PseH 
displays very little structural and binding similarity to other acetyltransferases associated with 
the biosynthesis of sugars for protein glycosylation. However crystallisation of PseH in complex 
with the co-factor shows the acetyl group protruding into the predicted substrate binding 
groove in a favourable position for direct acetyl transfer to occur to the desired C4 amino sugar 
substituent (Figure 3.2).232 
 
 
 
Figure 3.3 C.jejuni PseH (PDB 4XPL)232 crystal surface structure (purple, globular) in complex with the 
acetyl-CoA co-factor (ball and stick model) with the thio-acetyl group (circled) protruding into the 
predicted substrate binding groove. 
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The PseG gene locus (Cj1312) H. pylori homologue was originally assigned to code for a putative 
glycosyltransferase as it displayed significant alignment with conserved sequences of some UDP-
sugar transferases.180   PSI-BLAST homology sequencing of Cj1312 classified it as belonging to 
the metal-independent GT-B superfamily,233 however the amino acid sequence displays only 
modest overall identity with this class of protein. However due to a lack of other candidates, 
and its genome positioning, this gene was also highlighted as a potential glycosyl hydrolase for 
catalysing the desired cleavage of the UDP group during Pse5Ac7Ac (1.13) biosynthesis.228  
Biochemical analysis confirmed the role of PseG as a UDP-hydrolase, with the enzyme thought 
to employ a water molecule as the acceptor to yield the Pse5Ac7Ac precursor; 6-deoxy-AltdiNAc 
(3.10).228 Crystal structures highlighted an active site histidine residue that was found to be 
essential for hydrolysis and was proposed to abstract a water proton to activate it as a 
nucleophile.234 Investigations into the enzyme mechanism in the presence of D2O displayed that 
UDP hydrolysis of UDP-4-amino-4,6-dideoxy-AltdiNAc (3.9) results in an inversion of the 
stereochemistry at C1 (Scheme 3.4).228  
 
 
 
Scheme 3.4 The proposed mechanism for PseG catalysed UDP hydrolysis, utilising a histidine-activated 
and isoleucine-stabilised water molecule as a nucleophile to attack at the anomeric centre.234 
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The final enzyme, PseI was the first to be identified as being involved in the Pse5Ac7Ac (1.13) 
biosynthetic pathway as it displays homology to Neu5Ac synthetase sequences and mimics the 
final biosynthetic step for the production of sialic acids.180 This final step requires a sialic acid 
synthase (SAS) to catalyse the condensation of phosphoenolpyruvate with the sugar resulting in 
the desired nonulosonic acid.235 Genes displaying conserved features with other SAS were 
identified in C. jejuni and biochemical experiments confirmed one enzyme (PseI) that converted 
6-deoxy-AltdiNAc (3.10) (a potential Pse5Ac7Ac precursor) to Pse5Ac7Ac (1.13).236 The 
mechanism employed by the pseudaminic acid synthetase was found to be a metal dependent, 
C-O bond cleavage mechanism that proceeds in the ring open form (3.19) via generation of an 
oxocarbenium ion (3.20). Attack by a free hydroxyl produces a tetrahedral intermediate (3.21) 
which is followed by release of the phosphate group resulting in the formation of a nonulosonic 
acid (3.21) which can then ring close to Pse5Ac7Ac (1.13) (Scheme 3.5).236 
 
 
 
Scheme 3.5 C. jejuni PseI pseudaminic acid synthetase PEP condensation mechanism.  
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3.1.4 Exploitation of the pseudaminic acid biosynthetic pathway for synthesis of 
pseudaminic acid analogues 
During the biochemical analyses of the enzymes in the Pse5Ac7Ac (1.13) biosynthetic pathway, 
access to the enzyme substrates was required but some are not commercially available or easy 
to chemically derive. In particular, it was deemed impractical to chemically synthesise the 
proposed PseG substrate (3.9) with previous synthetic routes being costly, lengthy and 
extremely low yielding.196 Therefore PseB and PseC were utilised as synthetic tools to convert 
UDP-GlcNAc into UDP-4-amino-2,4,6-trideoxy-β-˪-AltNAc (3.8) which could then be selectively 
chemically acetylated to yield the desired product (3.9) (Scheme 3.6). Although the synthesis of 
UDP-4-amino-4,6-dideoxy-AltdiNAc (3.8) displayed high conversion, significant amounts of 
material were lost during intermediate purification steps reducing the overall yield to just 34 % 
of desired product (3.9).228 
 
 
Scheme 3.6 A chemoenzymatic route to the PseG substrate, UDP-6-deoxy-AltdiNAc (2.9); incubation of 
PseB, PseC, PLP and L-Glu in 50 mM Tris-HCl, pH 7.4, 37 °C, followed by acetylation with acetic anhydride 
and silver acetate in methanol.228 
Knowledge and potential exploitation of the full Pse5Ac7Ac (1.13) biosynthetic pathway 
provides an alternative route to the synthesis of Pse5Ac7Ac (1.13) and displays significant 
advantages over chemical synthesis. For example, stereochemistry is controlled, no toxic 
reagents are required and the synthesis does not require lengthy, complicated steps. 
Schoenhofen et al showed that, once purified, all of the recombinant biosynthetic enzymes 
could be combined along with their co-factors and UDP-GlcNAc (3.1), to produce Pse5Ac7Ac 
(1.13) in a “one-pot” reaction with a quantitative yield (Scheme 3.7). However less than 5 mgs 
of Pse5Ac7Ac (1.13) was produced using this method with the major limitation being the 
requirement for very expensive co-factors. Another disadvantage to this scheme was that, 
although quantitative conversion to Pse5Ac7Ac (1.13) was reported, the methods for protein 
production and purification had been generalised and as such may not be the conditions for 
optimal production of each enzyme.203 
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Scheme 3.7 One-pot enzymatic production of Pse5Ac7Ac (1.13) from UDP-GlcNAc (3.1); incubation of 
PseB, PseC, PLP, L-Glu, acetyl-CoA and PEP in 25 mM sodium phosphate, 50 mM NaCl pH 7.3, 37 °C.203 
This project began with the aim to standardise a route to Pse5Ac7Ac (1.13) that did not suffer 
from the shortcomings of the existing chemical and enzymatic syntheses. In particular it was 
desired to find a route whereby Pse5Ac7Ac (1.13) could feasibly be produced on a large scale > 
50 mg. It was decided that utilisation of enzymes from the Pse5Ac7Ac (1.13) biosynthetic 
pathway had the most scope for this; to gain maximum yields at minimal cost. Therefore initial 
focus fell on optimising production of the biosynthetic enzymes and probing their activity for 
production of Pse5Ac7Ac (1.13). 
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3.2 Pseudaminic acid biosynthetic enzyme production 
3.2.1 Optimising enzyme expression conditions 
PseB and PseC recombinant plasmids were a kind gift from the Tanner lab with the PseB pET30a 
recombinant plasmid designed to express C-terminal HexaHis tagged PseB and a PseC pFO4 
recombinant plasmid to express N-terminal HexaHis tagged PseC. The PseH, PseG and PseI genes 
were codon optimised for E. coli and recombinant plasmids designed and purchased from 
GenScript (Appendix 6). The pET15b vectors were utilised to yield N-terminal HexaHis tagged 
sequences for each gene with expression controlled by the T7 promoter. The PseB and PseC 
recombinant plasmids were transformed via electroporation into E. coli BL21 DE3 cells and PseH, 
PseG and PseI recombinant plasmids transformed via heat shock. Successful transformation 
confirmed by growth on antibiotic-containing LB agar plates (artificial selection) (Table 3.1). 
Table 3.1 Table of the recombinant plasmids containing pseudaminic acid biosynthetic enzymes and 
their associated antibiotic resistance. 
Enzyme Bacterial source Plasmid Restriction Enzyme 
sites 
Antibiotic resistance 
PseB C. jejuni pET30a NdeI-XhoI Kanamycin 
PseC C. jejuni pFO4 BamHI-EcoRI Ampicillin 
PseH C. jejuni pET15b BamHI-EcoRI Ampicillin 
PseG C. jejuni pET15b NdeI-BamHI Ampicillin 
PseI C. jejuni pET15b NdeI-BamHI Ampicillin 
Initially small scale grow ups were employed to confirm transformation, expression and 
purification techniques for the desired biosynthetic protein. Incorporation of the PseB, PseC, 
PseH, PseG and PseI expressing plasmids did not appear to be detrimental to bacterial growth 
which was monitored prior to induction of the protein of interest. OD600 measurements 
displayed that the growth of cells occurred at different rates; with PseH reaching the desired 
OD600 significantly faster than the others, and PseI significantly slower. It was hypothesised that 
the smaller length of PseH could aid in the smaller lag time however this only infers a relatively 
small change when comparing the sequence length of the entire plasmid (Appendix 6). 
Therefore it is expected that the plasmid copy number would be similar for all recombinant 
plasmids and that the observed differences was due to discrepancies in the health of the cells 
post transformation rather than any negative effects of basal protein expression. Although using 
the induction conditions detailed by Schoenhofen (0.1 mM IPTG, 37 °C, 4 hrs) produced enough 
protein to synthesise Pse5Ac7Ac (1.13) on a small scale, expression trials were carried out to 
optimise production and make this route more feasible for large scale synthesis. Three different 
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variables were explored in order to find optimum conditions for protein production; IPTG 
induction concentration, temperature post induction and time of incubation post induction 
(Table 3.2). 
Table 3.2 Expression trial conditions to optimise production of the biosynthetic enzymes. 
Condition A B C D E F G H 
Post induction 
incubation temp 16 °C 37 °C 
Post induction 
concentration 0.1 mM 0.5 mM 0.1 mM 0.5 mM 
Post induction 
incubation time 
4 hrs 20 hrs 4 hrs 20 hrs 4 hrs 20 hrs 4 hrs 20 hrs 
Protein production was monitored after lysis by imaging on SDS-PAGE and comparison of which 
conditions produced the most prominent protein bands (Figure 3.4). Only marginal increases in 
protein production of PseB and PseC were displayed; with little difference apparent between 
the two concentrations of IPTG and the time left incubating after IPTG induction. However by 
incubating at 37 °C instead of 16 °C, a more concentrated protein was observed indicative of 
higher protein production (Figure 3.4a, b). PseH protein production was equally deemed 
unaffected by IPTG concentration but production was increased when incubating for a longer 
period of time and marginally by the increase in temperature post induction (Figure 3.4c). 
 Analysis of the band of interest on the SDS-PAGE gel demonstrated that using the higher 
temperature post induction was the variable that most improved production of PseG and PseI 
production (Figure 3.4d, e). Additionally adding more IPTG had a small positive effect, as did 
incubating at 37 °C compared to 16 °C.  Therefore these modified conditions (Table 3.3) were 
employed during the subsequent large scale enzymatic grow ups in order to maximise enzyme 
production and hence reduce resources required for production of Pse5Ac7Ac (1.13) on a large 
scale. 
Table 3.3 Optimised conditions for production of pseudaminic acid biosynthetic enzymes. 
 IPTG concentration 
/ mM 
Post induction incubation 
temp / °C 
Post induction 
incubation time / hrs 
PseB 0.1 37 4 
PseC 0.1 37 4 
PseH 0.1 16 20 
PseG 0.5 37 4 
PseI 0.5 37 20 
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Figure 3.3 SDS PAGE analysis of crude samples of the biosynthetic enzymes under different induction 
conditions a) PseB, b) PseC, c) PseH, d) PseG, e) PseI. 
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3.2.2 Purification of the biosynthetic enzymes 
Following large scale production of the desired enzymes, the protein of interest was purified 
from other buffer soluble proteins by loading onto a Nickel affinity column and applying an 
increasing imidazole concentration gradient. Presence of a UV Abs280 peak during washing with 
higher concentrations of imidazole (after loading and washing the column with low 
concentrations of imidazole) confirmed over-expression of the His6-tagged protein. This peak 
occurred at similar concentrations of imidazole across purification of each biosynthetic enzyme 
(100-150 mM imidazole) (Appendix 7). The eluted proteins corresponding to these UV Abs280 
peaks were confirmed as the desired biosynthetic enzymes by SDS-PAGE analysis which 
displayed over-expressed, pure protein of the expected molecular weight (Figure 3.5). 
Favourably these larger scale expressions appeared to further increase the amount of purified 
enzyme per volume of media which was attributed to economies of scale with predicted lower 
percentage of cell loss during the collection and lysis of cells, and enzymatic loss during 
purification. Production of purified enzyme under these conditions (Table 3.4) was either equal 
to or greater than previously reported yields (7-11 mgL-1 LB).203  
Unfortunately, this increase in enzyme concentration during purification proved detrimental to 
the yield of soluble Pse C, with enzyme precipitation occurring during purification. As 
precipitation had not appeared during the smaller scale preparations it was hypothesised that 
aggregation could be a result of the increased concentration of PseC in imidazole containing 
buffer (a molecule that has previously been shown to affect protein stability in high 
concentrations). Dialysis buffer was therefore added to each elution fraction prior to purification 
of PseC to dilute its concentration (and that of the imidazole) as soon as possible after elution. 
However, precipitation still occurred using this method, even when adding detergents, such as 
glycerol and PEG, to the dialysis buffer. Subsequently, lysed cells containing PseC were purified 
in portions to mimic the smaller scale original purification process, unfortunately, not only was 
this method both time and cost ineffective, but it was to no avail and precipitation still occurred.  
It was hypothesised that modified PseC induction conditions, rather than purification 
conditions, may account for the apparent aggregation of PseC after purification. Therefore a 
large scale grow up of PseC was carried out using the lower induction temperature of 16 °C and 
still only left to incubate for 4 hours. Upon purification this batch of protein did not appear to 
precipitate and was subjected to desalting ahead of storage without apparent aggregation. 
Although these conditions were not optimum for PseC production, it was deemed a necessary 
reduction in order to maintain pure PseC solubility in the desired buffer system and hence these 
were used for all further protein preparations. 
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Table 3.4 The quantity of each biosynthetic enzyme purified per L of LB culture. 
 Molecular weight / kDa Quantity of enzyme per L LB / mg 
PseB 37.4 14 
PseC 42.3 9 
PseH 18.7 17 
PseG 31.3 11 
PseI 38.6 18 
 
 
 
Figure 3.4 Depiction of the purified C. jejuni Pse5Ac7Ac (1.13) biosynthetic enzymes on a SDS PAGE gel. 
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3.3 Enzymatic synthesis of pseudaminic acid  
3.3.1 Enzymatic synthesis of pseudaminic acid utilising enzymes from the 
Campylobacter jejuni biosynthetic pathway 
Subsequent to the large scale purifications of the biosynthetic enzymes, standardisation of the 
“one-pot” enzymatic synthesis of Pse5Ac7Ac (1.13) was attempted in house. Following the 
procedure outlined previously,203 a small-scale reaction mixture (0.1 mg) was constructed 
utilising the pure enzymes. UDP-GlcNAc (3.1) and the five biosynthetic enzymes were incubated 
(shaken 120 rpm, 37 °C) in a sodium phosphate buffer (50 mM, pH 7.4) with an excess of co-
factors (Table 2.5). A negative control reaction was also set up utilising identical conditions as 
above but without the inclusion of the first enzyme in the biosynthetic pathway; PseB and the 
reactions were monitored at time intervals by negative ion ESI LC-MS.  
Analysis of the negative control was run in parallel to the reaction mixture and importantly there 
was no detection of a peak at [M-H]- 333 Da, or appearance of any additional peaks compared 
to when the reaction mixture was first constructed.  Thus suggesting that the UDP-GlcNAc (3.1) 
starting material was stable in the “one-pot” reaction mixture and that the biosynthetic enzymes 
could not catalyse any side-reactions without PseB first converting UDP-GlcNAc (3.1) to UDP-4-
keto-6-deoxy-L-IdoNAc (3.7) (Figure 3.6a). Appearance of a peak corresponding to production 
of Pse5Ac7Ac (1.13) ([M-H]- 333 Da) was observed in the reaction mixture containing all of the 
biosynthetic enzymes (Figure 3.6b). Under these conditions, no peaks corresponding to the 
biosynthetic intermediate products were observed and full conversion to Pse5Ac7Ac (1.13) was 
estimated after two and a half hours, when the LCMS peak area relating to the starting material 
UDP-GlcNAc [M-H]- 606 Da could no longer be detected (Figure 3.6b). 
 
Table 3.5 General reaction components and concentrations for the “one-pot”small scale enzymatic 
synthesis of Pse5Ac7Ac (1.13) from UDP-GlcNAc (2.1) 
Reagent Concentration / mM 
UDP-GlcNAc 1.0 
Pyridoxal 5’ phosphate (PLP) 1.5 
L-glutamic acid 10.0 
Acetyl-Coenzyme A 1.5 
Phosphoenolpyruvate (PEP) 2.0 
PseB, PseC, PseH, PseG, PseI 0.38 mg mL-1 
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Figure 3.5 Negative ESI LC-MS of the small scale Pse5Ac7Ac (1.13) enzymatic reaction, a) negative control 
(reaction mixture without the first biosynthetic enzyme; PseB) after 2.5 hrs, demonstrating substrate 
UDP-GlcNAc (3.1) ([M-H]- 606 Da) stability and no detection of any of the biosynthetic products and b) 
analysis of the enzymatic synthesis at 2.5 hrs, demonstrating full conversion to the desired Pse5Ac7Ac 
(1.13) product [M-H]- 333 Da. 
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3.3.2 Enzymatic synthesis of pseudaminic acid utilising enzymes from the 
Aeromonas caviae biosynthetic pathway 
Although synthesis of Pse5Ac7Ac (1.13) has been previously demonstrated using the 
recombinant biosynthetic enzymes encoded by C. jejuni and H. pylori,203 the pathway has not 
been fully elucidated in vitro using the recombinant enzymes from A. cavaie (FlmA, FlmB, FlmD 
and NeuB) (Scheme 3.2). A. caviae flagellin and LPS are glycosylated with Pse5Ac7Ac (1.13) and 
when transposon mutants of FlmA, FlmB, FlmD or NeuB were inserted, a loss of motility and LPS 
O-antigen bands were recorded.229 Previous studies discovered these four genes in a genetic 
locus similar to that responsible for Pse5Ac7Ac (1.13) biosynthesis in C. jejuni and H. pylori and 
showed FlmD and NeuB to display homology with Neu5Ac (1.1) biosynthesis enzymes; UDP-
GlcNAc 2-epimerase and Neu5Ac synthetase respectively.229 
In order to ascertain if theses enzymes (FlmA, FlmB, Flm D and NeuB) did make up the A. caviae 
Pse5Ac7Ac (1.13) biosynthetic pathway, collaborators (Jon Shaw group, University of Sheffield) 
subjected purified enzymes to similar reaction conditions as the C. jejuni enzymes (Table 3.5). 
However under these conditions they were unable to detect turnover of UDP-GlcNAc (3.1) to 
Pse5Ac7Ac (1.13), or indeed identify production of any of the biosynthetic intermediates. 
Therefore it was decided to test these A. cavaie enzymes in the standardised procedure 
established for the C. jejuni enzymes in order to assess if these enzymes did indeed turnover to 
produce Pse5Ac7Ac (1.13) equivalently.  
Reactions were set up using a mixture of biosynthetic enzymes from A. cavaie and C. jejuni so 
that activity of each individual A. cavaie enzyme could be established (Table 3.6). Reactions 
containing C. jejuni PseB with the rest of the enzymes from either C. jejuni or A. cavaie displayed 
turnover of UDP-GlcNAc (3.1) to Pse5Ac7Ac (1.13) with equivalent conversions. However it was 
found that the reaction mixtures containing FlmA from A. cavaie displayed no turnover of UDP-
GlcNAc (3.1) in our standardised system (Figure 3.7).  
Table 3.6 The combination of C. jejuni and A. cavaie proposed Pse5Ac7Ac (1.13) biosynthetic enzymes 
trialled during activity experiments to elucidate the A. cavaie biosynthetic pathway. 
Experiment Enzyme composition 
A C. jejuni PseB, PseC, PseH, PseG, PseI 
B C. jejuni PseB, PseC, PseH, PseG, A. cavaie NeuB 
C C. jejuni PseB, PseC, PseH, PseI, A. cavaie FlmD 
D C. jejuni PseB, PseH, PseG, PseI, A. cavaie FlmB 
E C. jejuni PseC, PseH, PseG, PseI, A. cavaie FlmA 
F A. cavaie FlmA, FlmB, FlmD, NeuB 
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Figure 3.6 Negative ESI LC-MS of the Pse5Ac7Ac (1.13) enzymatic reaction a) the negative control with no 
PseB or FlmA showing detection of only UDP-GlcNAc (3.1) starting material after 4 hrs, b) conversion to 
Pse5Ac7Ac (1.13) after 4 hrs with C. jejuni PseB and A. cavaie Flm B, Flm D and NeuB and c) demonstrating  
A. cavaie FlmA inability to turnover UDP-GlcNAc (3.1). 
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It has previously been shown that it is not necessary to add in the PseB co-factor (NADPH) when 
utilising the purified enzyme as it remains tightly bound to the enzyme during this process and 
is re-oxidised during the enzymatic reaction. It was also considered that the PseB co-factor, 
NADPH may not be bound as tightly in FlmA as it is in PseB and hence addition of it to the 
reaction mixture may be required for FlmA activity. Comparison of the C. jeuni PseB sequence 
with H. pylori PseB and A. cavaie FlmA demonstrated that PseB from C. jejuni and H. pylori had 
a slightly higher level of identity than when comparing C. jejuni and A. caviae sequences, 61.1 % 
compared to 51.7 %. However general features were the same and in particular residues 
predicted to hydrogen bond the substrate and co-factor were conserved across all three 
sequences (Figure 3.8). However it was acknowledged that subtle differences between the 
enzymatic sequences can infer large alterations in the overall structure. Therefore it cannot be 
assumed that the NADPH co-factor is equivalently bound in FlmA as it is in PseB and hence 
addition of exogenous NADPH co-factor may be required for enzymatic activity.  
 
Figure 3.7 Sequence comparison of the H. pylori, C. jejuni and A. caviae PseB enzymes with residues 
highlighted that are involved in substrate (green) and co-factor (red) hydrogen bonding. 
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An additional reaction was set up incorporating NADPH (1.5 mM), the reaction mixture (Table 
3.5), A. cavaie FlmA, and C. jejuni PseC, PseH, PseG and PseI to test the requirement for 
exogenous co-factor. Production of Pse5Ac7Ac (1.13) was monitored using negative ESI LC-MS, 
however even after 24 hrs the only detectable sugar was the UDP-GlcNAc (3.1) starting material 
(Figure 3.9). As this result was identical to reactions without the addition of NADPH it was 
suggested that a lack of co-factor was not responsible for the lack of activity in this case. 
However there is still uncertainty over whether FlmA NADPH binding is analogous to C. jejuni 
and H. pylori PseB.  
 
Figure 3.8 Negative ESI LC-MS of the small scale enzymatic reaction employing A. cavaie FlmA and C. 
jejuni PseC, PseH, PseG and PseI in the standard reaction mixture with the inclusion of NADPH (1.5 mM). 
 
These results imply that A. caviae FlmA may not carry out the role it has been assigned; a UDP-
GlcNAc 5-inverting, 4,6- dehydratase, and that the Pse5Ac7Ac (1.13) biosynthetic pathway in 
this bacteria may diverge further from that found in C. jejuni and H. pylori. For example, as with 
B. thuringiensis,182 a partnership of enzymes may be required to convert UDP-GlcNAc (3.1) into 
the PseB product (3.7). Alternatively this FlmA enzyme could be less stable than the other A. 
caviae enzymes and the integrity of the protein may have been affected during transportation 
hence resulting in the lack of enzymatic activity. Further experiments into the potential activity 
of A. cavaie FlmA were discontinued due to a lack of available protein. The comparison between 
C.jejuni PseB and A. caviae FlmA activity does however highlight how minor changes in the 
synthesis of Pse5Ac7Ac (1.13) can have catastrophic downstream effects. 
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3.4 Conclusions and future work 
Promising developments along the pathway to a viable large scale synthesis of Pse5Ac7Ac (1.13) 
have been made. Induction conditions for the C. jejuni biosynthetic enzymes were explored and 
pure enzymes were combined in one pot to produce Pse5Ac7Ac (1.13). The activity of the 
proposed A.cavaie Pse5Ac7Ac (1.13) biosynthetic enzymes were investigated and FlmB, FlmD 
and NeuB were shown to behave analogously to their C. jejuni counterparts.   
Optimal conditions for the production of Pse5Ac7Ac (1.13) biosynthetic enzymes were 
established; different conditions were required for the maximum induction of each enzyme. 
Under the new conditions one of the enzymes; PseC, appeared to aggregate and precipitate 
during purification resulting in inactive protein. Therefore alternate purification conditions were 
investigated, such as the addition of detergents, to promote enzymatic solubility however under 
all conditions precipitation could not be prevented. Induction conditions were re-evaluated and 
it was found that by lowering the temperature after induction, precipitation of PseC could be 
avoided. Unfortunately this was detrimental to the yield of PseC and it could be useful in the 
future to explore further methods for promoting solubility whilst retaining yield. For example, 
co-expression of PseC with one of the other biosynthetic enzymes could help to promote PseC 
solubility. Alternatively re-design of the plasmid could be beneficial with incorporation of either 
a fusion solubility tag such as MBP or fusion to another of the biosynthetic genes. However it is 
unknown if this would result in detrimental effects on the activity of the enzymes and hence 
further investigations would be required.  
The purified Pse5Ac7Ac (1.13) displayed activity in a one-pot reaction (with their required co-
factors) to allow for the standardised fully enzymatic conversion of UDP-GlcNAc (3.1) to 
Pse5Ac7Ac (1.13). Mimicry of these conditions with the proposed Pse5Ac7Ac (1.13) biosynthetic 
enzymes from A. cavaie confirmed three of the enzymes to be active and form part of the 
Pse5Ac7Ac (1.13) biosynthetic pathway. However the proposed A. cavaie UDP-5-inverting-4,6-
dehydratase (FlmA) did not display turnover of UDP-GlcNAc (3.1), even upon addition of the 
NADPH co-factor to the reaction. Previous evidence presents FlmA as the first enzyme of the A. 
caviae Pse5Ac7Ac (1.13) biosynthetic pathway and hence further investigations into its activity 
are required. Initial experiments should focus on gene expression and purification with regards 
to minimising potential de-stabilising effects that could have occurred during transit from 
Sheffield.  Additionally crystallographic studies of this enzyme would aid in elucidating any 
potential structural differences compared to H. pylori PseB, which would help explain their 
difference in activity and confirm whether addition of exogenous co-factor is required. 
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4. Chapter 4 Optimising the PseB and PseC 
transformation of UDP-GlcNAc 
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4.1 PseB and PseC activity in the Pse5Ac7Ac biosynthetic pathway 
4.1.1 Campylobacter jejuni PseB; a UDP-GlcNAc 5-inverting-4,6-dehydratase 
Deoxysugars are an important class of carbohydrates that are often used to glycosylate cell 
surface structures, for example C. burnetii virenose is an important component of the LPS which 
has been shown to be critical for evading host defences.237 During the biosynthesis of deoxy 
sugars C6 deoxygenation is usually catalysed during the first step and the deoxy mechanisms 
have been heavily investigated.238 A proposed C6 deoxygenation enzyme was originally 
annotated as FlaA1 in H. pylori and sequence similarities suggested a nucleotide activated sugar 
as the likely substrate and a NAD(P)H co-factor binding site.225 UDP-GlcNAc (3.1) was initially 
proposed to be the substrate in activity assays and later confirmed by crystal structure 
complexes.230   
However, initial characterisation of this enzyme was ambiguous, with confusion over its catalytic 
activity, co-factor requirement and products released. Although PseB (FlaA1, Cj1293) displays 
conserved domains with 4,6-dehydratases it also displays remarkable sequence similarities with 
UDP-GlcNAc (3.1) C4 epimerases225 such as WbpP from P. aeruginosa.239 The 4,6-dehydratase 
activity was observed in all studies and PseB was assigned as a member of the short chain 
dehydrogenase/reductase (SDR) family240 and part of a sub-group that exhibits 4,6-dehydratase 
activity on nucleotide activated sugars to form deoxy-hexoses.241 However there was some 
uncertainty regarding the functionality and configuration of the observed 4-keto product with 
reports of production of both of the C4 epimers; UDP-4-keto-6-deoxy-˪-IdoNAc (3.7)230 and UDP-
4-keto-6-deoxy-GlcNAc (4.1).225 NMR data collected in situ confirmed the C. jeuni PseB initial 
product as UDP-4-keto-6-deoxy-˪-IdoNAc (3.13),230 observed as the hydrated form (4.2) in 
aqueous solution (Scheme 4.1).242 
The crystal structure revealed the characteristic SDR (S/T)YK catalytic triad in close proximity to 
the GlcNAc moiety as well as an aspartate and lysine. It also confirmed the presence of the 
tightly bound NADP(H) co-factor that requires regeneration during the reaction. An 
accumulation of the biochemical research and crystal structure of the UDP-GlcNAc 5-inverting-
4,6-dehydratase allowed for the mechanism to be proposed (Scheme 4.1).230 This mechanism 
first employs the (S/T)YK triad and NADP+ to oxidise the C4 hydroxyl producing the ketone 
intermediate (4.3) and reduced co-factor. This step is followed by Lys133 and Asp132 catalysed 
dehydration across the C5 (deprotonation) and C6 bonds (dehydration) forming the 4-keto-5,6-
ene derivative (4.4). Finally the reduced NADPH co-factor delivers a hydride to C6 and 
simultaneously a stabilised water molecule donates a proton to C5 from the opposite face to 
form the inverted methyl group of the first PseB product (3.7). 
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Scheme 4.1 PseB catalysed oxidation, dehydration and reduction of the substrate UDP-GlcNAc (3.1) to 
form the initial product UDP-4-keto-6-deoxy-˪-IdoNAc (3.7) which is in equilibrium with the hydrated 
form (4.2) in aqueous conditions. 
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4.1.2 Additional PseB catalysed epimerisation 
Further investigation of C. jejuni PseB biochemical mechanism revealed that in addition to acting 
as an inverting 4,6-dehydratase, PseB can also catalyse a further C5 epimerisation of the initial 
product, albeit at much lower rate (Scheme 4.2).242 Incubation of the initial PseB product, UDP-
4-keto-6-deoxy-˪-IdoNAc (3.7), with PseB resulted in conversion to the C5 epimer UDP-4-keto-
6-deoxy-GlcNAc (4.1), with no epimerisation occurring in the control containing no PseB. UDP-
4-keto-6-deoxy-GlcNAc (4.1) is the first intermediate (synthesised by PglF) in the biosynthesis of 
UDP-diNAcBac (4.5);241 a sugar essential in C.jejuni N-glycosylation.243 It may be that C. jejuni has 
evolved this secondary PseB catalysed epimerisation to ensure UDP-diNAcBac (4.5) production 
if PglF activity is compromised. 
 
 
Scheme 4.2 C. jejuni interlinking schemes from UDP-GlcNAc to two epimeric deoxysugar intermediates 
(3.7, 4.1) in the biosynthetic pathways of two sugars important for protein glycosylation. 
 
Full understanding of the complex mechanics of PseB turnover can only aid in vitro conversion 
of UDP-GlcNAc (3.1) to UDP-4-keto-6-deoxy-˪-IdoNAc (3.7), the first intermediate in the 
Pse5Ac7Ac (1.13) biosynthetic pathway. Prevention of the secondary PseB catalysed 
epimerisation is desired in order to promote activity of the Pse5Ac7Ac (1.13) pathway, however 
information is lacking on the catalytic turnover to this product (4.1).242 It would be useful to 
carry out additional mutation studies to elucidate any modifications which decrease the activity 
of this secondary reaction without perturbing the initial PseB reaction. However for the purpose 
of use in the enzymatic synthesis of Pse5Ac7Ac (1.13) it was deemed more practical to 
investigate and optimise the PseB and PseC reaction design to increase the efficiency of turnover 
of UDP-4-keto-6-deoxy-˪-IdoNAc (3.7) to the desired product UDP-4-amino-4,6-dideoxy-β-ɩ-
AltNAc (3.8). 
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4.1.3 PseC; a UDP-4-keto-6-deoxy-˪-IdoNAc aminotransferase  
A number of biomacromolecules employ amino sugars within their structures and biosynthesis 
often requires an aminotransferase catalysed transamination. PLP-dependent 
aminotransferases are classified into four subgroups via comparison of amino acid sequences 
aligned based on the predicted secondary structure.244 PseC enzymes are characterised as PLP-
dependent Type 1 aminotransferases and have been shown to catalyse transfer of an amino 
group to the C4 of UDP-4-keto-6-deoxy-˪-IdoNAc (3.7).4  
 
 
Figure 4.1 The H. pylori PseC (PDB 2FNU)4 homodimer (chain A ice blue, chain B gold), with the bound co-
factor and substrate indicating position of the active site at the dimer interface. 
H. pylori PseC exists as a homodimer in solution and in the crystal structure with both subunits 
contributing to each active site which is located near the dimer interface (Figure 4.1). Crystal 
structures of H. pylori PseC revealed the characteristic Type 1 aminotransferase PLP-binding site 
adjacent to the active site.245 In particular the highly conserved aspartic acid and phenylalanine 
residue were identified as Asp154 and Phe84 respectively in H. pylori PseC. Asp154 is orientated 
to interact with the pyridinium nitrogen, enhancing the electron sink nature of the co-factor, 
and the Phe84 ring is orientated to π-stack with the co-factor pyridine ring, stabilising binding 
of the co-factor (Figure 4.2a).  
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Crystal structures of H. pylori PseC in complex with PLP (3.11) showed it to form an internal 
aldimine with the Lys183 residue (Figure 4.2b) providing evidence for one of the intermediates 
in the proposed mechanism of the first half transamination reaction (Scheme 3.3, Page 79 ).4The 
identification of the natural amino donor of PLP-dependent aminotransferases has previously 
been ambiguous. However spectroscopic analysis of such enzymes consistently show turnover 
is achieved with ˪-glutamate (˪-Glu) as the free amino donor and activity with this donor is more 
efficient when compared to other amino acids e.g. ˪-glutamine or ˪-alanine.246 
 
 
Figure 4.2 H. pylori PseC crystal studies (PDB 2FN6)4 a) the co-factor binding site in complex with the PLP 
co-factor (3.11), highlighting Type 1 aminotransferase conserved residues and b) electron density of the 
PLP-enzyme internal aldimine intermediate (figure adapted from the original paper).4  
Co-crystallisation of PseC, PLP (3.11) and the proposed product UDP-4-amino-4,6-dideoxy-β-˪-
AltNAc (3.8) also provided insight into the second half transamination reaction as the enzyme 
was seen to act in reverse. Electron density in the active site could be attributed to a PMP-sugar 
aldimine (4.6) (Figure 4.3a) suggesting that a direct aminotransfer from the PMP (3.12) to the 
keto-sugar occurs and confirming the proximity of the co-factor binding site and active site.  
Lys183 was also identified as the catalytic residue for the second half reaction due to its 
orientation (Figure 4.3).4 A drastically reduced aminotransferase activity was identified upon 
Lys183Arg mutation hence confirming the importance of Lys183.4 These active site structural 
features eluded to the proposal of a mechanism mimicking that of ArnB (another UDP-4-keto 
aminotransferase)246 whereby the PMP amine attacks the substrate C4 and Lys183 is utilised in 
a transaldimination reaction trigger release. 
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Figure 4.3 The PMP-substrate external aldimine (ball and stick model) a) in complex with the surrounding 
H. pylori PseC residues (cyan chainA, yellow chain B) and b) with the catalytic Lys183 residue. 
During the first half transamination (Scheme 3.3)., initially an enzyme-PLP Schiff base forms 
(3.14), then a free amino donor (3.15) releases the enzyme from the internal aldimine (3.14) 
forming an external aldimine (3.16) via a transaldimination reaction. Finally hydrolysis occurs 
resulting in release of a glyoxylic acid (3.18) to produce free PMP (3.13) in the active site.231 In 
C. jejuni PseC a screen of all twenty amino acids as the amino donor revealed that maximum 
conversion was achieved using 10 mM glutamate (20 molar equivalents of the substrate).247 
The second amino transfer (Scheme 4.3) occurs via attack of the PMP amine to the sugar C4 
keto producing water and a ketimine intermediate (4.8). Lsy183 then acts as a base to abstract 
a labile proton (made so by the electron sink nature of the PMP pyridine ring) from the ketimine 
structure resulting in formation of a quinoid intermediate (4.9). Re-protonation at the sugar C4 
position allows for formation of the sugar-co-factor aldimine (4.10) which is then released in a 
transaldimination reaction to give the bound co-factor enzyme complex (3.13) and the free 
aminated sugar (3.8).  
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Scheme 4.3 The proposed PseC mechanism transferring an amino group from the PMP co-factor, 
generated in situ, to the keto-sugar (3.8) via formation of an external aldimine (4.10) that crystal 
structures have been shown as present in the active site during the reverse reaction.  
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4.1.4 Campylobacter jejuni PseC  
Although a structure for C. jejuni PseC has not been solved, detailed biochemical 
characterisation has been performed on this enzyme and similarities with the H. pylori sequence 
infers a similar fold. Sequence alignment reveals a 43.0 % identity between these enzymes and 
importantly, residues proximal to the co-factor and active site are almost always identical when 
comparing the C. jejuni PseC sequence with the H. pylori PseC sequence (Figure 4.4). For 
example the H. pylori catalytic residue Lys183 is aligned with the predicted C. jejuni catalytic 
residues; Lys181 surrounded by homologous residues. 
 
Figure 4.4 Alignment comparison of the H. pylori and C. jejuni PseC sequences with H. pylori residues 
shown to be proximal to the co-factor and active site highlighted (green). The conserved C. jejuni residues 
in these sites are also highlighted (cyan), along with the conserved catalytic lysine (magenta). 
NMR of the purified product from coupled C. jejuni PseB and PseC reactions confirmed the 
identity of the product as UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8) and suggested its role as 
the second enzyme in the Pse5Ac7Ac (1.13) biosynthetic pathway.226 Coupled reactions also 
revealed that aminotransferase activity occurred without the addition of exogenous PLP (3.11), 
suggesting that similarly to PseB, there is tight binding of the co-factor throughout 
purification.247 However it was found that introduction of PLP (3.11) into the reaction mixture 
could increase activity suggesting that the intracellular level of PLP (3.11) was not sufficient for 
saturation of PseC with its co-factor.  
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4.2 Investigations into the relationship between PseB and PseC  
4.2.1 Complications whilst monitoring the coupled PseB and PseC reaction 
 
Scheme 4.4 C. jejuni PseB and PseC full reaction scheme highlighting conversion to the PseB inverted by-
product (4.1) and the non-enzymatic production of the hydrated PseB products (4.2, 4.12). 
As previously discussed, when left in the presence of UDP-4-keto-6-deoxy-L-IdoNAc (3.7) C. 
jejuni PseB catalyses the epimerisation of this product at C5 (highlighted with an *) (Scheme 
4.4).242 This is problematic during the enzymatic synthesis of Pse5Ac7Ac (1.13)  as this epimer is 
not a substrate for PseC and does not form part of the Pse5Ac7Ac (1.13) biosynthetic pathway. 
Additionally activity analysis is complicated as the PseB ketone products (3.7, 4.1) exist in 
equilibrium with their hydrated forms (4. 2, 4.12) which have the same molecular weight as the 
starting material UDP-GlcNAc (3.1) (Scheme 4.4). Therefore monitoring the reaction with 
negative ESI LC-MS becomes more complex as the [M-H]- peak at 589 could be attributed to 
either the desired or un-desired PseB catalysed products (3.7, 4.1) and the [M-H]- peak at 606 
could be attributed to three different molecules (3.1, 4.2, 4.12), of which only one (4.2) is 
desired (Table 4.1).  
Table 4.1; LC-MS ESI [M-H]- values for the components of the C. jejuni PseB, PseC enzymatic synthesis 
 
  
Compound number 3.1 3.7 3.8 4.1 4.2 4.12 
LC-MS ESI [M-H]- / Da 606 589 590 589 606 606 
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4.2.2 Initial investigations into the coupled PseB and PseC reaction 
Although pleasing that all of the C. jejuni enzymes were active and that enzymatic turnover to 
Pse5Ac7Ac (1.13) had been achieved on a small scale (< 1mg), it was proposed that further 
investigations into each step were required in order to optimise turnover and prevent potential 
issues upon increasing the scale of the reaction.  It was decided to initially focus on the PseB and 
PseC enzymatic reactions with the intention to obtain conditions that would achieve optimal 
conversion to the PseC product (3.8). At the previously used concentrations of enzymes no 
biosynthetic intermediates were observed during the enzymatic synthesis of Pse5Ac7Ac (1.13) 
therefore lower concentrations of PseB and PseC were utilised in the following experiments to 
allow for tracking conversion (Scheme 4.5). A 50 mg UDP-GlcNAc (3.1) reaction mixture was set 
up by addition of PseB (25 µM), PseC (23 µM), PLP (1.5 mM) and L-Glu (10 mM) to UDP-GlcNAc 
(1 mM) in sodium phosphate buffer (50 mM, pH 7.4). The reaction was incubated (shaking 120 
rpm, 37 °C) and conversion to the PseC product (3.8) was monitored with negative ESI LC-MS 
(Figure 4.5). Although the use of LC-MS is a useful comparative tool and allows for relative 
conversions to be assigned, within this report it is not used as a quantitative measure. Different 
molecules have different ionisation potentials and hence conversions have only been assigned 
in order to relatively compare the effect of modifying the conditions.  
Upon addition of PseB and PseC the intensity of the [M-H]- 606 Da peak decreased which was 
attributed to PseB catalysed turnover of UDP-GlcNAc (3.1), and there was an increase in 
intensity of the peak corresponding to the PseB product (3.7) ([M-H]- 588 Da) and PseC product 
(3.8) ([M-H]- 589 Da) from 10 mins to 45 mins (Figure 4.5a, b). For example, the relative intensity 
of the PseC product (3.7) peak was 29 % after 10 minutes and increased to 42 % after 45 minutes 
(relative intensity calculated as a percentage of the total intensity of all peaks corresponding to 
sugar intermediates). It has previously been shown that hydration of the PseB product occurs in 
just a few minutes (producing a structure with the same molecular weight as UDP-GlcNAc 3.1) 
and hence upon the time scale of LC-MS analysis it can be assumed that conversion to the PseB 
hydrated product had begun prior to analysis. Therefore turnover to the PseB product could not 
be quantified during the reaction as the PseB hydrated product and the UDP-GlcNAc starting 
material (3.1) will both be contributing to the intensity of the [M-H]- 606 Da peak.  
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Scheme 4.5 The coupled C. jejuni PseB and PseC reaction converting UDP-GlcNAc (3.1) to the second 
Pse5Ac7Ac (1.13) biosynthetic intermediate UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8). 
 
 
Figure 4.5 C. jejuni PseB and PseC reaction progression a) after incubating for 10 mins displaying 
conversion to the PseC product (3.8), b) after incubating for 45 mins displaying increased conversion to 
the PseC product (3.8), and c) after incubating for 6 hrs displaying no further increase in conversion to the 
PseC product (3.8). 
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It was hoped that the inclusion of the PseC enzyme converting the ketone-PseB product (3.7) to 
the aminated product (3.8) would promote both the PseB catalysed depletion of UDP-GlcNAc 
(3.1) and the un-catalysed dehydration of the PseB hydrated product (4.2) and hence a decrease 
in intensity of the [M-H]- 606 Da peak would be observed as the reaction progressed. However 
the reaction did not progress as expected, with similar relative intensities of all peaks observed 
after 1 hr and after 6 hrs of incubation, with a significant [M-H]- 606 peak remaining (45 %) 
(Figure 4.5c). This was somewhat unprecedented considering the previously achieved 
conversion during the enzymatic synthesis of Pse5Ac7Ac (1.13). However as the reaction was on 
a larger scale and progressing more slowly it was proposed that the slower PseB catalysed 
secondary epimerisation had begun to compete with the PseC reaction and converted some of 
the UDP-4-keto-6-deoxy-L-IdoNAc (3.8) into the PseB epimeric by-product (4.1) which in the 
hydrated form (4.12) also has a [M-H]- of 606.  
Even though it was observed that turnover to the desired PseC product sugar (3.8) had halted 
under these conditions it was impossible to distinguish which sugar structures were still present 
in the solution. For example, the intensity of the [M-H]- 606 peak could be attributed to UDP-
GlcNAc (3.1) starting material or hydrated PseB by-product (4.2, 4.12) and the [M-H]- 588 peak 
could be the desired PseB product (3.7) or its C5 epimeric form (4.1). However the lack of further 
conversion was indicative that an equilibrium had been reached and the peaks at [M-H]- 588 Da 
and [M-H]- 606 Da could be attributed to the presence of the PseB by-products (4.1 and 4.12 
respectively).  
These initial results suggest that production of UDP-4-amino-4,6-dideoxy-β-ɩ-AltNAc (3.8) on a 
large scale could be more challenging than originally assumed. Although a modest conversion 
was achieved ~ 40 %, when comparing the relative intensity of the PseC product peak at [M-H]- 
589 Da, to the combined relative intensities of the other sugar substrates ([M-H]- 589 Da and 
[M-H]- 606 Da) after 6 hrs, it was proposed that optimisation of the enzyme concentrations could 
promote higher levels of conversion. In particular it was apparent that a significant proportion 
of the sugar compounds had undergone conversion to the PseB by-product (4.1), affecting the 
overall conversion to the desired PseC product (3.8) hence it was desired to attain conditions to 
prevent this.  
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4.2.3 The PseB and PseC coupled reaction in deuterium oxide 
To prevent formation of the proposed by-product it was necessary to remove UDP-4-keto-6-
deoxy-L-IdoNAc (3.7) from the solution as soon as it was formed. Therefore a series of 
experiments were designed using varying ratios of PseB:PseC in order to observe if an increase 
in PseC concentration could promote conversion to the PseC product (3.8) and out-compete the 
PseB secondary reaction (Scheme 4.4). These experiments were carried out in deuterated buffer 
to allow for the PseB hydrated forms to be distinguishable from UDP-GlcNAc (3.1) by negative 
ESI LC-MS as a solvent molecule is employed in the PseB mechanism.  
 
 
Scheme 4.6 Partial PseB mechanism highlighting the D2O solvent molecule utilised during the mechanism 
and the corresponding product detected by negative ESI LC-MS whereby all of the labile deuterium have 
undergone solvent exchange with the H2O/MeCN mobile phase. 
 
Previous experiments, in D2O, tracked by NMR identified formation of a C5-D bond during the 
PseB catalysed reaction, which is formed during the reduction of the alkene, hence formation 
of a stable C-D bond is observed (Scheme 4.6). Solvent exchange will also occur between labile 
bonds (such as hydroxyls) in these sugar molecules in D2O, however this potential complication 
is minimised during LC-MS analysis as they are subjected to an excess of H2O in the mobile phase 
and all labile bonds undergo deuterium-proton exchange. Therefore carrying out the reaction in 
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D2O allows for the production of PseB products (4.15, 4.16, 4.17, 4.18) with a [M-H]- of +1 
compared to their non-deuterated analogues resulting in the PseB hydrated forms (4.14, 4.15) 
being distinguishable from UDP-GlcNAc (3.1) (Table 4.2).  
Table 4.2 Negative ESI [M-H]- values for sugar molecules present in the deuterated PseB, PseC reaction 
 
 
 
 
 
 
 
 
 
 
 
In a 
deuterated solvent all of the labile N-H and O-H bonds will undergo solvent exchange and be 
deuterated so in negative ESI mass spectrometry a peak at a [M-H]-  600 would be expected for 
the deuterated PseC product (4.18). This peak is not observed using LC-MS analysis however, as 
the solvent system has an excess of H2O and therefore during analysis solvent exchange occurs 
with all labile deuterated bonds. Based on the proposed PseC mechanism, it was expected that 
a second stable deuterium would be incorporated into the sugar structure. Predictions of the 
position of the deuterium incorporation can be made based on the proposed PseC mechanism 
as during the synthesis of UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8) there is only one non-labile 
bond made; (Scheme 3.3 and Scheme 4.3).  
  
Sugar molecule LC-MS ESI [M-H]- in D2O 
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589 
     
 
 
607 
 
 
 
591 
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In deuterated solvent, it can be assumed that all labile protons will be solvent exchanged, for 
example the catalytic Lys181 amine will be deuterated (4.19) (Scheme 4.7). During the 
rearrangement from the quionoid intermediate (4.20) to the PMP-substrate aldimine (4.21), the 
active site lysine donates a deuterium to the sugar C4 position. Therefore a deuterium from the 
labile N-D bond is incorporated into the sugar ring (4.22) forming a stable C-D bond that is 
retained in the sugar ring during LC-MS analysis when all of the labile deuterium undergo solvent 
exchange (4.23) (Scheme 4.7). Negative ESI LC-MS analysis confirmed the incorporation of a 
non-labile deuterium during the PseC reaction as well as the one incorporated during the PseB 
reaction as the product peak was observed at an [M-H]-  of +2 compared to when the PseB, PseC 
coupled reaction is carried out in H2O ([M-H]-  589 in H2O, [M-H]-  591 in D2O) (Table 4.2).  
 
 
 
Scheme 4.7 Partial PseC mechanism in deuterium proposing formation of a stable C4 carbon-deuterium 
bond and the resulting sugar identified by negative ESI LC-MS. 
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4.2.4 Preventing formation of the PseB by-product 
Upon incubation (shaking 120 rpm, 37 °C) of Pse B (25 µM) and UDP-GlcNAc (1 mM) in a 
deuterated sodium phosphate buffer (50 mM, pH 7.4), the LC-MS peak corresponding to UDP-
GlcNAc (3.1) drastically diminished over 2 hours (Figure 4.6b,c). In its place arose two new peaks 
that were assigned to the singly deuterated versions of the keto tautomer (4.15, 4.17) and 
hydrated (4.16, 4.18) Pse B products. No such peaks were observed in the control (the reaction 
mixture without PseB) with only the [M-H]- 606 peak observed, indicative of no retaining solvent 
exchange occurring with the starting material, even after 12 hrs (Figure 4.6a).  
Negative ESI LC-MS analysis showed that after 30 minutes a considerable amount of UDP-
GlcNAc (3.1) remained in the reaction mixture containing PseB (64 % of the combined relative 
intensities of all of the sugar moieties). After two hours this had decreased to only a minor peak 
(13 %) showing efficient activity of the enzyme under these conditions (Figure 4.6b,c). During 
analysis it was observed that there was a higher intensity for the peak corresponding to the 
hydrated PseB product ([M-H]- 607) compared to the ketone PseB product peak ([M-H]- 589) 
suggesting that the position of equilibrium lay to the hydrated form and that conversion was 
fast. For example after 30 minutes, the ratio of deuterated ketone-PseB product (4.15, 4.17) to 
hydrated-PseB product (4.17, 4.18) was 1 : 4 (Figure 4.6b).  
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Figure 4.6 Negative ESI analysis of formation of the C. jejuni PseB products in deuterated solvent; a) 
control reaction of UDP-GlcNAc (3.1) after 12 hrs incubation displaying no conversion b) 30 mins after 
incubating UDP-GlcNAc (3.1) with PseB, c) 120 mins after incubating UDP-GlcNAc (3.1) with PseB and d) 
120 mins after addition of PseC and co-factors to the reaction mixture c). 
 
To investigate the C5 stereochemistry of the reaction mixture after two hours i.e whether it was 
still an intermediate of the Pse5Ac7Ac (1.13) biosynthetic pathway, PseC (and its co-factors) in 
D2O were added to the mixture. Negative ESI LC-MS analysis after two hours displayed no 
conversion to the deuterated PseC product (4.23) indicative that PseB had already catalysed all 
of its original product (4.15) into the epimeric by-product (4.17) (Figure 4.6d). Comparison of 
the ketone-PseB product (4.15, 4.17) with the hydrated product (4.16, 4.18) after this four hours 
of incubation showed an increased ratio of 1 : 5.2. Thus the previously observed remaining [M-
H]- 606 peak in non-deuterated PseB reactions was attributed to the formation of these 
hydrated products (4.16, 4.18) and the apparent low conversion rates to the PseB product (3.7) 
accounted for. 
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Unlike the sequential addition of PseC to the PseB reaction mixture, when PseB and PseC were 
added to the reaction mixture simultaneously, negative ESI LC-MS analysis confirmed the 
presence of deuterated PseB products (4.15-4.18) in addition to a peak corresponding to the 
doubly deuterated PseC product ([M-H]- 591) (4.23) (Figure 4.7). Repeats of the D2O 
experiments allowed for optimisation of enzymatic concentrations in order to maximise 
conversion to the Pse C product (4.23). Reaction mixtures in deuterated sodium phosphate 
buffer (50 mM, pH 7.4) containing UDP-GlcNAc (1 mM), PLP (1.5 mM), ˪-glu (10 mM) PseB (25 
µM) and PseC (25 µM or 125 µM) were incubated (shaking 120 rpm, 37 °C).  Negative ESI LC-MS 
after ten minutes using [PseB : PseC] ratios of either 1:1 or 1:5 revealed  little difference in the  
consumption of UDP-GlcNAc (3.1); with the [M-H]- 606 peak 56.7 % compared to 56.9 % 
respectively (of the total peak intensities of the combine sugar products) (Figure 4.7a,b).  This 
was also the case after two hours, whereby in both reactions the peak corresponding to UDP-
GlcNAc (3.1) had decreased similarly to 14 % and 16 %, suggesting that the concentration of 
PseC did not affect the overall rate of consumption of UDP-GlcNAc (3.1) in these conditions 
(Figure 4.7c,d).   
However, the concentration of PseC was found to have an effect on the production of PseC 
product (4.23), with the reaction mixture containing an excess of PseC, resulting in a higher 
conversion to the PseC product (4.23) and lower peak intensities for the PseB products (4.15-
4.18). Even after ten minutes of incubation the reaction mixtures showed some deviation with 
the reaction mixture with the higher PseC concentration having a 6 % conversion to the PseC 
product whereby the reaction with 25 µM PseC only had a 3 % conversion (Figure 4.7a,b).  
After incubating the reactions for two hours, a much larger difference in relative peak intensity 
for the conversion of PseB products to PseC product were observed between the two reactions 
containing different concentrations of PseC (Figure 4.7c, d). At a [PseB : PseC] ratio of 1:1, there 
was only a 38 % conversion to the PseC product (4.23) after two hours, with 48 % of the sugar 
species remaining as PseB products (4.15-3.18) (Figure 4.7c). The reaction mixture containing 
five fold higher concentration of PseC showed an increased conversion of 66 % to the PseC 
product (4.23) with only 20 % of the sugar species remaining as PseB products (Figure 4.7d). 
This ratio did not change after incubating the reaction mixture for 24 hours suggesting that the 
PseB, PseC equilibrium had been reached. This improvement upon conversion to the PseC 
product (3.8) was deemed sufficient for preventing significant formation of the PseB epimeric 
by-product during enzymatic synthesis of Pse5Ac7Ac (1.13) whereby the formation of the PseC 
product would be even further promoted by its subsequent conversion to the other biosynthetic 
intermediates. 
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Figure 4.7 Negative ESI analysis of formation of the C. jejuni PseB (4.13-4.16) and PseC products (4.17) in 
deuterated solvent whilst investigating the effect of increasing the PseC concentration; a) concentration 
ratio of [PseB : PseC]  of 1 : 1 after 10 mins incubation, b) concentration ratio of [PseB : PseC]  of 1 : 5 after 
10 mins incubation, c) concentration ratio of [PseB : PseC]  of 1 : 1 after 2 hrs incubation, d) concentration 
ratio of [PseB : PseC]  of 1 : 5 after 2 hrs incubation.  
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4.3 Conclusions and future work 
Although the previously optimised production of the biosynthetic enzymes demonstrated in 
vitro turnover from UDP-GlcNAc (3.12) to Pse5Ac7Ac (1.13) in a one pot reaction on a small 
scale, restrictions to using the biosynthetic pathway were highlighted. Before large scale 
synthesis of Pse5Ac7Ac (1.13) could be attempted, it was imperative that these were addressed 
and resolved. 
These experiments focussed on exploring the relationship between the PseB and PseC 
enzymatic reactions, and the potential deviations that can occur from the Pse5Ac7Ac (1.13) 
biosynthetic pathway. Notably the PseB secondary epimerisation posed an issue for the 
enzymatic synthesis of Pse5Ac7Ac (1.13) as the resulting product (4.1) does not make up part of 
the Pse5Ac7Ac (1.13) biosynthetic pathway, but the UDP-diNAcBac (4.5) pathway instead. 
Although the mechanism to the desired PseB product has been defined, little is known about 
the secondary reaction and hence PseB could not be engineered to prevent formation of this 
product. Therefore it was proposed that the reaction would have to be optimised to remove 
UDP-4-keto-6-deoxy-L-IdoNAc (3.7) as soon as it was formed to prevent formation of the 
epimeric by-product. This was achieved by monitoring the PseB and PseC reactions in D2O and 
modifying the ratio of the concentrations of the enzymes. It was found that by increasing the 
concentration of PseC to five times that of PseB, conversion to the PseC product could be 
considerably increased after two hours compared to using equal concentrations of PseB and 
PseC.  
Further investigations into preventing the formation of the PseB by-product could focus on 
determining the residues implicated in the PseB mechanism. Mutation studies have highlighted 
active site residues essential for the catalysis of the initial inversion and dehydration but were 
found not to perturb the secondary epimerisation step.242 Therefore this suggests that different 
residues could be involved in the different mechanisms and hence further studies to identify the 
secondary reaction catalytic residues would aid in the design of rational mutations that could 
reduce the rate of the second epimerisation reaction without perturbing the initial reaction. 
Furthermore, investigations of the inter-linking of sugar pathways in other Pse5Ac7Ac (1.13) 
biosynthesising species could allow for identification of an UDP-GlcNAc (3.1) 5-inverting-4,6-
dehydratase that does not catalyse the secondary epimerisation to form a Pse5Ac7Ac (1.13) 
biosynthetic by-product. 
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5.1 Utilisation of acetyltransferases as synthetic tools 
5.1.1 The PseH catalysed acetyl transfer step 
 
Scheme 5.1 C. jejuni Pse5Ac7Ac (1.13) biosynthetic pathway highlighting the acetyltransfer step. 
The third step in the Pse5Ac7Ac (1.13) biosynthetic pathway is the transfer of an acetyl group 
to C4 of UDP-4-amino-4,6-dideoxy-β-ɩ-AltNAc (3.8) (Scheme 5.1).248 Enzymatically this step is 
catalysed by PseH, an aminoglycoside N-acetyltransferase from the GNAT superfamily, and as 
such, utilises acetyl-CoA (5.1) as a co-factor.249 It has been proposed that this family of 
acetyltransferase enzymes drives nucleophilic attack by orientating a basic residue so that it can 
deprotonate the amino group and employing an acidic residue to stabilise the de-acetylated 
thiolate anion.250 Crystal structures of C.jejuni PseH identified Tyr128 as the general acid to 
stabilise the proposed thiolate ion formed following acetyl transfer to UDP-4-amino-4,6-
dideoxy-β-ɩ-AltNAc (3.8) however an acidic residue close enough to deprotonate the C4 amino 
group was not observed. Docking of the substrate into the H. pylori PseH crystal structures 
showed a well-ordered water molecule hydrogen bonded to a serine positioned proximal to the 
C4 amino group that could mediate deprotonation of the substrate (Scheme 5.2).251  
 
 
Scheme 5.2 Acetyltransfer mechanism for synthesis of UDP-4-acetamido-4,6-dideoxy-β-ɩ-AltNAc (3.9) 
showing the C. jejuni PseH catalytic acid; Tyr128, and the proposed water mediated amine deprotonation.  
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5.1.2 Acetyl-CoA binding in GNAT enzymes 
Acylated amines are common in many biological, industrially relevant molecules and 
pharmaceuticals,252 and are generally introduced via acetyl transfer onto an amine.253 Chemical 
attachment of this functionality onto complex structures can be selectively challenging, 
however. Enzyme catalysed amine acetylation is commonly observed in nature with the majority 
employing acetyl-CoA (5.1) as an acetyl donor with a vast range of acceptor molecules.254  
The GCN5-related N-acetyltransferase (GNAT) superfamily consists of more than 100,000 
members found in all kingdoms of life.255 It encompasses a wide range of acceptor molecules 
including bacterial aminoglycoside transferases,256 histone (and other proteins) N-
acetlytransferases257 and arylamine N-acetyltransferases.258 This diversity of function is 
reflected in the vast array of cellular processes that these enzymes are involved in; for example  
drug resistance,259 biosynthesis,232 metabolism,260 and DNA replication.261 
Although the GNAT family has low sequence homology there is conservation of the core fold in 
all structures to date.250 Structural characterisation of over twenty GNAT enzymes has revealed 
conserved secondary elements consisting largely of antiparallel β sheets (six or seven strands) 
connected by loops or one of the four conserved α helices (Figure 5.1a).249 Another notable 
structural feature is the “β-4 bulge” forcing the β-4 and β-5 strands apart at one end to form a 
V-shape cleft (Figure 5.1b).250 Crystal structures in complex with the (acetyl)-CoA co-factor 
(5.1/5.2) show this cleft to be the co-factor binding site in all structures. Acetyl-CoA (5.1) is 
bound shaped like the letter ‘L’ and interactions with the enzyme occur with residues in the 
proximal α3, α4, β4 and β5 secondary structures (Figure 5.1b).249  
 
Figure 5.1 Crystal structure of the C. jejuni PseH acetyltransferase (PDB 4XPL)232 highlighting a) the 
canonical secondary structure of GNAT enzymes and b) the co-factor V-shape cleft binding site between 
strands β4 and β5 with the bound acetyl-CoA (5.1) co-factor (orange globular structure). 
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Figure 5.2 Breakdown of the structure of acetyl-CoA (5.1) and CoA (5.2) into substructures; the 
pantetheine arm, pyrophosphate group and adenosine moiety. 
Whilst considering the binding interaction of acetyl-CoA (5.1) with GNAT enzymes it is useful to 
divide the molecule into sub-structures; the thio-acetate, the pantetheine arm, the 
pyrophosphate group and the adenosine group (Figure 5.2). Across all members, binding of the 
acetyl-CoA co-factor (5.1) appears to be largely reliant on the strong interactions with the acetyl-
CoA pantetheine arm with seemingly fewer contributory interactions at more distal distances 
from the acetyl group.262 Certain residues in the β-4 and β-5 strands are homologous across 
species and structural studies complexed with (acetyl)-CoA (5.1/5.2) depict strong hydrogen 
bonding interactions between the acetyl-CoA pantetheine arm and these residues.249 For 
example in C. jejuni PseH three hydrogen bonds exist between the pantetheine arm and the 
surrounding residues; the Ala85 backbone amide can hydrogen bond with one of the 
pantetheine carbonyls whilst the other carbonyl hydrogen bonds with the Asn121 side chain 
and the amide proximal to the co-factor acetyl group has a hydrogen bond to the Leu83 
backbone carbonyl (Figure 5.3).232 It is believed that these hydrogen bonds, along with a host of 
other pantetheine-enzyme interactions help to hold the thio-ester in place for catalytic transfer. 
Generally in GNAT enzymes, the pyrophosphate group oxygens are found to interact with the 
α3 helix backbone amide bonds although the number of interactions available and their strength 
varies greatly between enzymes.249  The C. jejuni PseH crystal structure in complex with acetyl-
CoA (5.1) shows the pyrophosphate group arranged between two lysine residues with the Lys90 
sidechain suggested to form a hydrogen bong to one of the pyrophosphate oxygens. Other 
hydrogen bonds occur between pyrophosphate oxygens and amides in the protein back bone 
such as with Gly91 (Figure 5.3).232 Unsurprisingly the solvent exposed adenosine part of acetyl-
CoA (5.1) has been to shown to bind in a variety of conformations in GNAT crystal structures. 
The C. jejuni PseH crystal structure shows adenosine electron density in a number of position 
with only a few weak interactions with enzyme residues.232 
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Figure 5.3 Crystal structure of C. jejuni PseH (PDB 4XPL)232 in complex with its co-factor acetyl-CoA (5.1) 
(ball and stick model, carbon-bright green, oxygen-red, nitrogen-blue, su;phur-yellow, phosphorus-
magenta) showing hydrogen bonds (black dotted lines) between residues (stick model, carbon-ice blue, 
oxygen-red, nitrogen-blue) and the pantetheine arm and pyrophosphate group.  
Members of the GNAT superfamily appear to mainly rely on the strong interactions with the 
acetyl-CoA pantetheine arm for binding of the co-factor with seemingly fewer contributory 
interactions at more distal distances from the acetyl group. The tight binding of the pantetheine 
arm is somewhat unsurprising as the acetyl group needs to be held in the correct conformation 
to be transferred to the substrate. The exact mechanism of transfer is unknown for PseH and, 
in particular, there is uncertainty surrounding the catalytic base residue. Crystal structures in 
complex with the product or substrate and mutagenesis studies could provide further insight 
into the potential the catalytic residues. 
Although acetyl Co-A (5.1) is critical in multiple cellular processes,263 it’s complex structure 
renders it an expensive co-factor for use in vitro.  This expense of acetyl-CoA (5.1) is the major 
limitation for the utilisation of GNAT enzymes for synthesis and therefore investigations have 
focussed on eliminating the requirement for excess acetyl-CoA (5.1). Elucidation of the binding 
interactions has aided in rational design of other acetyl donors that could act as the co-factor 
for GNAT enzymes. It is has previously been shown that for some enzymes, binding affinity may 
be somewhat retained with substrates that mimic only the acetyl-CoA pantetheine arm and 
hence these simple molecules may be used in place of acetyl-CoA (5.1) for the enzyme catalysed 
acetyl transfer.264  
123 
 
5.1.3 Acetyl-transfer methods during enzymatic syntheses 
It has been estimated that acetyl-CoA (5.1) is used in ~4 % of all known enzyme reactions,264 
many involving highly specific and selective acetyl transfers that could be synthetically useful 
tools for desired acetyl transfer reactions. Despite this molecule being abundant in cells and 
used ubiquitously as an acetyl donating group, its complex structure means that it is also costly 
and complicated to chemically synthesise.255 Therefore methods to reduce the amount of acetyl-
CoA (5.1) required have been investigated to allow for use of acetyltransferases in synthesis to 
be more economically viable. Chemical acetylation can be an attractive alternative instead of 
use of an acetyltransferase as it completely removes the need for the acetyl-CoA (5.1) co-factor, 
and is especially effective in the synthesis of simple molecules.265 However in some cases it can 
be more advantageous to perform enzymatic acetyl-transfer; during an enzymatic synthesis266 
or when reacting more complex structures with multiple sites of potential acetylation,267 for 
example. Both chemical and enzymatic schemes for acylation of amines have been explored and 
are discussed below with emphasis on methods that are selective, low cost and applicable to 
use within enzymatic pathways to carbohydrates.  
A multitude of chemical acetylation protocols exist, suggesting many different potential 
reagents and conditions for amine acetylation,268-271 however not all are suitable for acetyl 
transfer onto aminoglycosides. Most importantly for this reaction, it is desired for the method 
to be highly selective for amine acetylation so that it is not necessary to protect other functional 
groups such as the free hydroxyls often present in sugar molecules, however this is difficult to 
achieve fully. For example, the simple sugar GlcN (5.3) can be N-acetylated with acetic anhydride 
in 10 % methanol and Dowex 1 (carbonate form). A 43 % yield is reported after filtration and 
crystallisation and although the GlcNAc (5.4) product is the major form, minor (< 1 %) O-
acetylated products can be detected.272 Additionally chemical acetylation methods should 
preferentially only use non-toxic, readily available reagents and solvents under mild conditions. 
Chemical methods are often flawed for use within in vitro enzymatic workflows, as the 
components of the chemical reactions are invariably incompatible with subsequent enzyme 
reactions and can reduce enzyme efficiency or require additional purification and solvent 
exchange steps. 
 
Scheme 5.3 A synthetic route of acetyltransfer to GlcN (5.3) to produce GlcNAc (5.4).  
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Nature has developed acetyl-CoA (5.1) regeneration systems itself to prevent the need for 
continual synthesis of such a complex and important molecule. For example in aerobic 
organisms acetyl-CoA (5.1) is an initiator of the Krebs cycle and its regeneration is catalysed by 
three enzymes involved in fixing pyruvic acid, formation of a disulphide bond and donation of 
the acetyl group.273 Less complex natural systems have also been identified that only require 
one enzyme for the catalysis of acetyl transfer onto CoA (5.2) and of these, acetyl-CoA 
synthetase (ACS), phosphotransacetylase (PTA) or carnitine acetyltransferase (CAT) are 
generally employed in vitro.274 Each enzyme displays efficient transfer of an acetyl group to CoA 
(5.1) and can be used in situ to regenerate acetyl-CoA (5.2).275 However industrial utilisation is 
still far from simple as issues arise with the substrates and co-factors needed for these enzymatic 
reactions.  ACS requires another expensive co-factor ATP to catalyse the coupling of carboxylic 
acids to CoA (5.2),276 and PTA and CAT require acyl substrates that can be difficult to prepare 
and are unstable limiting their practicality for wide use as acetyl-CoA (5.1) regenerators.277-278 
Chemical methods for regeneration of acetyl-CoA (5.1) have also been investigated, with 
syntheses detailing the use of small molecules such as acid anhydrides279 or N-
hydroxysuccinimide esters of fatty acids.280 However these methods cannot be utilised 
efficiently in all reaction schemes. They are generally not specific for CoA reacetylation and 
require organic solvents so cannot be carried out in situ within enzymatic reactions, 
necessitating extra purification steps and extended synthetic routes. One chemical regeneration 
factor, acetyl-thoicholine iodide (5.5), has been identified that can overcome these issues.281 
This regeneration factor is water soluble and importantly is primed for attack by the CoA thiol 
(5.2) as it has an electron withdrawing group which increases the electrophilicity of the carbonyl. 
The electron withdrawing group also aids in prevention of the reverse reaction by decreasing 
the nucleophilicity of the resulting thiol (5.6) (Scheme 5.4). Acetyl-thiocholine iodide (5.5) was 
found to act as an efficient regeneration factor of acetyl-CoA (5.1) during enzymatic reactions 
with substoichiometric levels of acetyl-CoA (5.1) for example during the citrate synthase 
catalysed synthesis of citric acid.281 
 
Scheme 5.4 Mechanism for the acetyl transfer from acetyl-thiocholine iodide (5.5) to CoA (5.1). 
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5.1.4 Introduction to the promiscuity of aminoglycoside N-acetyltransferases co-
factor binding sites 
A number of acetyl-transferase enzymes utilising acetyl-CoA (5.1) as the co-factor have 
displayed co-factor promiscuity in the structure the CoA (5.2) molecule and in the structure of 
acylated group they will transfer to the acceptor molecule. This suggests that acetlytransferases 
could be used in vitro to enzymatically transfer a variety of small acylated derivatives from CoA 
analogues onto natural acceptor molecules.  
It has been proposed that the reactivity of the acetyl transfer utilising acetyl-CoA (5.1) stems 
from the thio-ester and is largely unaffected by the distal parts of the acetyl-CoA (5.1) 
structure.282 Additionally acetyltransferase crystal structures in complex with the co-factor have 
shown that the majority of enzyme-co-factor binding interactions occur between the parts of 
the acetyl-CoA (5.1) structure proximal to the thioacetate group.262 Therefore CoA analogues 
have been synthesised that mimic the thioacetate and pantetheine part of the acetyl-CoA (5.1) 
structure, such as S-acetylcysteamine, with the aim to provide less expensive acetyltransferase 
co-factor alternatives to acetyl-CoA (5.1).264 For example, the rate of acetyl-transfer to GlcN-1-
P (5.7), to form GlcNAc-1-P (5.8), catalysed by the Pyrococcus furiosus bifunctional GlcN-1-P (5.7) 
actyltransferase/GlcNAc-1-P uridylyltransferase was reduced only 2-3 fold when using N-
acetylcysteamine thioester (5.9) compared to acetyl-CoA (5.1) (Scheme 5.5).283 This 
demonstrates that the need for acetyl-CoA (5.1) can be removed by exploring the activity of 
acetyl-transferase enzymes with much less expensive unnatural co-factor substitutes.  
 
Scheme 5.5 Acetyltransferase catalysed acetylation of GlcN-1-P utilising the natural co-factor acetyl-CoA 
(5.1) or N-acetylcysteamine thioester (5.9). 
Additionally PatB, a peptidoglycan O-acetyltransferase, that catalyses transfer of an acetyl group 
from a trans-membrane protein to the C6 hydroxyl of MurNAc 284 can accept acetyl-CoA (5.1) as 
an acetyl donor as well as a number of structurally different molecules. For example,  PatB was 
shown to catalyse acetyltransfer from p-nitro-phenol-acetate to chitotriose285 and 4-
methylumbelliferyl acetate to  chitopentaose286. This suggests that some acetyltransferases may 
126 
 
have even greater donor promiscuity and that co-factor substitutes may not need to be limited 
to acetyl-CoA (5.1) analogues. 
Some acetyltransferase enzymes have also been shown to catalyse transfer a number of 
different acyl-CoA groups onto substrates, highlighting a potential strategy for the introduction 
of additional functionality onto amine groups. Naturally, a number of acyl-CoA structures exist 
and are utilised as co-factors for specific transfer reactions. For example N-myristoyl 
transferases exhibit specificity for their native co-factor; myristoyl-CoA, catalysing transfer of 
the myristoyl group onto amino-terminal glycine residues.211 As acetyl-CoA (5.1) is more 
abundant than other acyl derivatives enzymes utilising it often display less specificity and have 
been shown to accept a number of acyl-CoA donors. However activity can quickly decrease as 
the acyl group differs more greatly from an acetyl group, for example during analysis of 
Streptomyces rubellomurinus FrbF catalysed acyl transfer to CMP-3-aminopropylphosphonate, 
with propionyl-CoA, malonyl-CoA and acetoacetyl-CoA were found to yield quantifiable 
amounts of product however the expected product was not detected using hydroxybutyryl-CoA 
and glutaryl-CoA.287 
Visualisation of glycans in their native cellular environment is heavily desired to aid insight into 
their roles and to better understand the significance of these cellular structures. The Bertozzi 
group has been at the front-line for enabling such studies via metabolic labelling of glycans with 
bioorthogonal handles.288-290 It has been shown that a number of simple azido-labelled sugars 
can be transported into cells and successfully displayed in place of the native sugars on cell 
structures within cell surface glycoconjugates.289 In this strategy the azido-tagged sugars are 
processed by biosynthetic enzymes to afford more complex sugars to be displayed on glycans 
e.g. chemically synthesised ManNAz can be fed to cells and processed into Neu5Az291 which can 
then be bioorthogonally tagged on cell surfaces using a variety of “click” chemistries.292 
Although production of ManNAz is not synthetically challenging, labelling of more complex 
sugars with azido groups can be chemically challenging. Therefore other techniques for 
installation of azido groups into carbohydrates have been investigated. Due to their promiscuity 
surrounding the acyl group, some acetyltransferase enzymes have been proposed as suitable 
for catalysing azido-acyl transfer to carbohydrate substrates.293 However due to the cost and 
complexity of the CoA structure (5.1), it is desired to be able to use azido-derivatives of small 
structural mimics of CoA (5.1) as azido-acyl donors with acetyltransferases. This has been 
demonstrated by incorporation of bioorthogonal handles during the PatB catalysed acylation of 
MurNAc with N-acylcysteamine thioesters.294 
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Synthesis of Pse5Ac7Az (5.10) has previously been achieved in vitro and in vivo and visualised 
through fluorescent click labelling of C. jejuni flagellin.295 This strategy used PseB and PseC to 
synthesise a C4 amino group (3.8) which was then chemically acetylated with chloroacetic 
anhydride (5.11) to give UDP-2-acetamido-4-chloroacetamido-4,6-dideoxy-β-ɩ-AltNAc (5.12). 
Following enzymatic hydrolysis of the UDP group with PseG, treatment with sodium azide 
afforded the Pse5Ac7Az biosynthetic precursor, UDP-4-azidoacetamido-4,6-dideoxy-β-ɩ-AltNAc 
(5.14). It was shown that this molecule could be turned over by PseI in vitro (Scheme 5.6) and 
in vivo when fed to C. jejuni cells. However this strategy to Pse5Ac7Az (5.10) requires alternating 
between chemical and enzymatic steps resulting in a number of time consuming purifications 
and solvent exchanges en route to the desired final compound.295  
 
Scheme 5.6 A chemo-enzymatic route to the Pse5Ac7Az (5.10) utilising a combination of enzymatic and 
chemical steps. 
 
One of the major limitations of scaling up the in vitro enzymatic synthesis of Pse5Ac7Ac (1.13) 
lies with the expense of acetyl-CoA (5.1) which is required in excess during the PseH catalysed 
acetyl-transfer. Three alternate methods for acetyl-transfer have been explored; chemical 
acetylation, enzyme catalysed acetylation coupled with acetyl-CoA (5.1) co-factor regeneration 
and use of other acetyl-donating co-factor substitutes. The methods were evaluated based on 
availability, cost, practicality and viability for use within the enzymatic system for production of 
Pse5Ac7Ac (1.13).   
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5.2 Acetylation during the chemo-enzymatic synthesis of Pse5Ac7Ac 
5.2.1 Chemical acetylation of UDP-4-amino-4,6-dideoxy-β-˪-AltNAc 
After considering a number of chemical methods it was decided to use a heterogeneous silver 
acetate catalyst with acetic anhydride to selectively acetylate the C5 amine.296 This method had 
already been detailed for the synthesis of UDP-4-acetamido-4,6-dideoxy-β-˪-AltNAc (3.9) and 
observed to selectively form the desired acetamido product with quantitative conversion.228 The 
silver acetate (5.15) is utilised as a catalyst, activating the acetic anhydride (5.16) by coordinating 
to a carbonyl oxygen. Hence, electron density is further drawn away from the carbonyl carbon, 
increasing its electrophilicity and making it more susceptible to nucleophilic attack. This 
promotion of carbonyl electrophilicity removes the requirement for addition of a base to 
deprotonate the amine prior to the acetylation step and this occurs after acetyl transfer, 
producing acetic acid (5.17) as a by-product (Scheme 5.7).  
 
Scheme 5.7 Chemical acetylation of UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8) to afford UDP-4-
acetamido-4,6-dideoxy-β-˪-AltNAc (3.9) using a silver acetate catalyst (5.15) to activate the acetic 
anhydride making it more susceptible to nucleophilic attack. 
A chemo-enzymatic synthesis of UDP-4-acetamido-4,6-dideoxy -β-˪-AltNAc (3.9) was proposed 
(Scheme 5.8). The PseH reagent was prepared using a coupled PseB and PseC reaction; UDP-
GlcNAc (1 mM) was suspended in 50 mM Tris-HCl (pH 7.4) with PseB (25 µM) and PseC (25 µM) 
along with the PseC co-factors PLP (2.5 mM) and ˪-Glu (10 mM). The reaction was shaken (120 
rpm) at 37 °C and monitored by negative ESI LC-MS for 5 hrs (Figure 5.4a).   
 
Scheme 5.8 Enzymatic synthesis of UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8) followed by chemical 
acetylation to UDP-4-acetamido-4,6-dideoxy-β-˪-AltNAc (3.9) using a silver acetate catalyst (4 equiv) and 
acetic anhydride (11.5 equiv) in MeOH, at room temperature for 3 hrs. 
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Acetic anhydride (11.5 equivs) and silver acetate (1 equiv) were added to the crude PseC product 
(3.8) in methanol and the reaction monitored by negative ESI LC-MS. Equivalents were 
calculated based on quantitative conversion (1.65 µmol) to the PseC product (3.8) as yield could 
not be calculated from the mass of the crude reaction. A decrease in relative intensity of the [M-
H]- 589 peak was observed alongside the appearance of the expected peak with a [M-H]- of 631 
corresponding to the acylated sugar molecule (3.9). After 3 hrs the presence of the substrate 
(3.8) was no longer detectable by negative ESI LC-MS (Figure 5.4b). The heterogenous catalyst 
was removed by filtration and product lyophilised three times in water to remove excess acetic 
anhydride. Contrary to the previously published strategy,228 this synthesis has shown that time-
costly purification steps between enzymatic and chemical steps are unnecessary for substrate 
turnover. Additionally it was discovered that the amount of silver acetate catalyst required for 
efficient turnover was much less than previously published (1 equiv instead of 4 equiv)228 
bypassing the need for excess acetyl-CoA (5.1) and an extensive chemical synthesis to afford 
Pse5Ac7Ac (1.13). However despite advantages over previously published syntheses, the use of 
chemical acetylation within the enzymatic synthesis of Pse5Ac7Ac (1.13) does require two 
additional work-up procedures and no longer has the benefits of being a one-pot system.  
 
Figure 5.4 Negative ESI LC-MS demonstrating a) Enzymatic conversion of the PseC product (3.8) and b) 
chemical acetylation to afford the PseH (3.9) product.   
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5.2.2 In situ regeneration of acetyl-CoA using acetyl thiocholine iodide 
Regeneration of sub-stoichiometric amounts of acetyl-CoA (5.1) in situ during PseH turnover 
was also investigated as an acetylation strategy. Regeneration of acetyl-CoA (5.1) occurs 
specifically through attack of the CoA thiol (5.2) formed as a by-product during PseH turnover 
(Scheme 5.9). Therefore thioesters are ideal regeneration factors, whereby a thioester exchange 
could occur in situ to enable regeneration of acetyl-CoA (5.1). This could facilitate the enzymatic 
synthesis of Pse5Ac7Ac (1.13) in a one-pot procedure, while also enabling the reduction of the 
quantity of acetyl-CoA (5.1) initially required for optimal conversion. Acetyl thiocholine iodide 
(5.5) was investigated as a low cost, commercially available CoA (5.1) acetyl donor which is 
stable and soluble under aqueous conditions (Scheme 5.9). The electronegative nitrogen in the 
choline group was suggested to promote the desired reaction by increasing the electropositivity 
of the carbonyl carbon in the acetylated structure (5.5) and deter the reverse reaction by 
drawing electron density away from the resulting thiol (5.6).  
 
 
Scheme 5.9 Regeneration of acetyl-CoA (5.1) in situ during the enzymatic synthesis of UDP-4-acetamido-
4,6-dideoxy-β-˪-AltNAc (3.9). 
In order to ascertain the efficiency of acetyl-CoA (5.1) regeneration within this system, a number 
of small scale (0.1 mg UDP-GlcNAc) reaction mixtures were set up containing UDP-GlcNAc (1 
mM), Pse B (25 µM), Pse C (125 µM) and their associated co-factors. PseH (50 µM) was added 
to the reaction mixture and two controls were devised; a negative control containing 0 mM 
acetyl-CoA (5.1) and 20 mM acetylthiocholine iodide, and a positive control containing 1.5 mM 
acetyl-CoA (5.1). To the remaining reactions, increasing concentrations (0 mM to 20 mM) of 
acetyl thiocholine iodide (5.5) were added and all reactions were shaken (120 rpm) at 37 °C.  
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The reactions were monitored with negative ESI LC-MS and relative turnover to acetylated 
product (3.9) was calculated as a percentage of the total sugar compounds present in the 
reaction mixture. Qualitative conversion was observed when comparing the m/z 631 ion trace 
(Pse H product) of all of the reactions after 4 hrs. It was observed that addition of 
acetylthiocholine iodide (5.5) to the reactions containing sub-stoichiometric amounts of acetyl-
CoA (5.1) increased conversion to the PseH product (3.9) and hence acted as a co-factor 
regenerator, although this did not occur as efficiently compared to the reaction containing 
excess acetyl-CoA (5.1) (Figure 5.5). 
 
 
Figure 5.5 Overlay of the LC-MS negative ESI m/z 631 extracted ion count traces after 4 hrs showing the 
effect of addition of the acetylthiocholine iodide on PseH catalysed acetyltransfer whilst using sub-
stoichiometric amounts of acetyl-CoA (5.1). 
Analysis of the negative ESI LC-MS data showed that there was no detectable conversion to the 
acetylated sugar (3.9) in the reaction mixture with 0 mM acetyl-CoA (5.1) and 20 mM 
acetylthiocholine iodide (5.5) suggesting that it could not act as the co-factor itself, and nor 
could any of the other reaction constituents (Figure 5.6a). Decrease of the acetyl-CoA (5.1) 
concentration to 0.15 mM with no regeneration factor showed a marked decrease in the 
turnover to the PseH product (3.9); with only 44 % conversion (Figure 5.6b). However this 
conversion could be increased to 66 % with the addition of 2 mM acetylthiocholine iodide (5.5) 
(Figure 5.6c) and 72 % conversion when the reaction included 20 mM acetylthiocholine iodide 
(5.5) (Figure 5.6d). 
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Figure 5.6 Negative ESI LC-MS analysis of conversion to the PseH product (3.9) from UDP-GlcNAc (3.1), 
investigating the use of acetylthiocholine iodide (5.5) as a regeneration factor with sub-stoichiometric 
amounts of acetyl-CoA (5.1) a) 0 mM acetyl-CoA (5.1) and 20 mM acetylthiocholine iodide (5.5), b) 0.15 
mM acetyl-CoA (5.1) and 0 mM acetylthiocholine iodide (5.5), c) 0.15 mM acetyl-CoA (5.1) and 2 mM 
acetylthiocholine iodide (5.5), and d) 0.15 mM acetyl-CoA (5.1) and 20 mM acetylthiocholine iodide (5.5). 
As the reaction containing 0.15 mM acetyl-CoA (5.1) and 20 mM acetylthiocholine iodide (5.5) 
displayed the highest level of conversion (72 %) to the PseH product, reactions using this 
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concentration of acetylthiocholine iodide (5.5) were further explored. Additionally, in order to 
further exploit this regeneration method, CoA (5.2) was trialled instead of acetyl-CoA (5.1) due 
to its lower cost. Similar reaction mixtures were constructed UDP-GlcNAc (1 mM), Pse B (25 µM), 
Pse C (125 µM), their associated co-factors and PseH (50 µM). However the concentration of 
acetythiocholine iodide (5.5) across reactions was kept constant (20 mM) and increasing 
concentrations of acetyl-CoA (5.1) (0 mM to 0.15 mM) were added. All reactions were shaken 
(120 rpm) at 37 °C and monitored with negative ESI LC-MS. After 4 hrs, negative LC-MS ESI 
showed that production of UDP-4-acetamido-4,6-dideoxy-β-˪-AltNAc (3.9) could be achieved in 
reaction mixtures containing 20 mM acetylthiocholine iodide (5.5) and all concentrations of CoA 
(5.2) screened (Figure 5.7, 5.8). However, as anticipated, comparison of the m/z 631 ion trace 
showed that conversion decreased as the CoA (5.1) concentration was decreased from 0.15 mM 
to 0.0015 mM; suggestive that the supply of acetyl-coA (5.1) was limiting the rate of the reaction 
(Figure 5.7).  
 
Figure 4.7 Overlay of the LC-MS negative ESI m/z 631 extracted ion count traces after 4 hrs showing the 
effect of decreasing the concentration of CoA from sub-stoichiometric to catalytic amounts on PseH 
catalysed acetyltransfer in the presence of 20 mM regeneration factor; acetylthiocholine iodide (5.5). 
Comparison of the relative intensities of the product (3.9) peak, as a percentage of the total 
intensity of peaks corresponding to sugar products showed that utilising 20 mM regeneration 
factor (5.5) with substoichiometric amounts of CoA (5.2) generated turnover to the PseH 
product (3.9). A 65 % conversion was achieved when the concentration was ten-fold less than 
the original amount of acetyl-CoA (5.1) required (Figure 5.8a). Decreasing the concentration by 
another factor of ten (0.015 mM) reduced the conversion rate to 49 % (Figure 5.8b) and a 44 % 
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conversion was still achieved when catalytic amounts of CoA (5.2) were utilised (0.0015 mM) 
(Figure 5.8c). 
 
Figure 5.8 LC-MS negative ESI mass spectra demonstrating conversion to the acetylated PseH product 
(3.9) using 20 mM regeneration factor (5.5) and substoichiometric amounts of coA (5.2); a) 0.15 mM CoA 
(5.2), b) 0.015 mM CoA (5.2), c) 0.0015 mM CoA (5.2), d) 0mM CoA (5.2). 
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In order to practically use this co-factor regeneration strategy in the “one-pot” synthesis of 
Pse5Ac7Ac (1.13), further optimisation was required to increase the conversion rate. Therefore 
identical reactions mixtures were constructed as before, with varying concentrations of CoA 
(5.2), however in these reactions, the concentration of the regeneration factor (5.5) was 
increased to 100 mM. Notably, increasing the concentration of acetyl thiocholine iodide (5.5) 
from 20 mM to 100 mM drastically reduced the effect of decreasing the concentration of CoA 
(5.2) from 0.15 mM to 0.0015 mM (Figure 5.9).  
 
Figure 5.9 Overlay of the LC-MS negative ESI m/z 631 extracted ion count traces after 4 hrs showing the 
effect of decreasing the concentration of CoA from sub-stoichiometric to catalytic amounts on PseH 
catalysed acetyltransfer in the presence of 100 mM regeneration factor; acetylthiocholine iodide (5.5). 
Upon comparison of the relative intensities of the product (3.9) peak after 4 hrs in negative LC-
MS analysis, as a percentage of the total sugars in the reaction mixture, the reactions had much 
more similar levels of conversion to the PseH product (3.9) when decreasing the CoA 
concentration; 68 %, 64 % and 61 % respectively (Figure 5.10).  
This strategy successfully demonstrated a synthetic route to UDP-4-acetamido-4,6-dideoxy-β-˪-
AltNAc (3.9) in a “one-pot” enzymatic system where use of a regeneration co-factor could 
compensate for using a vastly reduced concentration of CoA (5.2) (1000 fold decrease compared 
to the original synthesis). Therefore these reaction conditions were deemed suitable for 
potential use in a large scale synthesis as the activity mainly retained but the cost of the reaction 
is drastically reduced. For example, using acetyl-CoA (5.2) at a concentration of 1.5 mM in a 
reaction containing 100 mg UDP-GlcNAc (3.1) the cost of the required quantity of co-factor 
would be £1864 (calculated using Sigma prices) but using 0.0015 mM CoA and 10 mM acetyl-
thiocholine iodide (5.5) it was calculated to only cost £124 for the equivalent reaction. 
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Figure 5.10 LC-MS negative ESI mass spectra demonstrating conversion to the acetylated PseH product 
(3.9) using 100 mM regeneration factor (5.5) and substoichiometric amounts of CoA (4.4) ; a) 0.15 mM 
CoA (5.2), b) 0.015 mM CoA (5.2), c) 0.0015 mM CoA (5.2), d) 0 mM CoA (5.2).  
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After the promising results utilising a regeneration factor for the synthesis of the PseH product 
(3.9) it was attempted to expand this reaction for the “one-pot” enzymatic synthesis of 
Pse5Ac7Ac (1.13). A reaction containing UDP-GlcNAc (1 mM), PLP (2.5 mM), ˪-Glu (10 mM), CoA 
(0.0015 mM), acetylthiocholine iodide (100 mM), PEP (1.5 mM) and the biosynthetic enzymes 
PseB (25 µM), PseC (125 µM), PseH (50 µM), PseG (30 µM) and PseI (25 µM) in sodium 
phosphate buffer (50 mM, pH 7.4) was incubated, shaking (120 rpm) at 37 °C. Negative ESI LC-
MS analysis indicated that that the addition of 100 mM acetylthiocholine iodide (5.5) in the 
reaction mixture did not have an adverse effect on the activities of the final biosynthetic 
enzymes; PseG and PseI as conversion to the Pse5Ac7Ac (1.13) product was observed. After 5 
hrs negative ESI LC-MS showed complete conversion to Pse5Ac7Ac (1.13) using this new system; 
100 mM acetylthiocholine iodide (5.5) and 0.0015 mM CoA (5.2), as determined by the lack of 
peaks corresponding to the Pse5Ac7Ac (1.13) biosynthetic starting material (3.1) and 
intermediates (3.7-3.10) (Figure 5.11). 
 
Figure 5.11 LC-MS negative ESI demonstrating successful production of Pse5Ac7Ac (3.1) in the “one-pot” 
system when employing 0.0015 mM CoA (5.2) and 100 mM acetyl thiocholine iodide (5.5). 
In situ co-factor regeneration during the PseH reaction makes the one-pot enzymatic synthesis 
of Pse5Ac7Ac (1.13) far more economically viable, potentially facilitating large scale production. 
However a potential limitation for the general use of acetyl thiocholine iodide (5.5) as a 
regeneration factor surrounds its anticipated reactivity as an acetyl transfer agent, which could 
result in non-selective acetylation during attempted synthesis of other pseudaminic acid 
derivatives. Therefore other alternatives for acetyl transfer regeneration factors could be 
investigated. 
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5.2.3 N-acetyl cysteamine thioacetate as a PseH co-factor substitute 
Analysis of the binding of C. jejuni PseH to acetyl-CoA (5.1) provides a potentially powerful 
insight for the design of alternative co-factors. Briefly, the adenosine group of acetyl-CoA is 
surface bound, fairly flexible and thought to only marginally contribute to binding interactions 
with C. jejuni PseH. Contrastingly the pantetheine moiety and pyrophosphate group are more 
deeply inserted into the co-factor binding groove and participate in diverse interactions with 
nearby residues. Thus suggesting mimics of these portions of acetyl-CoA (5.1) could behave as 
substitute co-factors, potentially removing the requirement for even catalytic quantities of CoA 
(5.2) in the enzymatic synthesis of Pse5Ac7Ac (1.13).   
N-acetyl cysteamine thioacetate (5.9) was recognised as a short-chain acetyl donor that is 
structurally similar to part of the acetylated pantetheine arm of acetyl-CoA (5.1). The structure 
is composed of the thioacetate group which is susceptible to nucleophilic attack in 
acetyltransferase reactions and an N-acetylcysteamine that has been proposed to make key 
binding interactions with C. jejuni PseH.232   It has recently been shown to act as an acetyl donor 
for PatB catalysed O-acetylation peptidoglycan synthesis.294 This molecule was therefore also 
investigated as a co-factor substitute in PseH catalysed acetylation as it mimics the most tightly 
bound portion of the acetyl-CoA (5.1) structure and can be easily accessed from readily available 
reagents.297  
 
Scheme 5.10 Synthetic route to N-acetyl cysteamine thioacetate; addition of acetic anhydride to 
cysteamine HCl in H2O at pH 8.0, 0 °C, followed by stirring at pH 7.0 at 0 °C for 2 hrs.  
Following a literature procedure,297 the N-acetyl cysteamine thioacetate (5.9) was successfully 
synthesised via acetyl transfer from acetic anhydride (5.16) to cysteamine HCl (5.18) (Scheme 
5.10). Acetic anhydride (3 equivs) was added dropwise to an aqueous solution of cysteamine 
HCl (1 equiv) at pH 8.0, 0 °C. Following addition, the reaction was modified to pH 7.0 and stirred 
on ice for 2 hrs when the reaction was deemed to reach completion, as determined by TLC 
(Scheme 5.10). Spectroscopic analysis (NMR and MS) of this reaction after work-up confirmed 
formation of the desired product (5.9) and demonstrated that no further purification was 
required.  
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To ascertain whether the N-acetyl cysteamine thioacetate (5.9) was capable of acting as a co-
factor substrate in PseH catalysed acetylation, “one-pot” synthesis of Pse5Ac7Ac (1.13) was 
attempted on a 0.1 mg scale. First, controls were set up by addition of UDP-GlcNAc (3.1) to 
either PseB, PseC, PseG, PseI (and their co-factors) and PseH (with no co-factor) (Figure 5.12a) 
or PseB, PseC, PseG, PseI (and their co-factors) and 100 mM N-acetyl cysteamine thioester (5.9) 
(with no PseH) (Figure 5.12b). Both reactions resulted in enzyme-catalysed conversion to the 
PseC product (3.8) but no production of the acetylated sugar intermediate (3.9) or any of the 
further intermediates in the Pse5Ac7Ac (1.13) biosynthetic pathway. Hence confirming that 
none of the molecules in the enzymatic reaction mixture can act as alternate PseH co-factors 
(Figure 5.12a) and that N-acetyl cysteamine thioester (5.9) cannot acetylate UDP-4-amino-4,6-
dideoxy-β-˪-AltNAc (3.8) without the PseH enzyme under these conditions (Figure 5.12b).  
 
 
 
Figure 5.12 LC-MS negative ESI analysis of the PseH controls demonstrates that the reaction halts at the 
PseC product intermediate (3.8) in the one-pot, enzymatic synthesis of Pse5Ac7Ac (1.13) containing a) 
PseB, PseC, PseG, PseI (their co-factors) and PseH or b) PseB, PseC, PseG, PseI (their co-factors) and N-
acetyl cysteamine thioester (5.9). 
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Pleasingly upon incubation (shaking 120 rpm, 37 °C) of PseB (25 µM), PseC (125 µM), (and their 
co-factors), in addition to PseH (50 µM) and 10 mM N-acetyl cysteamine thioacetate (5.9), the 
reaction displayed conversion to the acetylated sugar product (3.9) (Figure 5.13). Upon 
comparison of the intensity of the product associated with the PseH product ([M-H]- 631), a 
conversion of 45 % after 4 hrs was observed. 
 
Figure 5.13 LC-MS negative ESI analysis after 4 hrs, demonstrating conversion to the PseH product (3.9) 
using N-acetylcysteamine thioacetate (5.9) as a PseH co-factor substitute in a reaction consisting of UDP-
GlcNAc (1 mM), PLP (1.5 mM), ˪-glutamate (10 mM), PseB (25 µM), PseC (125 µM) and PseH (50 µM) in 
sodium phosphate buffer (50 mM, pH 7.4).    
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5.2.4 Other alternate PseH co-factor substitutes 
Following the positive results investigating co-factor substitutes with N-acetylcysteamine 
thioacetate (5.9), the promiscuity of the C. jejuni PseH (acetyl)-CoA (5.1/5.2) binding site was 
further probed. The acceptance of substitute acetyl donors varies greatly between different 
acetyltransferase enzymes and structural modifications distal to the thioacetate group can have 
great effects on the sutiability as a co-factor. For example, this work has shown that C. jejuni 
PseH will accept N-acetylcysteamine thioacetate (5.9) as a co-factor substitute but not acetyl-
thiocholine iodide (5.5). They both contain an ethane-thioacetate moiety which mimics part of 
the natural co-factor structure and has been shown to have favourable interactions with the 
PseH co-factor binding site. However the functionality at the other end of the molecules differs 
from an amide in N-acetylcysteamine thioacetate (5.9) to a tri-methylated positive amine group 
in acetylthiocholine iodide (5.5). Therefore it was postulated that this moiety may prevent 
acetylthiocholine iodide (5.5) from binding to PseH, either through steric bulk, charge repulsion 
or the change in hydrophilicity at the amine with the surrounding residues.   
Additionally, some acetyltransferases have been shown to have a considerable flexibility in the 
structure of the acetyl-donor that they can utilise. Of particular interest was the identification 
that p-nitrophenyl acetate (5.19) can be employed as an acetyl donor in place of acetyl-CoA (5.1) 
during kinetic studies, to measure the rate of enzyme catalysed acetyl transfer.286, 298-301 In order 
to investigate the acetyl donor promiscuity of C. jejuni PseH, its ability to catalyse acetyl-transfer 
reactions utilising phenolacetate and phenolthioacetate derivatives (Figure 5.15) in the absence 
of acetyl-CoA (5.1) was also investigated.   
 
 
Figure 5.15 Phenolacetate (5.19-5.21) and phenolthioacetate (5.22-5.24)  structures proposed as putative 
acetyl-transferase co-factor alternatives. 
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Prior to incubation within the enzymatic reaction (for synthesis of UDP-4-acetamido-4,6-
dideoxy-β-ɩ-AltNAc (3.8) or of Pse5Ac7Ac (1.13) from UDP-GlcNAc (3.1)), solubility tests of the 
phenolacetate and phenolthioacetate derivatives were carried out under aqueous conditions. 
Three of the compounds; phenyl acetate (5.20), p-tolyl acetate (5.21) and S-phenyl thioacetate 
(5.22) were soluble at the stock (100 mM) and reaction (10 mM) concentration in sodium 
phosphate buffer (50 mM pH 7.4). However it was found that p-nitrophenyl acetate (5.19), S-(4-
nitrophenyl)thioacetate (5.23), and S-(p-tolyl)thioacetate (5.24) required a solution of 10 % 
DMSO in sodium phosphate buffer (50 mM pH 7.4) to be soluble at the reaction concentration 
(10 mM).  
A 5X reaction mixture stock was assembled for all of the following reactions containing UDP-
GlcNAc (5 mM), PLP (7.5 mM) and ˪-glutamate (50 mM) in sodium phosphate buffer (50 mM pH 
7.4). After addition of any other components, the required volume of sodium phosphate buffer 
(50 mM pH 7.4) was added to dilute the stock to the 1X reaction mixture previously used. An 
initial enzymatic reaction was set up for the synthesis of UDP-4-acetamido-4,6-dideoxy-β-ɩ-
AltNAc (3.8) from UDP-GlcNAc (3.1) to investigate the potential effect of DMSO in the reaction 
mixture. To an aliquot of the 5X stock, acetyl-CoA (1.5 mM), PseB (25 µM), PseC (125 µM), PseH 
(50 µM), PseG (30 µM), and PseI (25 µM) were added and DMSO included to a final 
concentration of 10 % in sodium phosphate buffer (50 mM pH 7.4). The aliquot was incubated 
37 °C, shaking (120 rpm) and monitored after 4 hrs with negative ESI LC-MS. Analysis showed 
conversion to the Pse5Ac7Ac (1.13) product, suggesting that the inclusion of 10 % DMSO did not 
affect the enzymatic activity (Figure 5.16).  
 
 
Figure 5.16 Enzymatic synthesis of Pse5Ac7Ac (1.13) from UDP-GlcNAc (3.1) in 10 % DMSO, sodium 
phosphate buffer (50 mM, pH 7.4) containing UDP-GlcNAc (1 mM), PLP (1 mM), ˪-glutamate (10 mM), 
acetyl-CoA (1.5 mM), PEP (1.5 mM), PseB (25 µM), PseC (125 µM), PseH (50 µM), PseG (30 µM) and PseI 
(25 µM).  
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Negative controls for each of the potential substitute co-factors (5.19-5.24) were constructed 
whereby the 5X stock was incubated with PseB (25 µM), PseC (125 µM) and 10 mM acetyl-donor 
(5.9 or 5.19-5.24) in sodium phosphate buffer (50 mM pH 7.4) or 10 % DMSO in sodium 
phosphate buffer (50 mM pH 7.4) as required.  To monitor PseH catalysed acetyl transfer the 
same reactions as above were assembled but with the addition of PseH (50 µM).   
After 3 hrs of incubation (120 rpm, 37 °C), negative ESI LC-MS analysis was used to monitor 
conversion to the acetylated product (3.9) via inspection of the [M-H]- 631 peak. In all reactions 
without PseH there was no observation of turnover to the PseH product, suggesting that the 
acetyl donors (5.9, 5.19-5.24) are not reactive enough to undergo non-enzymatic acetyl transfer 
to the sugar amine (3.8) (Appendix 8). 
 All of the reaction mixtures containing phenolacetate and phenolthioacetate co-factors 
demonstrated PseH catalysed turnover to the PseH product, with a [M-H]- 631 peak observed in 
the negative ESI LC-MS traces. Comparison of the relative intensity of the [M-H]- 631 peak  in 
these reactions showed that conversion was highest with S-phenyl thioacetate (5.22) and phenyl 
acetate (5.20) 22 % and 21 % respectively.  Conversion to the PseH product (3.9) was found to 
decrease to 10 % with p-tolyl acetate (5.21) as the co-factor and just 7 % with p-nitrophenyl 
acetate (5.19).  (Figure 17). Less than 5 % conversion to the PseH product (3.9) was detected in 
reactions containing S-(4-nitrophenyl)thioacetate (5.23) and S-(p-tolyl)thioacetate (5.24); 5 % 
and 3 % respectively, suggesting that PseH was not able to utilise these molecules as effective 
acetyl donors. 
These results were somewhat unexpected when considering the reactivity of thioesters 
compared to esters and the electronic effects of the para-groups. Thioesters are more reactive 
than esters as there is less orbital overlap between the 3p orbitals in sulphur and 2p carbon 
orbitals than the 2p oxygen and 2p carbon orbitals. Therefore the sulphur lone pair is less 
delocalised compared to the oxygen lone pair and hence it less readily stabilised by resonance 
and the carbon in a thioester carbonyl is more electropositive than the carbon in a ester carbonyl 
(Scheme 5.11).302 
 
Scheme 5.11 The resonance forms of esters and thioesters. 
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Figure 5.17 Negative ESI LC-MS investigating the ability of different PseH co-factors to promote 
conversion from UDP-GlcNAc (3.1) to the PseH product (3.9) in an enzymatic reaction; UDP-GlcNAc (1 
mM), PLP (1.5 mM), ˪-glu (10 mM), PseB (25 M), PseC (125 M) and PseH (50 M) a) 10 mM S-phenyl 
thioacetate (5.22), b) 10 mM phenyl acetate (5.20), c) 10 mM p-tolyl acetate (5.21), d) 10 mM p-
nitrophenyl acetate (5.19), e) 10 mM S-(p-tolyl)thioacetate (5.24) and f) 10 mM S-(4-
nitrophenyl)thioacetate (5.24). 
The expected increase in reactivity was observed to some extent when comparing reactivity of 
reactions containing S-phenyl thioacetate (5.22) and phenyl acetate (5.20). The reaction 
containing the thioester compound (5.22) showed a marginally higher conversion to the 
acetylated product, 22 %, compared to 21 % for the reaction containing phenyl acetate (5.20). 
However the opposite was found when comparing S-(p-tolyl)thioacetate (5.24) and p-tolyl 
acetate (5.21)  with the former displaying almost no turnover (5 %) to the acetylated product 
(2.9) and the latter showing a small amount of PseH catalysed acetyl donation (10 % conversion). 
It was proposed that the difference in expected conversion could be due to the difference in 
solubility rather than the reactivity of the molecule. The thioester containing compound (5.24) 
required addition of DMSO to aid in solubility and solvation with this solvent may have 
prevented S-(p-tolyl)thioacetate (5.24) from being able to access the co-factor binding site.  
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Upon comparing the different para-substituents it was expected that the nitro-containing 
compounds would be more efficient acetyl donors than their non-substituted counterparts and 
that the methyl derivatives would be less so. Evidence for the latter was demonstrated when 
comparing the relative conversions of phenyl acetate (5.20) and p-tolyl acetate (5.19), 21 % and 
10 % respectively and, S-phenyl thioacetate (5.22) and S-(p-tolyl)thioacetate (5.24), 22 % and 5 
% respectively. The positive inductive effect of the methyl group added electron density towards 
the benzene ring, resulting in a less electrophilic carbonyl carbon hence decreasing acetyl 
donation. Substitution with the p-methyl group appeared to attenuate acetyl transfer to a 
greater degree in the thioester compared to the ester. However solubility and solvation may 
also have been a factor in the thiophenyl acetates as S-(p-tolyl)thioacetate (5.24) required 
addition of DMSO to be soluble.  It was surprising to observe that the electron-withdrawing 
nitro-substituted compounds demonstrated a reduced propensity for acetyl-transfer compared 
to their p-methyl substituted and non-substituted counterparts. It was proposed that, similarly 
to acetylthiocholine iodide (5.5), the steric bulk or the charge of the nitro group could be causing 
unfavourable interactions between the compound and the PseH co-factor binding site, and 
hence account for the reduced conversion to the PseH product (3.9) despite the favourable 
electronic effects. 
C. jejuni PseH can readily accept some phenolacetate and phenolthioacetate derivatives as 
acetyl donors and utilise them in the enzymatic synthesis of UDP-4-acetamido--4,6-dideoxy-β-˪-
AltNAc (3.9). Unfortunately the level of conversion could not be improved upon from those 
established with N-acetylcysteamine thioacetate (5.9) however the difference in conversion 
levels has provided insight into the PseH co-factor binding site and the variety of molecules that 
it can accept. Importantly it has highlighted the slow rate of turnover with p-nitrophenyl acetate 
(5.19) which could aid in reaction design for the kinetic analysis of C. jejuni PseH. 
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5.3 Manipulation of the acetylation step for the synthesis of pseudaminic acid C7 
derivatives 
5.3.1 Utilisation of the PseH co-factor substitutes to introduce other C7 
functionality 
A strategy for production of pseudaminic acid C7 derivatives was devised utilising the Pse5Ac7Ac 
(1.13) biosynthetic enzymes under the optimised conditions previously discussed. It was 
decided to exploit the co-factor promiscuity of PseH to allow for introduction of a C4 N-acyl 
group during the synthesis of an acylated PseH product (5.25).  Due to its cost and structural 
complexity it was undesired to attempt synthesis of acyl-CoA derivatives, so derivatives of the 
co-factor substitutes were considered. Derivatives of N-acetylcysteamine thioacetate (5.9) were 
focussed on due to their proposed facile synthesis and efficiency as acyl-donors when used with 
PseH (Scheme 5.12). In order to potentially allow for production of pseudaminic acids with 
manufactured C7 functionality in a one-pot chemo-enzymatic synthesis, without the need for 
expensive co-factors or time costly purification steps.  
 
Scheme 5.12 Introduction of desired C7 functionality in pseudaminic acids utilising a co-factor substitute. 
Introduction of a bioorthogonal tag to Pse5Ac7Ac (1.13) allows for a handle for detection, 
purification and quantification of Pse5Ac7Ac (1.13) if desired. Based on observation of the active 
site structures of the biosynthetic enzymes, and considering the chemistry performed during 
the synthesis, it was hypothesised that small modifications to the C7 acetamido group may be 
accepted and remain in the sugar during enzymatic synthesis of Pse5Ac7Ac (1.13). Importantly 
a previously synthesised Pse5Ac7Az precursor (5.14) was shown to be taken up by C. jejuni and 
was accepted by the downstream biological machinery to display Pse5Ac7Az (5.10) on the 
flagellin.  
It was proposed that an improved one-pot synthetic route to access Pse5Ac7Az (5.10) would aid 
in its use for labelling other Pse5Ac7Ac (1.13) containing bacterial surface structures. Therefore 
initial investigations focussed on the enzymatic synthesis of Pse5Ac7Az (5.10) with introduction 
of the azido group during the PseH catalysed acyl-transfer from N-acetylcysteamine 
thioazidoacetate (5.26).  
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5.3.2 Synthesis of N-acetylcysteamine thioazidoacetate 
Three protocols were investigated for synthesis of N-acetylcysteamine thioazidoacetate (5.26) 
utilising amide synthesis strategies to form a thioester between azidoacetic acid (5.27) and N-
acetylcysteamine (5.28). Each employed a combination of a coupling reagent to react with the 
azido acetic acid (DCC or HCTU) and further increasing its reactivity with the thiol, promoting 
synthesis of the thio-ester.  
 
 
Scheme 5.13 Three synthetic strategies for coupling azidoacetic acid and N-acetylcysteamine HCl to 
form N-acetylcysteamine thioazidoacetate (5.26). 
DCC (0.84 mmol) (a, c) or HCTU (0.924 mmol) (b) and azidoacetic acid (0.76 mmol) were 
suspended in DCM and stirred on ice for five minutes. DMAP (0.76 mmol) (a), Et3N (1.54 mmol) 
(b) or HoBt (0.76 mmol) (c) and N-acetylcysteamine (0.84 mmol) were added and the reaction 
left to warm to room temperature overnight (Scheme 5.13). In reactions a and b, TLC analysis 
displayed depletion of the reagents after 16 hrs and formation of a spot with a Rf of 0.28 (similar 
to that of the literature for N-acetylcysteamine thioazidoacetate (5.26). However a number of 
other products were also present in the mixture suggesting that although there was no 
azidoacetic acid (5.27), the reaction may still contain some intermediate species. Reaction c 
appeared to react more slowly, with reagents still present after 72 hrs and hence this reaction 
was discontinued. Following column chromatography of a and b, a yield of 17 % product was 
achieved in crude a and 55 % gained from crude b. NMR analysis of combined N-
acetylcysteamine thioazidoacetate (5.26) from both synthetic strategies (a, b) revealed peaks 
corresponding to the literature values for the desired product but also impurities (Appendix 9). 
However it was deemed unnecessary to purify N-acetylcysteamine thioazidoacetate (5.26) 
further for preliminary results as none of the remaining impurities were the aromatic structures 
and it was proposed that impurities of the other solutes would not affect the reaction. 
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5.3.3 Utilisation of N-acetylcysteamine thioazidoacetate in the enzymatic 
synthesis of a Pse5Ac7Az 
 
Scheme 5.14 One-pot enzymatic route to Pse5Ac7Az (5.10), utilising the C. jejuni Pse5Ac7Ac (1.13) 
biosynthetic enzymes and an azido-tagged PseH co-factor substitute (5.26). 
A reaction mixture composed of UDP-GlcNAc (1 mM), PLP (1 mM), ˪-Glu (10 mM), PEP (1.5 mM), 
PseB (25 µM), PseC (125 µM), PseH (50 µM), PseG (30 µM), and PseI (25 µM) in sodium 
phosphate (50 mM, pH 7.4) was assembled in order to analyse conversion to Pse5Ac (1.13) and 
Pse5Ac7az (5.10) using N-acetylcysteamine thioacyl derivatives. A positive control aliquot 
included the addition of N-acetylcysteamine thioacetate (10 mM) and the other aliquot included 
either N-acetylcysteamine thioazidoacetate (10 mM) or N-acetylcysteamine thioazidoacetate 
(10 mM) with CoA (0.015 mM) added.  Negative ESI LC-MS analysis of this set of reactions 
displayed a number of additional m/z peaks in the mass spectra (discussed below) and hence it 
was deemed unsuitable to quantify the level of conversion. However analysis after 4 hrs 
displayed conversion to Pse5Ac7Ac (1.13) in the reaction containing N-acetylcysteamine 
thioacetate (10 mM), but with some remaining UDP-GlcNAc (3.1) also observed (Figure 5.18a). 
Only suagar peaks corresponding to UDP-GlcNAc (3.1) and the PseC product (3.8) were observed 
in the reaction mixture contining N-acetylcysteamine thioazidoacetate (10 mM) suggesting that 
it could not be utilised by PseH as a substitute co-factor (Figure 5.18b). However in the negative 
ESI LC-MS analysis of the reaction containing N-acetylcysteamine thioazidoacetate (10 mM) and 
CoA (0.015 mM), a peak corresponding to the desired Pse5Ac7Az (5.10) product was observed 
that was not present in the other spectra.  
From this preliminary data it can be tentatively proposed that Pse5Ac7Az (5.10) can be produced 
in a one-pot enzymatic synthesis with the acetylazido group transferred during the PseH 
catalysed reaction in the presence of CoA. It was speculated that the steric hindrance or charge 
of the azido group may be less favourable for PseH binding compared to the acetyl group in N-
acetylcysteamine thioacetate (5.9) and hence it is less effective as a PseH co-factor substitute, 
explaining why Pse5Ac7Az (5.10) was not observed without the addition of CoA (5.2). The 
occurrence of a number of other significant peaks during analysis of these reactions was 
unprecedented and especially  surprising in the synthesis of Pse5Ac7Ac (1.13) as the same stock 
of N-acetylcysteamine thioacetate (10 mM) was used in this reaction as in previous reaction for 
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the synthesis of the PseH product (3.9). The additional peaks could not be assigned to any 
protential side reactions that were proposed and hence it was hypothesised that these 
molecules could have been contaminants from the LC-MS and noted that the quality of other 
data recorded had also decreased at this time. Additionally the chromatography column had 
demonstrated deterioration over the course of this project and could have been contaminated. 
In order to ascertain the presence of these peaks it was proposed to repeat this experiment 
after a full quality check of the equipment and on a large enough scale to allow for confirmation 
of production of Pse5Ac7Az (5.10) by NMR. 
 
Figure 5.18 LC-MS negative ESI analysis after 4 hrs, demonstrating conversion to a) Pse5Ac7Ac (1.13) using 
N-acetylcysteamine thioacetate (5.9) as a PseH co-factor substitute or b) Pse5Ac7Az (5.10) using N-
acetylcysteamine thioazidoacetate (5.22) as a PseH co-factor substitute, c) Pse5Ac7Az (5.10) using N-
acetylcysteamine thioazidoacetate (5.22) and 0.015 mM CoA (5.2) as a PseH co-factor substitute in a 
reaction consisting of UDP-GlcNAc (1 mM), PLP (1 mM), ˪-glutamate (10 mM), PseB (25 µM), PseC (125 
µM), PseH (50 µM), PseG (30 µM) and PseI (25 µM)  in sodium phosphate buffer (50 mM, pH 7.4).  
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5.3.4 Extending the utilisation of N-acetylcysteamine thioacyl derivatives 
to access other pseudaminic acid derivatives  
This method was further utilised in the Fascione lab (Matthew Best, MChem) in order to 
synthesise another prevalent pseudaminic acid; Pse5Ac7Fm (5.29). Following synthesis of N-
acetylcysteamine thioformyl (5.30), Pse5Ac7Fm (5.29) production was attempted using the one-
pot enzymatic methodology employed above but with inclusion of N-acetylcysteamine 
thioformyl (10 mM). Unfortunately conversion was heavily attenuated compared to synthesis 
of Pse5Ac7Ac (1.13) as N-acetylcysteamine thioformyl (5.30) appeared to react with a PseC co-
factor. Therefore to obtain a higher yield, a two-step synthesis was employed (Scheme 5.15) 
whereby the PseB and PseC reaction with UDP-GlcNAc (3.1) was allowed to occur and then 
addition of PseH, PseG and PseI (and co-factors including N-acetylcysteamine thioformyl) 
produced Pse5Ac7Fm (5.29) from the PseC product (3.8).  
 
Scheme 5.15 Two-step enzymatic route to Pse5Ac7Fm (5.29), utilising the C. jejuni Pse5Ac7Ac (1.13) 
biosynthetic enzymes and a formyl PseH co-factor substitute (5.30). 
  
152 
 
5.4 Conclusions and future work 
The requirement for the use of the acetyl-CoA (5.1) has been eliminated by the development of 
three strategies for the selective acetyl transfer to the amino group of UDP-4-amino-4,6-
dideoxy-β-˪-AltNAc (3.8). These methods have been successfully used in the enzymatic 
production of Pse5Ac7Ac (1.13) from UDP-GlcNAc (2.1) elucidating an economically viable, 
efficient, one-pot synthesis. 
Modifications to the previously published chemo-enzymatic synthesis of UDP-4-acetamido-4,6-
dideoxy-β-˪-AltNAc (3.9), successfully avoided time costly purification steps and reduced the 
number of equivalents of catalyst required for synthesis. However there are two limitations that 
make this method unfavourable for the large scale synthesis of Pse5Ac7Ac (1.13) and derivatives 
compared to using acetyl-CoA (5.1). Firstly the ease of the onepot synthesis is lost and even-
though the reduction in cost compensates for this factor, it is still suboptimal. Additionally it was 
desired to develop a synthetic strategy that could be applicable to other pseudaminic acid 
derivatives, however the specitifity for acetylation of the 4-amino group in this reaction relies 
on no other amino groups being present in the sugar structure.  
Investigations regarding the in situ regeneration of the PseH co-factor using acetyl thiocholine 
iodide (5.5) and CoA (5.2) as reagents, re-estabilshed the one-pot synthesis of Pse5Ac7Ac (1.13) 
whilst drastically reducing the expense of this process compared to use of the natural co-factor 
(5.1). However to atttain comparable turnover with catalytic amounts of CoA (5.1), high 
concentrations of the regeneration factor were required (5.5, 100 mM) which can be criticised 
for low atom economy and may invoke down-stream purification issues. 
 N-acetylcysteamine thioacetate (5.9), synthesised from readily available materials, was 
identified as an ideal direct replacement for acetyl-CoA (5.1) as a PseH co-factor and was 
successfully employed in acetyl-transfer to UDP-4-amino-4,6-dideoxy-β-˪-AltNAc (3.8). The 
added benefit of this system was in its predicted generalisation for the synthesis of other 
pseudaminic acid derivatives using N-acetylcysteamine thioacyl derivatives. Preliminary results 
utilising this system in this way resulted in production of Pse5Ac7Az (5.10) and Pse5Ac7Fm 
(5.29). However optimisation was required in both reactions; for the synthesis of Pse5Ac7Ac 
(5.10) CoA (5.2) was required in the reaction mixture and for the synthesis of Pse5Ac7Fm (5.29), 
the synthesis was carried out in two sequential steps. Despite these setbacks and potential need 
for optimisation with different functionalities, this strategy utilising N-acetylcysteamine thio acyl 
derivatives, provides a general method for the chemo-enzymatic production of pseudaminic 
acid C7 derivatives with significant advantages over existing syntheses. 
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6. Chapter 6 Concluding remarks 
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6.1 Conclusions and future work 
Preliminary PA2794 characterisation to gain insight into the natural substrate unfortunately did 
not allow for the definitive allocation of the natural ligand. The crystal structure data was 
concistent with the previously published data,3 suggestive that binding of a sugar with the 
Neu5Ac (1.1) C5 stereochemistry is unfavourable in the most energetically favourable 
conformation of the transition state structure (Figure 2.13). However non-enzyme electron 
density in the active site was attributed to solute molecules (Figure 2.15) rather than the 
Pse5Ac7Ac (1.13) ligand which could be attributed to; the higher concentration of solute 
molecules, the addition of Pse5Ac7Ac (1.13) being after crystallisation making the active site 
inaccessible, or a low binding affinity to free Pse5Ac7Ac (1.13). Future work could address such 
issues by establishing alternate PA2794 purification and crystallisation conditions with 
Pse5Ac7Ac (1.13) or by foccussing on the synthesis of Pse5Ac7Ac (1.13) analogues that would 
have an expected higher affinity with this putative pseudaminidase. Further investigations could 
also include trialling different pseudaminic acid derivatives native to Pseudomonas aeruginosa 
such as Pse5hB7Fm.187 
Due to the lack of availability of pseudaminic acid derivatives and chemical probes, full 
characterisation of any pseudaminic acid processing enzymes is yet to be reported. This project 
developed a strategy towards the synthesis of Pse5Ac7Ac (1.13) on a large scale in order to 
supply the quantity of material required for future studies (Scheme 6.1). This has elucidated a 
one-pot chemo-enzymatic pathway to Pse5Ac7Ac (1.13) that has eliminated any issues that 
previously occurred with the use of the enzymatic synthesis. 
 
Scheme 6.1 One-pot chemo-enzymatic pathway to Pse5Ac7Ac (1.13) utilising the five C. jejuni 
biosynthetic enzymes with substitution of the PseH co-factor acetyl-CoA (5.1) with N-acetyl cysteamine 
thioacetate (5.9). 
The second step in the pathway is catalysed by PseC and this enzyme was observed to have 
solubility under the induction conditions used for optimal yields. Although this was successfully 
rectified by using different induction conditions, it is disappointing to lose yield of this enzyme 
in particular as it is needed at a higher concentration during Pse5Ac7Ac (1.13) synthesis than 
the other enzymes. This was discovered through monitoring conversion to the PseB and PseC 
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products in D2O, whereby overall conversion to the PseC product (3.8) was achieved by out-
competing the secondary PseB reaction with increasing the concentration of PseC (Figure 4.7). 
Further exploration of the PseB mechanism could aid in design of mutants to prevent this 
secondary PseB catalysed epimerisation.242 However it was also hypothesised that expressing 
the bound PseB and PseC enzymes together could also increase conversion to the PseC product 
as the catalyst for the second reaction (PseC) would be held in close proximity to the product of 
the first reaction (3.7). This could also have the additional benefit of promoting PseC solubility 
and allow for induction condtions to be utilised that allow for maximum enzymatic production. 
The main limitation for using a purely enzymatic route for the synthesis of Pse5Ac7Ac (1.13) was 
the cost of the co-factor for the third step of the biosynthetic pathway; PseH catalysed acetyl 
transfer from acetyl-CoA (5.1).232 Use of this co-factor was eliminated by the development of a 
strategy to generate acetyl-CoA (5.1) in situ via acetyl transfer by having high concetrations of a 
regeneration factor (acetylthiocholine iodide 5.5) and sub-stoichiometric amounts of CoA (5.2). 
Additonally the necessity for acetyl-CoA was completely abolished when an alternate co-factor, 
N-acetylcysteamine thioacetate 5.9, was successfullty utilised in the one-pot synthesis of 
Pse5Ac7Ac (1.13) with comparable turnover (Figure 5.13). A siginifanct advantage of this latter 
stategy was the ease of synthesis of other N-acetylcysteamine thioacyls allowing for the 
proposed applicability of these methods to introduce other desired C7 functionalities. However 
preliminary results with other N-acetylcysteamine thioacyl derivatives highlighted the need for 
considerations of the structural integrity of the PseH co-factor binding site and potential steric 
clashes with the acyl derivatives. Crystal structures in complex with N-acetylcysteamine 
thioacetyl derivatives would provide further insight into the binding dynamics and interactions 
with the thioacyl groups in particular. 
Development of this chemo-enzymatic synthesis of Pse5Ac7Ac (1.13) is primed for expansion to 
production on a large scale for the first time. After establishing purification techniques, further 
processing of this sugar, adapting methodology established for Neu5Ac (1.1), will produce the 
desired glycosides, inhibitors and inactivators. The characterisation of PA2794 can therefore 
then be re-visited, which it has not been done since its crystallisation in 2009,3 and fully 
investigated with the predicted natural ligand. Knowledge of a synthetic route to pseudaminic 
acid chemical probes will surely facilitate the characterisation of other pseudaminic acid 
processing enzymes and promote investigation of a multitude of potential therapeutic targets.   
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7. Chapter 7 Experimental 
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7.1 General methods 
Unless otherwise specified, all chemical reagents were obtained from commercial sources and 
used without further purification. Pse5Ac7Ac was custom ordered from Sussex Research 
Laboratries Inc. (Ottawa, ON Canada) Recombinant plasmids were either kindly gifted (PseB, 
PseC Tanner Research Lab, University of British Columbia, Canada) or purchased from Genscript. 
LB recipe; 
NaCl 1 % (w/v), Tryptone 1 % (w/v), Yeast 0.5 % (w/v) in dH2O and autoclave. 
LB agar recipe; 
NaCl 1 % (w/v), Tryptone 1 % (w/v), Yeast 0.5 % (w/v), Agar 1.5 % (w/v) in dH2O and autoclave. 
TYP recipe; 
Tryptone 1.6 % (w/v), Yeast extract 2.4 % (w/v), NaCl 0.5 % (w/v), K2HPO4 1 % (w/v) in dH2O and 
autoclave. 
SOC recipe; 
Tryptone 2 % (w/v), Yeast extract 0.5 % (w/v), KCl 2.5 mM, NaCl 10 mM, MgCl2 10 mM, MgSO4 
10 mM, Glucose 20 mM in dH2O and autoclave. 
Electrocompetent E. coli BL21 DE3 cells; 
A single E. coli BL21 DE3 culture was inoculated in LB (10 mL) 225 rpm, 37 °C, overnight. 5 mL of 
culture was added to 1 L LB in a 2L baffled flask and incubated 180 rpm, 37 °C, until an OD600 of 
0.6 and placed immediately on ice. The cells were pelleted (1000 xg, 20 mins, 4 °C in pre-cooled 
tubes), supernatant removed and the cell pellets resuspended in sterile ice cold dH2O (800 mL). 
Cells were pelleted (1000 xg, 20 mins, 4 °C) with the dH2O being discarded and the cell pellets 
resuspended in sterile ice cold dH2O (400 mL). Cells were pelleted again (1000 xg, 20 mins, 4 °C) 
with the dH2O being discarded and the cell pellets resuspended in sterile ice cold 10 % glycerol 
(v/v) dH2O (40 mL). Cells were pelleted once more (1000 xg, 20 mins, 4 °C), supernatant removed 
and pellets resuspended in 10 % glycerol (v/v) dH2O (1 mL), aliquoted into 50 µL portions, flash 
frozen in liquid nitrogen and stored -80 °C. 
Chemically competent E. coli BL21 DE3 cells; 
A single E. coli BL21 DE3 culture was inoculated in LB (10 mL) 225 rpm, 37 °C, overnight. 5 mL of 
culture was added to 1 L LB in a 2L baffled flask and incubated 180 rpm, 37 °C, until an OD600 of 
0.3-0.4 and placed immediately on ice for 20 minutes, swirling occasionally. The cells were 
pelleted (3000 xg, 15 mins, 4 °C in pre-cooled tubes), supernatant removed and the cell pellets 
resuspended in sterile ice cold 100 mM MgCl2 (100 mL). Cells were pelleted (2000 xg, 15 mins, 
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4 °C) with the supernatant discarded and the cell pellets resuspended in sterile ice cold 100 mM 
CaCl2 (200 mL) and left on ice for 20 minutes. Cells were pelleted again (2000 xg, 15 mins, 4 °C) 
with the supernatant discarded and the cell pellets resuspended in sterile ice cold 85 mM CaCl2 
15 % glycerol (v/v) dH2O (40 mL). Cells were pelleted once more (1000 xg, 15 mins, 4 °C), 
supernatant removed and pellets resuspended in 85 mM CaCl2 15 % glycerol (v/v) dH2O (1 mL), 
aliquoted into 50 µL portions, flash frozen in liquid nitrogen and stored -80 °C. 
Electrotransformation; 
Electrocompetent cells (50 µL) and the plasmid (100 ng µL-1) were thawed on ice (20 mins) and 
an electroporation cuvette (0.2 cm) was placed on ice. 1 µL plasmid was added to the cells, 
gently mixed and placed on ice for 20 mins. This mixture was transferred to the electroporation 
cuvette and electroporated (BIORAD GENEPULSER II). TYP media (1 mL) was immediately added 
to the electroporation cuvette and incubated 180 rpm, 37 °C, 1 hour. Cells were centrifuged (10, 
000 xg, 30 seconds), 600 µL of the supernatant was discarded and the pellet resuspended in the 
remaining media. Cells were streaked onto a LB agar plate containing the appropriate antibiotic 
resistance and incubated 37 °C, overnight then stored 6 °C. 
Heat shock; 
Chemically competent cells (50 µL) and the plasmid (100 ng µL-1) were thawed on ice (20 mins). 
2 µL plasmid was added to the cells, gently mixed and placed on ice for 15 mins. This mixture 
was placed in a 42 °C water bath for 60 seconds then immediately placed on ice for 120 seconds. 
SOC media (1 mL) was added to the cells and incubated 180 rpm, 37 °C, 1 hour. Cells were 
centrifuged (10, 000 xg, 30 seconds), 600 µL of the supernatant was discarded and the pellet 
resuspended in the remaining media. Cells were streaked onto a LB agar plate containing the 
appropriate antibiotic resistance and incubated 37 °C, overnight then stored 6 °C. 
Glycerol stocks; 
LB (15 mL) containing the appropriate antibiotic resistance was inoculated with a single colony 
from a LB agar plate, and incubated 180 rpm, 37 °C, overnight. A 500 µL aliquot was mixed with 
500 µL glycerol 50 % (v/v), flash frozen in liquid N2 and immediately stored at -80 °C. 
Protein storage; 
Proteins were stored in their dialysis buffers at 6 °C for up to a week. Longer storage involved 
concentration to 1 mg mL-1 and division into 1 mL aliquots, flash freezing in liquid N2 and 
immediately storing at -80 °C. 
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE); 
5 x SDS reducing sample buffer recipe; 
SDS 10 % (w/v), Glycerol 20 % (w/v), Bromophenol blue 0.05 % (w/v), Tris-HCl 200 mM 
pH 6.8, β-mercaptoethanol 10 mM, in dH2O. 
SDS resolving gel buffer; 
SDS 0.4 % (w/v), Tris-HCl 1.5 M pH 8.8, in dH2O. 
SDS stacking gel buffer; 
 SDS 0.4 % (w/v), Tris-HCl 0.5 M pH 6.8, in dH2O. 
SDS running buffer 4X; 
 Glycine 160 mM, Tris 0.1 M 
Staining solution; 
0.1 % Coomassie Brilliant Blue R-250, 50 % MeOH, 10 % glacial acetic acid 
Destaining solution 
50 % MeOH, 10 % glacial acetic acid 
12 % acrylamide gels were used throughout and made up as follows; 
2.5 mL resolving buffer, 4.2 mL acrylamide and 3.2 mL dH2O were combined and gently inverted. 
50 µL APS 20 % (w/v) was added and the solution inverted, followed by addition of 16 µL TEMED, 
a further inversion and pipetted into the gel plates. Once set, 1.3 mL stacking buffer, 0.5 mL 
acrylamide and 3.2 mL dH2O were combined and gently inverted. 25 µL APS 20 % (w/v) was 
added and the solution inverted, followed by addition of 8 µL TEMED a further inversion and 
pipetted onto the resolving gel and ladders placed in to form wells.  
Protein samples contained 3 µL 5 x SDS reducing sample buffer and 12 µL sample, held at 95 °C 
for 5 minutes, 10 µL of sample was loaded per well. Gels were subjected to electrophoresis for 
30 mins (Flowgen Consort E734), then stained and destained. 
 
DNA gel; 
0.35 g of agarose was added to 50 mL TAE 1X and boiled (in the microwave, 3 x 1 minute), then 
set aside to cool. 5 µL Sybasafe was added, the solution was poured into the gel mould and a 
comb added.  
DNA samples consisted of 2 µL 6x gel loading dye and 10 µL sample, and 10 µL of sample was 
added per well. Gels were subjected to electrophoresis for 60 mins (Flowgen Consort E734), 
then imaged (GelDoc). 
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UV-vis; 
Bacterial growth curves were derived from measuring absorbance at a wavelength of 600 nm 
conducted on a Ultra-violet U1900 (Hitachi) spectrometer utilising UV solutions 2.2 software 
(Hitachi). Protein concentrations were calculated (equation 1) from absorbance measured at a 
wavelength of 280 nm on a nanodrop (Denovix DS-II FX Spectrometer/Fluorometer). 
𝐶𝑜𝑛𝑐 (𝑀) =  
𝐴
𝜀(𝑑𝑚 𝑚𝑜𝑙−1 𝑐𝑚−1)𝑙 (𝑐𝑚)
    equation 1 
 
Liquid Chromatography Mass Spectrometry (LC-MS);  
All mass spectrometry was carried out using negative ion mode electrospray ionisation, unless 
otherwise detailed, on a Bruker HCTultra ETD II system (Bruker Daltonics) mass spectrometer in 
The University of York Centre of Excellence in Mass Spectrometry (CoEMS). A Waters C18 
column was fitted to a high performance Dionex UltiMate® 3000 LC system (ThermoScientific) 
equipped with an UltiMate® 3000 Diode Array Detector. Chromeleon® 6.80 SR12 software 
(ThermoScientific) combined with esquireControl version 6.2, Build 62.24 software (Bruker 
Daltonics), and Bruker compass Hystar 3.2-SR2, Hystar version 3.2, Build 44 software (Bruker 
Daltonics). 
General procedure; 
Solvent A - Water, Formic Acid 0.1 % (v/v) 
Solvent B - Acetonitrile, Formic Acid 0.1 % (v/v) 
The general method employed a flow-rate of 300 µL min-1, followed pre-equilibrium of the 
column in solvent A 95 % for 30 seconds followed by application of a linear gradient; solvent B 
70 % to 30 % over 6 minutes. The column was washed in 95 % solvent B for 1 minute before 
solvent A 95 % was applied for 1 minute to re-equilibrate the column.  
During analysis of mass spectra a buffer peak was observed (~1 min) as well as a peak during 
the final wash stage and as such data from this part of the run was emitted from spectra. 
 
NMR;  
NMR data was collected on a Jeol ECS400 NMR Spectrometer or the Bruker AVIIIHD500 FT-NMR 
Spectrometer made available at The University of York Centre for Magnetic Resonance. 
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7.2 PA2794 and PA2794 F129A mutant 
PA2794 F129A mutation 
P. aeruginosa PA2794 recombinant plasmid was designed and purchased from GenScript. The 
sequence was E. coli codon optimised and ligated into a pET15b plasmid between the NdeI and 
BamHI restriction sites resulting in a N-terminal His6 tagged protein. Site directed mutagenesis 
was carried out on the PA2794 pET15b recombinant plasmid to produce the 
phenylalanine129alanine mutant. Primers were designed using snap gene to replace the TTC 
phenylalanine codon with GCC.  
Forward primer; 5’- GGC GCG GAT TAC AAC GCC GCG CAC GGC AAG AGC -3’ 
Reverse primer; 5’- ACC ACG CGC CAG GGT GAA -3’ 
PCR reaction mixtures were composed according to the 5 x Phusion GC buffer manufacturer 
conditions (Table 1) and subjected to thermocycling conditions as follows; 
98 °C     30 seconds 
98 °C     10 seconds 
55, 58.4, 61.8, 65.2, 68.6, 72.0 °C 30 seconds x 35 
72 °C     210 seconds 
72 °C     10 minutes 
4 °C     Hold 
 
Table 1; Components of the PCR reaction mixture 
Component Per 20 µL reaction / µL 
5 x Phusion GC buffer 4 
DNTPs (10 mM) 0.4 
Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
PA2794 recombinant plasmid (20 ng µL-1) 0.2 
DMSO 0.6 
Phusion DNA polymerase 0.2 
dH2O 12.6 
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The resulting DNA was transformed via heat shock into E. coli Top-10 cells and after incubation 
(37 °C, 220 rpm, 45 minutes) the cell culture was spread onto LB agar plates containing ampicillin 
(100 µg mL-1) and incubated 37 °C, overnight. A single colony was incubated in LB (10 mL) 
containing ampicillin (100 µg mL-1) and incubated 37 °C, 180 rpm, overnight. The cells were 
centrifuged (12,000 x g, 5 mins, table top centrifuge), the supernatant was discarded and cell 
pellet subjected to a miniprep (Qiagen, QIAprep Spin, following the manufacturer’s guidelines) 
to extract the DNA plasmid for sequencing (GATC Sanger sequencing). 
PA2794 and PA2794 F129A transformation 
Following conformation that the mutation had been successful, the plasmid containing the 
PA2794 F129A and the native P. aeruginosa PA2794 pEt15b recombinant plasmid were 
transformed via heat shock into chemically competent E. coli BL21(DE3) cells, which had been 
previously prepared. Following incubation (37 °C, 220 rpm, 45 minutes) the cell culture was 
spread onto LB agar plates containing ampicillin (100 µg mL-1) and incubated 37 °C, overnight.  
PA2794 and PA2794 F129A expression 
A single colony was inoculated in liquid LB media containing ampicillin (100 µg mL-1) (15 mL) and 
incubated 180 rpm, 37 °C overnight. 2 mL of culture was added per litre of media in baffled flasks 
for aerobic growth at 180 rpm, 37 °C until an OD600 of 0.6 was reached. At this point, the cells 
were induced with 0.5 mM IPTG and proteins were expressed under a variety of conditions 
during trial experiments and then for 18 hours at 16 °C in all subsequent grow ups. 
Centrifugation (6000 x g, 40 mins, 6 °C, Beckman Avanti centrifuge J-25) after the appropriate 
time afforded cell pellets which were stored at -80 °C until required or used straight away. 
PA2794 and PA2794 F129A purification 
Lysis buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol, 10 mM imidazole Benzonase (25 U/L 
grow up), protease inhibitor tablet (used as instructed). 
Equilibrium buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol, 10 mM imidazole. 
Elution buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol, 500 mM imidazole. 
Size exclusion buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol. 
Cell pellets were defrosted on ice and resuspended in cold lysis buffer. The solution was 
sonicated on ice 20 x 30 second intervals (Soniprep 150), centrifuged (20, 000 x g, 20 min, 6 °C, 
Beckman Avanti centrifuge J-25) and the resulting supernatant filtered (0.22 µm).  
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The supernatant was loaded onto a HisTrap HP Ni2+ affinity column (5 mL), pre-equilibrated with 
equilibrium buffer (AKTA Start, GE Healthcare Life Technologies). The same programme was 
applied in each case and eluent monitored by UV Abs280;  
Equilibrium buffer for 7 column volumes, linear gradient from 10 mM imidazole to 300 mM 
imidazole over 15 column volumes, elution buffer for 5 column volumes. 
Fractions containing protein were analysed by SDS PAGE and those containing purified over-
expressed protein were combined and concentrated to a volume of 2 mL using 30 kDa MWCO 
falcon tubes. The resulting 2 mL was centrifuged (12,000 x g, 2 mins, table top centrifuge) and 
the supernatant applied to the size exclusion column (120 mL, HiLoad 16/600 S200, 
GEHEalthcare) and fractions collected when an increase in UV Abs280 was detected. Fractions 
containing protein were analysed by SDS PAGE and those containing purified over-expressed 
protein were combined and concentrated 3.5 mg mL-1 and stored. 
PA2794 crystallography 
PA2794 48 well sitting drop trays were setup to screen conditions based on previously 
published crystallography conditions (0.1 M bicine pH 5.0, PEG 6K 10 % (w/v) or 0.1 M 
imidazole pH 8.0, PEG 8K 10 % (w/v)) from the stock solutions below;  
1 M bicine pH 4.44, pH 5.01 or pH 5.53, adjusted with concentrated NaOH and HCl 
1 M imidazole pH 7.51, pH 8.02, pH 8.50, adjusted with concentrated NaOH and HCl 
PEG 6K 50 % (w/v) (stirred to resuspend) 
PEG 8K 25 % (w/v) (stirred to resuspend) 
Mosquito robot was utilised to dispense either 0.3 µL or 0.5 µL PA2795 (3.5 mg mL-1) or PA2794 
(3.5 mg mL-1), Pse5Ac7Ac (1 mM) for co-crystallisation attempts, into each drop followed by 0.5 
µL well solution. The tray was sealed and left at room temperature for crystals to develop for at 
least 10 days. Pse5Ac7Ac (1.13) was introduced to crystals either as a solid or 0.5 µL Pse5Ac7Ac 
(1 mM in well solution). 
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Conditions for apo PA2794 
 
Alternative conditions for ligand bound PA2794 attempts 
 
Regular crystals were fished from the solution and placed in a cryo solution (well solution 
containing 20 % glycerol) for 1 minute then flash frozen in N2 (l) and stored in N2 (l) prior to 
diffraction testing. X-ray diffraction was carried out in-house using facilities in the YSBL; a Rigaku 
MicroMAx 007HF generator, RAXIS IV++ imaging plate detector and an Actor robotic sample 
changer. 
Crystals that successfully diffracted were stored in in N2 (l) and delivered to the Diamond 
synchrotron facilities. Data was processed using CCP4i2, refined using REFMAC 5 and Coot, and 
graphics developed on CCP4MG.  
  
PEG 6K
14%
16%
18%
20%
22%
24%
26%
28%
0.3 µL: 0.5µL 0.5 µL: 0.5µL 0.3 µL: 0.5µL 0.5 µL: 0.5µL 0.3 µL: 0.5µL 0.5 µL: 0.5µL
Bicine 0.1 M pH 4.5 Bicine 0.1 M pH 5.0 Bicine 0.1 M pH 5.5
PEG 8K
8%
10%
12%
14%
16%
18%
20%
22%
0.3 µL: 0.5µL 0.5 µL: 0.5µL 0.3 µL: 0.5µL 0.5 µL: 0.5µL 0.3 µL: 0.5µL 0.5 µL: 0.5µL
Imidazole 0.1 M pH 7.5 Imidazole 0.1 M pH 8.0 Imidazole 0.1 M pH 8.5
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7.3 Campylobacter jejuni Pse5Ac7Ac biosynthetic enzymes  
Transformation 
A Gene Pulser II Electroporation system, consisting of a Gene Pulser II Unit and a Capacitance 
Expander II Unit, was employed for electroporation of the PseB and PseC recombinant plasmids 
into electrocompetent E. coli BL21(DE3) cells, which had been previously prepared. The PseH, 
PseG and PseI recombinant plasmids were introduced into chemically competent E. coli 
BL21(DE3) cells, which had been previously prepared according to literature procedures, via 
heat shock.  
Expression 
All bacterial growths were performed in LB media containing antibiotic; Kanamycin (50 µg mL-1) 
(PseB) or Ampicillin (100 µg mL-1) (PseC, PseH, PseG, PseI). Freshly transformed cells (or glycerol 
stocks) were streaked onto LB agar plates containing appropriate antibiotics and incubated 37 
°C, overnight. A single colony was inoculated in liquid media (15 mL) and incubated 180 rpm, 37 
°C overnight. 2 mL of culture was added per litre of media in baffled flasks for aerobic growth at 
180 rpm, 37 °C until an OD600 of 0.6 was reached. At this point, protein expression was induced 
with IPTG using optimised conditions as discussed. Centrifugation (6000 x g, 40 mins, 6 °C, 
Beckman Avanti centrifuge J-25) after the appropriate time afforded cell pellets which were 
stored at -80 °C until required. 
Purification 
Lysis buffer; 50 mM sodium phosphate buffer, pH7.4, 400 mM NaCl, 10 mM imidazole, 
Benzonase (25 U/L grow up), protease inhibitor tablet (used as instructed). 
Equilibrium buffer; 50 mM sodium phosphate buffer, pH7.4, 400 mM NaCl, 10 mM imidazole. 
Elution buffer; 50 mM sodium phosphate buffer, pH7.4, 400 mM NaCl, 500 mM imidazole. 
Desalting buffer; 25 mM sodium phosphate buffer, pH7.4, 50 mM NaCl. 
Cell pellets were defrosted on ice and resuspended in cold lysis buffer. The solution was 
sonicated on ice 20 x 30 second intervals (Soniprep 150), centrifuged (20, 000 x g, 20 min, 6 °C, 
Beckman Avanti centrifuge J-25) and the resulting supernatant filtered (0.22 µm). The 
supernatant was loaded onto a HisTrap HP Ni2+ affinity column (5 mL), pre-equilibrated with 
equilibrium buffer (AKTA Start, GE Healthcare Life Technologies). The following programme was 
applied in each case and the eluent monitored by UV Abs280;  
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Equilibrium buffer for 7 column volumes, linear gradient from 10 mM imidazole to 300 mM 
imidazole over 15 column volumes, elution buffer for 5 column volumes. 
Fractions containing protein were analysed by SDS PAGE and those containing purified over-
expressed protein were combined and buffer exchanged into dialysis buffer using a desalting 
column (HiPrep 26/10 Desalting, GEHealthcare) and either used straight away or prepped for 
storage. 
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7.4 Chemo-enzymatic syntheses 
C. jejuni enzymatic synthesis of Pse5Ac7Ac (2.1) 
Initial reaction mixtures were composed of 1 mM UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 
10 mM L-Glutamic acid, 1.5 mM acetyl-coA, 1.5 mM phosphoenolpyruvate in either Tris-HCl 
buffer (50 mM, pH 7.4) or sodium phosphate buffer (50 mM, pH 7.4). Addition of the C. jejuni 
biosynthetic enzymes each to a final concentration of 0.38 mg mL-1 was used to initiate the 
reaction and the mixture was incubated 180 rpm, 37 °C. Small scale reactions were carried out 
on < 1mg scale. 
A. cavaie enzymatic synthesis of Pse5Ac7Ac (2.1) 
Reaction mixtures were composed of 1 mM UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 10 mM 
L-Glutamic acid, 1.5 mM acetyl-coA, 1.5 mM phosphoenolpyruvate in sodium phosphate buffer 
(50 mM, pH 7.4). Biosynthetic enzymes were added to final concentration of (0.38 mg mL-1) in 
reactions with a total volume of 1 mL as follows: 
Experiment Enzyme composition 
A C. jejuni PseB, PseC, PseH, PseG, PseI 
B C. jejuni PseB, PseC, PseH, PseG, A. cavaie NeuB 
C C. jejuni PseB, PseC, PseH, PseI, A. cavaie FlmD 
D C. jejuni PseB, PseH, PseG, PseI, A. cavaie FlmB 
E C. jejuni PseC, PseH, PseG, PseI, A. cavaie FlmA 
F A. cavaie FlmA, FlmB, FlmD, NeuB 
 
All reactions were incubated 37 °C overnight, with aliquots taken at regular intervals for testing.  
 
PseB and PseC experiments in deuterium oxide 
PseB and PseC were dialysed into deuterated Tris-HCl buffer (50 mM, pH 7.4) by repeated 
concentrating to 1 10⁄  of their original volumes and addition of the deuterated buffer. Reaction 
mixtures were composed of final concentrations of 1 mM UDP-GlcNAc, 10 mM L-Glu and 1.5 
mM PLP in deuterated Tris- HCl buffer (50 mM, pH 7.4). PseB was added to a final concentration 
of 25 µM for experiments only containing PseB and the reaction incubated 120 rpm, 37 °C, after 
2 hours PseC was added to a final concentration of 0.1 mg mL-1.  For experiments containing 
both PseB and PseC, PseB was added to a final concentration of 25 µM to the reaction mixture 
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after PseC had been added to a final concentration of 25 µM or 125 µM and the reaction 
incubated 120 rpm, 37 °C. 
Chemical acetylation 
PseC to a final concentration of 25 µM followed by PseB to a final concentration of 25 µM, were 
added to a reaction mixture composed of 1 mM UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 10 
mM L-Glutamic acid in Tris-HCl buffer (50 mM, pH 7.4), with a final volume of 16.5 mL and 
incubated 180 rpm, 37 °C. Aliquots were removed at regular intervals and monitored with LC-
MS negative ESI. After 4.5 hours, enzymes were removed using molecular weight cut off falcon 
tubes (30 kDa) and the resulting solution lyophilised.  
Crude PseC product was resuspended in MeOH (5 mL), acetic anhydride (100 µL, 11.5 mmol) 
and silver acetate (20 mg, 0.12 mmol) were added and the reaction mixture stirred for 4 hours. 
The reaction was filtered through celite, concentrated in vacuo, and resuspended in dH2O (5 mL) 
and lyophilised three times in dH2O to remove remaining acetic anhydride.  
Acetyl-coA regeneration 
PseC to a final concentration of 125 µM and PseH to a final concentration of 50 µM followed by 
PseB to a final concentration of 25 µM, were added to reaction mixtures composed of 1 mM 
UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 10 mM L-Glutamic acid in sodium phosphate buffer 
(50 mM, pH 7.4). An initial trial had the following added and reactions were incubated 120 rpm, 
37 °C and monitored with LC-MS negative ESI after 3 hours; 
1. 0 mM acetyl-coA, 20 mM acetylthiocholine iodide 
2. 0.15 mM acetyl-coA, 0 mM acetylthiocholine iodide 
3. 0.15 mM acetyl-coA, 2 mM acetylthiocholine iodide 
4. 0.15 mM acetyl-coA, 20 mM acetylthiocholine iodide 
5. 1.5 mM acetyl-coA, 0 mM acetylthiocholine iodide 
Further reactions (of the core mixture above) consisted of acetylthiocholine iodide to a final 
concentration of 20 mM or 100 mM with rincrasing amounts of CoA (0 mM, 0.0015 mM, 0.015 
mM, 0.15 mM) and incubated 120 rpm 37 °C.The reaction mixture was monitored with LC-MS 
negative ESI after 4 hours. 
A reaction mixture composed of 1 mM UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 10 mM L-
Glutamic acid, 0.0015 mM CoA, 100 mM acetylthiocholine iodide, 1.5 mM phosphoenolpyruvate 
in sodium phosphate buffer (50 mM, pH 7.4) was incubated 120 rpm 37 °C with PseB (25 µM), 
PseC (125 µM), PseH (50 µM), PseG (30 µM) and Pse I (25 µM). Aliquots were taken at regular 
intervals and monitored with LC-MS negative ESI for production of Pse5Ac7Ac.  
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Acetyl-coA co-factor substitution 
Control reaction mixtures composed of 1 mM UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 10 
mM L-Glutamic acid, 1.5 mM phosphoenolpyruvate in sodium phosphate buffer (50 mM, pH 
7.4), with PseB (25 µM), PseC (125 µM), PseG (30 µM), Pse I (25 µM) and either PseH (50 µM) or 
10 mM N-acetyl cysteamine thioacetate.  As well as a DMSO control reaction that contained the 
core mixture above with PseH (50 µM), 1.5 mM acetyl-CoA and 10 % DMSO. Reaction mixtures 
were incubated 120 rpm, 37 °C and aliquots monitored with LC-MS negative ESI for production 
of Pse5Ac7Ac. 
A reaction mixture containing 1 mM UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 10 mM L-
Glutamic acid, in sodium phosphate buffer (50 mM, pH 7.4), with PseB (25 µM), PseC (125 µM), 
PseH (50 µM) with 10 mM N-acetyl cysteamine thioacetate, 10 mM phenyl acetate, 10 mM p-
tolyl acetate, 10 mM S-phenyl thioacetate, 10 mM p-nitrophenyl acetate, 10 mM S-(4-
nitrophenyl)thioacetate, or 10 mM S-(p-tolyl)thioacetate (with the latter three suspended as a 
10X stock in DMSO) were incubated 120 rpm, 37 °C. Aliquots were taken at regular intervals and 
monitored with LC-MS negative ESI. 
Enzymatic synthesis of Pse5Ac7Az 
1 mM UDP-GlcNAc, 1 mM pyridoxal 5’ phosphate, 10 mM L-Glutamic acid, 1.5 mM 
phosphoenolpyruvate in sodium phosphate buffer (50 mM, pH 7.4), were incubate (120 rpm, 37 
°C) with PseB (25 µM), PseC (125 µM), PseH (50 µM), PseG (30 µM), Pse I (25 µM) and either 10 
mM N-acetyl cysteamine thioacetate or 10 mM N-acetyl cysteamine thioazidoacetate. Aliquots 
were monitored with LC-MS negative ESI.  
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7.5 Chemical synthesis 
S-(2-acetamindoethyl) ethanethioate (SNAc) 
 
 
Cysteamine HCl (1 g, 8.8 mmol) was suspended in dH2O (8 mL) and the pH was adjusted to 8.0 
using 4 N KOH on ice. Whilst maintaining the pH at 8 with 4 N KOH, acetice anhydride (2.5 mL, 
24.5 mmol) was added dropwise. 1 N HCl was added to adjust the pH to 7.0 and the reaction 
mixture was stirred at 0 °C for 2 hours. Brine (10 mL) was added to the reaction mixture and the 
product was extracted with DCM (3 x 10 mL). The organic layer was dried (MgSO4) and 
condensed azeotroping with toluene. The resulting white solid appeared pure by mass spec and 
NMR. RF 0.56 (5:1 (v/v) DCM:MeOH). 1H NMR (500 MHz, Chloroform-d) δ 3.23 (q, J = 6.5 Hz, 2H), 
2.87 (t, J = 6.8 Hz, 2H), 2.19 (s, 3H), 1.83 (s, 3H) (Appendix 9). 
 
 
S-(2-(2-azido)acetamido)ethyl ethanethioate (SNAz) 
 
 
 
A) Azidoacetic acid (57 µL, 0.77 mmol) was added to DCC (0.173 g, 0.84 mmol) suspended 
in anhydrous DCM (11 mL) and stirred for 5 minutes under a N2 atm in a water/ice bath. 
DMAP (0.093 g, 0.76 mmol) and N-acetyl cysteamine (89 µL, 0.84 mmol) were added 
and the reaction mixture was left stirring to warm to r.t overnight.  
B) Azidoacetic acid (57 µL, 0.77 mmol) was added to HCTU (0.382 g, 0.924 mmol) 
suspended in anhydrous DCM (11 mL) and stirred at 0 °C for 5 minutes under a N2 atm 
in a water/ice bath. N-acetyl cysteamine (89 µL, 0.84 mmol) and EtN3 (215 µL, 1.54 
mmol) were added and the reaction mixture was left stirring to warm to r.t overnight.  
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C) Azidoacetic acid (57 µL, 0.77 mmol)  was added to a DCC (0.173 g, 0.84 mmol) suspended 
in anhydrous DCM (11 mL) and stirred for 5 minutes under a N2 atm in a water/ice bath. 
N-acetyl cysteamine (89 µL, 0.84 mmol) and HoBt (0.104 g, 0.77 mmol) were added and 
the reaction mixture was left stirring to warm to r.t overnight.  
Reaction mixtures A) and B) were filtered in vacuo, condensed and resuspended in ethyl 
acetate (20 mL). After filtering the filtrate was washed with brine (20 mL), dried (NaSO4) 
and condensed in vacuo to afford a syrup. The crude oils were purified by flash column 
chromatography (silica gel; step-wise gradient of hexane and ethyl acetate; hexane, hexane-
ethyl acetate 3:1 (v/v), hexane-ethyl acetate 2:1 (v/v), hexane-ethyl acetate 1:1 (v/v), 
hexane-ethyl acetate 1:2 (v/v), hexane-ethyl acetate 1:3 (v/v), ethyl acetate 1, pure fractions 
were combined and condensed to afford a syrup. RF 0.28 (1:1 (v/v) ethyl acetate:hexane). 
1H NMR (500 MHz, Methanol-d4) δ 4.12 (s,2H), 3.33 (t, J = 6.6 Hz, 2H), 3.06 (t, J = 6.6 Hz, 2H), 
1.90 (s, 3H) (Appendix 9). 
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1. PA2794 sequences 
PA2794 DNA coding sequence, optimised for E. coli. 
ATGAACACCTATTTTGATATTCCGCATCGCCTGGTGGGCAAAGCGCTGTATGAAAGCTAT 
TATGATCATTTTGGCCAGATGGATATTCTGAGCGATGGCAGCCTGTATCTGATTTATCGC 
CGCGCGACCGAACATGTGGGCGGCAGCGATGGCCGCGTGGTGTTTAGCAAACTGGAAGGC 
GGCATTTGGAGCGCGCCGACCATTGTGGCGCAGGCGGGCGGCCAGGATTTTCGCGATGTG 
GCGGGCGGCACCATGCCGAGCGGCCGCATTGTGGCGGCGAGCACCGTGTATGAAACCGGC 
GAAGTGAAAGTGTATGTGAGCGATGATAGCGGCGTGACCTGGGTGCATAAATTTACCCTG 
GCGCGCGGCGGCGCGGATTATAACTCCGCGCATGGCAAAAGCTTTCAGGTGGGCGCGCGC 
TATGTGATTCCGCTGTATGCGGCGACCGGCGTGAACTATGAACTGAAATGGCTGGAAAGC 
AGCGATGGCGGCGAAACCTGGGGCGAAGGCAGCACCATTTATAGCGGCAACACCCCGTAT 
AACGAAACCAGCTATCTGCCGGTGGGCGATGGCGTGATTCTGGCGGTGGCGCGCGTGGGC 
AGCGGCGCGGGCGGCGCGCTGCGCCAGTTTATTAGCCTGGATGATGGCGGCACCTGGACC 
GATCAGGGCAACGTGACCGCGCAGAACGGCGATAGCACCGATATTCTGGTGGCGCCGAGC 
CTGAGCTATATTTATAGCGAAGGCGGCACCCCGCATGTGGTGCTGCTGTATACCAACCGC 
ACCACCCATTTTTGCTATTATCGCACCATTCTGCTGGCGAAAGCGGTGGCGGGCAGCAGC 
GGCTGGACCGAACGCGTGCCGGTGTATAGCGCGCCGGCGGCGAGCGGCTATACCAGCCAG 
GTGGTGCTGGGCGGCCGCCGCATTCTGGGCAACCTGTTTCGCGAAACCAGCAGCACCACC 
AGCGGCGCGTATCAGTTTGAAGTGTATCTGGGCGGCGTGCCGGATTTTGAAAGCGATTGG 
TTTAGCGTGAGCAGCAACAGCCTGTATACCCTGAGCCATGGCCTGCAGCGCAGCCCGCGC 
CGCGTGGTGGTGGAATTTGCGCGCAGCAGCAGCCCGAGCACCTGGAACATTGTGATGCCG 
AGCTATTTTAACGATGGCGGCCATAAAGGCAGCGGCGCGCAGGTGGAAGTGGGCAGCCTG 
AACATTCGCCTGGGCACCGGCGCGGCGGTGTGGGGCACCGGCTATTTTGGCGGCATTGAT 
AACAGCGCGACCACCCGCTTTGCGACCGGCTATTATCGCGTGCGCGCGTGGATT 
 
PA2794 amino acid sequence expressed by a pET15b recombinant plasmid, highlighting the N-
terminal hexa-his tag (red) and thrombin cleavage site (blue) MW 47151 g mol-1). 
 
MGSSHHHHHHSSGLVPRGSHMNTYFDIPHRLVGKALYESYYDHFGQMDILSDGSLYLIYR
RATEHVGGSDGRVVFSKLEGGIWSAPTIVAQAGGQDFRDVAGGTMPSGRIVAASTVYETG
EVKVYVSDDSGVTWVHKFTLARGGADYNFAHGKSFQVGARYVIPLYAATGVNYELKWLES
SDGGETWGEGSTIYSGNTPYNETSYLPVGDGVILAVARVGSGAGGALRQFISLDDGGTWT
DQGNVTAQNGDSTDILVAPSLSYIYSEGGTPHVVLLYTNRTTHFCYYRTILLAKAVAGSS
GWTERVPVYSAPAASGYTSQVVLGGRRILGNLFRETSSTTSGAYQFEVYLGGVPDFESDW
FSVSSNSLYTLSHGLQRSPRRVVVEFARSSSPSTWNIVMPSYFNDGGHKGSGAQVEVGSL
NIRLGTGAAVWGTGYFGGIDNSATTRFATGYYRVRAWI 
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2. PA2794 F129A sequences 
PA2794 F129A DNA coding sequence, with the mutation highlighted in green. 
ATGAACACCTATTTTGATATTCCGCATCGCCTGGTGGGCAAAGCGCTGTATGAAAGCTAT 
TATGATCATTTTGGCCAGATGGATATTCTGAGCGATGGCAGCCTGTATCTGATTTATCGC 
CGCGCGACCGAACATGTGGGCGGCAGCGATGGCCGCGTGGTGTTTAGCAAACTGGAAGGC 
GGCATTTGGAGCGCGCCGACCATTGTGGCGCAGGCGGGCGGCCAGGATTTTCGCGATGTG 
GCGGGCGGCACCATGCCGAGCGGCCGCATTGTGGCGGCGAGCACCGTGTATGAAACCGGC 
GAAGTGAAAGTGTATGTGAGCGATGATAGCGGCGTGACCTGGGTGCATAAATTTACCCTG 
GCGCGCGGCGGCGCGGATTATAACGCCGCGCATGGCAAAAGCTTTCAGGTGGGCGCGCGC 
TATGTGATTCCGCTGTATGCGGCGACCGGCGTGAACTATGAACTGAAATGGCTGGAAAGC 
AGCGATGGCGGCGAAACCTGGGGCGAAGGCAGCACCATTTATAGCGGCAACACCCCGTAT 
AACGAAACCAGCTATCTGCCGGTGGGCGATGGCGTGATTCTGGCGGTGGCGCGCGTGGGC 
AGCGGCGCGGGCGGCGCGCTGCGCCAGTTTATTAGCCTGGATGATGGCGGCACCTGGACC 
GATCAGGGCAACGTGACCGCGCAGAACGGCGATAGCACCGATATTCTGGTGGCGCCGAGC 
CTGAGCTATATTTATAGCGAAGGCGGCACCCCGCATGTGGTGCTGCTGTATACCAACCGC 
ACCACCCATTTTTGCTATTATCGCACCATTCTGCTGGCGAAAGCGGTGGCGGGCAGCAGC 
GGCTGGACCGAACGCGTGCCGGTGTATAGCGCGCCGGCGGCGAGCGGCTATACCAGCCAG 
GTGGTGCTGGGCGGCCGCCGCATTCTGGGCAACCTGTTTCGCGAAACCAGCAGCACCACC 
AGCGGCGCGTATCAGTTTGAAGTGTATCTGGGCGGCGTGCCGGATTTTGAAAGCGATTGG 
TTTAGCGTGAGCAGCAACAGCCTGTATACCCTGAGCCATGGCCTGCAGCGCAGCCCGCGC 
CGCGTGGTGGTGGAATTTGCGCGCAGCAGCAGCCCGAGCACCTGGAACATTGTGATGCCG 
AGCTATTTTAACGATGGCGGCCATAAAGGCAGCGGCGCGCAGGTGGAAGTGGGCAGCCTG 
AACATTCGCCTGGGCACCGGCGCGGCGGTGTGGGGCACCGGCTATTTTGGCGGCATTGAT 
AACAGCGCGACCACCCGCTTTGCGACCGGCTATTATCGCGTGCGCGCGTGGATT 
 
PA2794 F129A codon sequence expressed by a pET15b recombinant plasmid, highlighting the 
mutation (green), N-terminal hexa-his tag (red) and thrombin cleavage site (blue) MW 47151 g 
mol-1). 
 
MGSSHHHHHHSSGLVPRGSHMNTYFDIPHRLVGKALYESYYDHFGQMDILSDGSLYLIYR
RATEHVGGSDGRVVFSKLEGGIWSAPTIVAQAGGQDFRDVAGGTMPSGRIVAASTVYETG
EVKVYVSDDSGVTWVHKFTLARGGADYNAAHGKSFQVGARYVIPLYAATGVNYELKWLES
SDGGETWGEGSTIYSGNTPYNETSYLPVGDGVILAVARVGSGAGGALRQFISLDDGGTWT
DQGNVTAQNGDSTDILVAPSLSYIYSEGGTPHVVLLYTNRTTHFCYYRTILLAKAVAGSS
GWTERVPVYSAPAASGYTSQVVLGGRRILGNLFRETSSTTSGAYQFEVYLGGVPDFESDW
FSVSSNSLYTLSHGLQRSPRRVVVEFARSSSPSTWNIVMPSYFNDGGHKGSGAQVEVGSL
NIRLGTGAAVWGTGYFGGIDNSATTRFATGYYRVRAWI 
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3. PA2794 and PA2794 F129A Akta trace for Ni-His trap purification  
Equilibrium buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol, 10 mM imidazole. 
Elution buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol, 500 mM imidazole. 
Lysate (55 mL) loaded onto the Ni-His trap column, followed by washing with equilibrium buffer 
(25 mL). Fractions (3 mL) were collected duting application of a linear gradient of 0-100 % elution 
buffer over 80 mL.  
 
 
3.1 PA2794 Akta trace; demonstrating binding and elution of a hexa-his tagged protein. 
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Equilibrium buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol, 10 mM imidazole. 
Elution buffer; 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol, 500 mM imidazole. 
Lysate (110 mL) loaded onto the Ni-His trap column, followed by washing with equilibrium buffer 
(25 mL). Fractions (3 mL) were collected duting application of a linear gradient of 0-100 % elution 
buffer over 80 mL.  
 
3.2 PA2794 F129A Akta trace; demonstrating binding and elution of a hexa-his tagged protein. 
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4. PA2794 and PA2794 F129A Akta trace for size exclusion purification 
 
4.1 PA2794 size exclusion Akta trace in 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol. 
 
 
4.2 PA2794 F129A size exclusion Akta trace in 50 mM Tris-HCl buffer, pH7.5, 10 % glycerol. 
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5. Crystallography statistics 
 PA2794 apo PA2794 ligand 
Data collection   
Space group P213 P213 
Cell dimensions     
    a, b, c (Å) 126.6, 126.6, 126.6 127.7, 127.7, 127.7 
        ()  90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 89.52-1.22 73.70-1.94 
Rsym or Rmerge 0.096 (2.104) 0.083 (1.159) 
Rpim 0.023 (0.521) 0.020 (0.284) 
CC1/2 0.999 (0.538) 1.000 (0.838)  
I / I 15.7 (1.5) 26.1 (3.6) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 
Redundancy 19.5 (18.2) 19.8 (18.8) 
   
Refinement   
No. reflections 55643 54719 
Rwork / Rfree 0.133/0.152 0.200/0.227 
No. atoms   
    Protein 3432 3350 
    Ligand/ion 41 30 
    Water 479 114 
B-factors   
    Protein 16.4 42.7 
    Ligand/ion 38.3 57.0 
    Water 29.6 38.8 
R.m.s deviations   
    Bond lengths (Å) 0.021 0.0106 
    Bond angles () 2.23 1.734 
 
Rmerge = 𝛴ℎ𝛴𝑖(
|<𝐼ℎ>−𝐼ℎ,𝑖|
𝛴ℎ𝛴𝑖𝐼ℎ,𝑖
) 
h = the unique reflections and i = their symmetry-equivalent contributors  
Rpim = 
𝛴ℎ𝑘𝑙 √
1
𝑛−1
 𝛴𝑗=𝐼
𝑛  |𝐼ℎ𝑘𝑙𝑗−〈𝐼ℎ𝑘𝑙〉|
𝛴ℎ𝑘𝑙 𝛴𝑗 𝐼ℎ𝑘𝑙𝑗
 
 
Rfree = Σ|𝐹𝑜𝑏𝑠 − 𝐹𝑐𝑎𝑙𝑐|/𝛴𝐹𝑜𝑏𝑠  
Fobs = experimentally obtained structure factor amplitudes and Fcalc = calculated structure 
factor amplitudes 
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6. Campylobacter jejuni biosynthetic enzymes. 
 E. coli codon optimised DNA sequences for purchased genes and amino acid sequences of all 
enzymes. 
 
6.1 PseB (Cj1293) MW 37372 g mol-1 
MFNGKNILITGGTGSFGKTYTKVLLENYKPNKIIIYSRDELKQFEMSSIFNSNCMRYFIG 
DVRDKERLSVAMRDVDFVIHAAAMKHVPVAEYNPMECIKTNIHGAQNVIDACFENGVKKC 
IALSTDKACNPVNLYGATKLASDKLFVAANNIAGNKQTRFSVTRYGNVVGSRGSVVPFFK 
KLIAQGSKELPITDTRMTRFWISLEDGVKFVLSNFERMHGGEIFIPKIPSMKITNLAHAL 
APNLSHKIIGIRAGEKLHEIMISSDDSHLTYEFENYYAISPSIKLVDQESDFSINALGEK 
GQKVKDGFSYSSDNNPQWASEKELLDIINHTEGF 
 
6.2 PseC (Cj1294) MW 42317 g mol-1 
MLTYSHQNIDQSDIDTLTKALKDEILTGGKKVNEFEEALCEYMGVKHACVLNSATSALHL 
AYTALGVQEKIVLTTPLTFAATANAALMAGAKVEFIDIKNDGNIDEKKLEARLLKESENI 
GAISVVDFAGNSVEMDEISNLTKKYNIPLIDDASHALGALYKSEKVGKKADLSIFSFHPV  
KPITTFEGGAVVSDNEELIDKIKLLRSHGIVKKRLWDSDMVELGYNYRLSDVACALGINQ 
LKKLDHNLEKREEIANFYDKEFEKNPYFSTIKIKDYKKSSRHLYPILLFPEFYCQKEELF 
ESLLHAGIGVQVHYKPTYEFSFYKKLLGEIKLQNADNFYKAELSIPCHQEMNLKDAKFVK 
DTLFSILEKVKKGYCG 
 
6.3 PseH (Cj1313) MW 15103 g mol-1 
ATGCTGATTAAACTGAAAAACTTCGCGGAACTGAATAGCCAGGAAATTAAACTGATCTTCAAATGGCGTAACCACC
CGGACATTAGCCAATTCATGAAGACCAAACACATCGACTTCGAGGAACACCTGCGTTTTATTCGTAACCTGCACCA
GGATAGCAACAAGAAATACTTCCTGGTGTTTCAGGACGAGCAAATCATTGGTGTGATCGATTTCGTTAACATTACC
ACCAAAAGCTGCGAATTTGGCCTGTATGCGATCCCGGACCTGAAGGGTGTGGGCCAAGTTCTGATGAACGAGATC
AAGAAATACGCGTTCGAAATTCTGAAGGTGGACACCCTGAAAGCGTATGTTTTTAAGGATAACCACAAGGCGCTG
AAACTGTACCAGCAAAACCACTTTACCATTTATGATGAGGACAAGGACTTTTATTATGTGTGCCTGAAACAGAGCC
ACTGCAAGGCGCTGCCGAGCTAA 
 
MIKLKNFTELNSQEIELIFKWRNHPDINQFMKTKYIDFEEHLRFLKKLHQDSSKKYFLVF  
QDEQIIGVIDFVNITTKSCEFGLYAKPNLKGVGQILMNEIIKYAFENLKVNTLKAYVFKD 
NRKALKLYQQNHFTIYDEDKDFYHICLKQSDCKALPS 
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6.4 PseG (Cj1312) MW 31319 g mol-1 
ATGAAGGTGCTGTTCCGTAGCGACAGCAGCAGCCAGATCGGTTTTGGCCACATTAAGCGTGACCTGGTGCTGGCG
AAACAATACAGCGATGTTAGCTTTGCGTGCCTGCCGCTGGAGGGTAGCCTGATCGACGAAATTCCGTACCCGGTT
TATGAACTGAGCAGCGAGAGCATCTACGAACTGATCAACCTGATTAAAGAGGAGAAATTCGAGCTGCTGATCATT
GATCACTATGGTATCAGCGTGGACGATGAGAAGCTGATTAAACTGGAAACCGGCGTTAAGATCCTGAGCTTTGAC
GATGAAATTAAACCGCACCACTGCGACATCCTGCTGAACGTGAACGCGTACGCGAAGGCGAGCGATTATGAGGG
TCTGGTGCCGTTCAAATGCGAAGTTCGTTGCGGCTTTAGCTACGCGCTGATCCGTGAGGAATTCTATCAGGAAGC
GAAGGAAAACCGTGAGAAGAAATACGACTTCTTTATTTGCATGGGTGGCACCGATATCAAAAACCTGAGCCTGCA
GATTGCGAGCGAGCTGCCGAAGACCAAAATCATTAGCATCGCGACCAGCAGCAGCAACCCGAACCTGAAGAAAC
TGCAAAAGTTCGCGAAACTGCACAACAACATCCGTCTGTTTATTGATCACGAGAACATTGCGAAGCTGATGAACG
AAAGCAACAAACTGATCATTAGCGCGAGCAGCCTGGTGAACGAGGCGCTGCTGCTGAAGGCGAACTTTAAAGCG
ATCTGCTACGTTAAGAACCAAGAAAGCACCGCGACCTGGCTGGCGAAGAAAGGCTATGAGGTTGAATACAAATAT
TAA 
 
MLDKILYFKTLIRADSGSKIGHGHVRRDLILAKNFKDVSFACIDLPGSLTGEIPCPVFTL  
KSADINELVNLIKEHKFELLIIDHYGISAADEKLIKEQTNVKILCFDDNYKEHFCDYLLN 
VNIYAQPQKYVNLVPANCELVFSPLVRSEFYDEAKIKREKKFDCFIALGGTDALNLTAKI 
ASNLLAKNKKVAAITTSANANLANLQNLADSESNFSLFINSNEVARLMNESEILVISASS 
LVNEALVLGAKFKAVRVADNQNEMAQWLAANGREIYEADEICLNL 
 
6.5 PseI (Cj1317) MW 38647 g mol-1 
ATGCATATGCAAATTGGTAACTTTAACACCGACAAGAAGGTTTTTATCATTGCGGAACTGAGCG
CGAATCATGCGGGTAGCCTGGAGATGGCGCTGAAGAGCATCAAAGCGGCGAAGAAAGCGGGT
GCGGACGCGATCAAGATTCAGACCTACACCCCGGATAGCCTGACCCTGAACAGCGACAAAGAG
GACTTCATCATTAAAGGTGGCCTGTGGGACAAGCGTAAACTGTACGAACTGTATGAGAGCGCG
AAAACCCCGTATGAATGGCACAGCCAGATCTTCGAAACCGCGCAAAACGAGGGTATTCTGTGCT
TCAGCAGCCCGTTTGCGAAGGAAGACGTGGAGTTCCTGAAACGTTTTGATCCGATCGCGTACAA
GATTGCGAGCTTCGAAGCGAACGATGAGAACTTTGTGCGTCTGATTGCGAAAGAGAAGAAACC
GACCATCGTTAGCACCGGCATTGCGACCGAGGAAGAGCTGTTCAAGATCTGCGAAATTTTTAAG
GAAGAGAAAAACCCGGACCTGGTGTTCCTGAAGTGCACCAGCACCTATCCGACCGCGATCGAG
GATATGAACCTGAAAGGTATTGTTAGCCTGAAGGAAAAATTTAACGTTGAGGTGGGTCTGAGC
GACCACAGCTTCGGCTTTCTGGCGCCGGTGATGGCGGTTGCGCTGGGTGCGCGTGTTATCGAA
AAGCACT TCATGCTGGACAAAAGCATTGAAAGCGAGGATAGCAAGTTTAGCCTGGACTTCGAT
GAATTTAAAGCGATGGTGGATGCGGTTCGTCAAGCGGAGAGCGCGCTGGGTGATGGCAAGCT
GGACCTGGATGAAAAGGTGCTGAAAAACCGTGTTTTCGCGCGTAGCCTGTACGCGAGCAAAGA
TATCAAGAAAGGCGAGATGTTTAGCGAAGAGAACGTGAAGAGCGTTCGTCCGAGCTTCGGTCT
GCACCCGAAATT TTATCAAGAACTGCTGGGCAAGAAGGCGAGCAAGGACATCAAGTTCGGTGA
CGCGCTGAAGCAAGGCGATTTCCAATAA  
 
MQIGNFNTDKKVFIIAELSANHAGSLEMALKSIKAAKKAGADAIKIQTYTPDSLTLNSDK 
EDFIIKGGLWDKRKLYELYESAKTPYEWHSQIFETAQNEGILCFSSPFAKEDVEFLKRFD 
PIAYKIASFEANDENFVRLIAKEKKPTIVSTGIATEEELFKICEIFKEEKNPDLVFLKCT 
STYPTAIEDMNLKGIVSLKEKFNVEVGLSDHSFGFLAPVMAVALGARVIEKHFMLDKSIE 
SEDSKFSLDFDEFKAMVDAVRQAESALGDGKLDLDEKVLKNRVFARSLYASKDIKKGEMF 
SEENVKSVRPSFGLHPKFYQELLGKKASKDIKFGDALKQGDFQ 
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7. Campylobacter jejuni enzymes Akta trace for Ni-His trap purification. 
Equilibrium buffer; 50 mM sodium phosphate buffer, pH7.4, 400 mM NaCl, 10 mM imidazole. 
Elution buffer; 50 mM sodium phosphate buffer, pH7.4, 400 mM NaCl, 500 mM imidazole. 
Lysate (30-50 mL) loaded onto the Ni-His trap column, followed by washing with equilibrium 
buffer (25 mL). Fractions (3 mL) were collected duting application of a linear gradient of 0-100 
% elution buffer over 50 or 75 mL.  
 
7.1 PseB Akta trace; demonstrating binding and elution of a hexa-his tagged protein. 
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7.2 PseC Akta trace; demonstrating binding and elution of a hexa-his tagged protein. 
 
7.3 PseH Akta trace; demonstrating binding and elution of a hexa-his tagged protein. 
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7.4 PseG Akta trace; demonstrating binding and elution of a hexa-his tagged protein. 
 
7.5 PseI Akta trace; demonstrating binding and elution of a hexa-his tagged protein. 
184 
 
8. LC-MS negative ESI of controls for co-factor substitute reactions 
Reaction mixtures containing UDP-GlcNAc (1 mM), PLP (1.5 mM) and ˪-glutamate (10 mM), PseB 
(25 µM), PseC (125 µM) and 10 mM acetyl-donor (5.9 or 5.19-5.24) in sodium phosphate buffer 
(50 mM pH7.4) or 10 % DMSO in sodium phosphate buffer (50 mM pH7.4) as required, were 
monitored by LC-MS negative ESI after > 3 hours for conversion to the PseH product (3.9) as 
estimated by appearance of a [M-H]- 631 peak. 
 
 
8.1 N-acetylcysteamine thioacetate (4.9) 10 mM 
 
 
8.2 p-nitrophenyl acetate (4.19) 10 mM 
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8.3 S-phenyl thioacetate (4.22) 10 mM 
 
8.4 S-(p-tolyl)thioacetate 10 mM 
 
 
 
8.5 p-tolyl acetate (4.21) 10 mM 
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8.6 Phenyl acetate (4.20) 10 mM 
 
 
8.7 S-(4-nitrophenyl)thioacetate (4.24) 10 mM  
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9. NMR 
 
 
9.1 N-acetylcysteamine thioacetate (5.9) proton NMR 
 
9.2 N-acetylcysteamine thioazidoacetate (5.26) proton NMR 
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List of Abbreviations 
Abs Absorbance 
Acetyl-CoA Acetyl-Coenzyme A 
ACS Acetyl-CoA synthetase 
Acyl-CoA Acyl-Coenzyme A 
ATP Adenosine Triphosphate 
cAMP Cyclic Adenosine Monophosphate 
CAT Carnitine acetyltransferase 
cDNA Complementary DNA 
CF Cystic Fibrosis 
CFG Consortium for Functional Glycomics 
CFTR Cystic Fibrosis Transmembrane conductance Regulator 
CMP-Neu5Ac Cytidine Monophosphate N-acetylneuraminic acid 
CMP-Pse5Ac7Ac Cytidine Monophosphate N, N’-diacetylpseudaminic acid 
CoA Coenzyme-A 
CPS Capsular polysaccharide 
CTP Cytidine Triphosphate 
D2O Deuterium oxide 
DCC N,N'-dicyclohexylcarbodiimide 
DCM Dichloromethane 
DMAP 4-Dimethylaminopyridine 
DMSO Dimethyl sulfoxide 
DNA Deoxyribose nucleic acid 
ESI Electrospray Ionisation 
Et3N Triethylamine 
Equiv Equivalents 
GH Glycosyl hydrolase 
GlcN Glucosamine 
GlcN-1-P Glucosamine-1-phosphate 
GlcNAc N-acetylglucosamine 
GlcNAc-1-P N-acetylglucosamine-1-phosphate 
GNAT GCN5-related N-acetyltransferase 
GT Glycosyltransferase  
HCTU 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate 
HOBt Hydroxybenzotriazole 
Hrs Hours 
IPTG Isopropyl β-ᴅ-1-thiogalactopyranoside 
Kb Kilobases 
kDa Kilodaltons 
KDN 2-keto-3-deoxy- ᴅ-glycero-ᴅ-galacto-2-nonulosonic acid 
LB Lysogeny Broth 
LC-MS Liquid Chromatography-Mass Spectrometry 
Leg5Ac7Ac N, N’-diacetyl-legionaminic acid 
˪-Glu ˪-Glutamate 
LPS Lipopolysaccharide 
ManNAc N-acetylmannosamine 
189 
 
ManNAc-6-P N-acetylmannosamine-6-phosphate 
ManNAz N-azidoacetylmannosamine 
MeOH Methanol 
Mins Minutes 
µL Microlitre 
µM Micromolar 
mM Millimolar 
MS Mass spectrometry 
Mu-Neu5Ac 4-Methylumbelliferone-α-N-acetylneuraminic acid 
MurNAc N-acetylmuramic acid 
NAD+ Nicotine Adenine Dinucleotide 
NADP+ Nicotine Adenine Dinucleotide Phosphate 
Neu5Ac 5-acetamido-3,5-ᴅ-glycero-ᴅ-galacto-2-nonulosonic acid, 
 N-acetylneuraminic acid 
Neu5Ac2en 2-deoxy-2,3-dehydro-N-acetylneuraminic acid 
Neu5Az N-azidoacetylneuraminic acid 
Neu5Gc N-glycolylneuraminic acid 
NMR Nuclear Magnetic Resonance 
PCR Polymerase chain reaction 
PEG Poly(ethylene glycol) 
PEP Phosphoenolpyruvate 
PLP Pyridoxal 5’-phosphate 
PMP Pyridoxamine 5’-phosphate 
Pse5Ac7Ac 5,7-diacetamido-3,5,7,9-tetradeoxy-˪-glycero-˪-manno-2-nonulosonic acid, 
 N,N'-diacetylpseudaminic acid 
Pse5Ac7Az N-acetyl-N'-azidoacetylpseudaminic acid 
Pse5Ac7RHb N-acetyl-N'-(3-hydroxybutanoyl)pseudaminic acid 
Pse5RHb7Fm N-(3-hydroxybutanoyl)-N'-formylpseudaminic acid 
PTA Phosphotransacetylase 
Rf Retention factor 
Rpm Revolutions per minute 
SDR Short Chain Dehydrogenase/Reductase family 
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
TLC Thin layer chromatography 
Tris Tris(hydroxymethyl)aminomethane 
UDP Uridine Diphosphate 
UDP-diNAcBac Uridine Diphosphate N, N’-diacetylbacillosamine 
UDP-GlcNAc Uridine Diphosphate N-acetylglucosamine 
UV Ultraviolet 
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